# kidney

## INTERNATIONAL

Volume 26, 1984


### Editor
**Roscoe R. Robinson**, Nashville

### Assistant Editors
**Claude Amiel**, Paris
**Vincent W. Dennis**, Durham

### Editorial Board
**Thomas E. Andreoli**, Houston
**Vittorio E. Andreucci**, Naples
**A. W. Asscher**, Cardiff
**Knut Aukland**, Bergen
**Peter Balint**, Budapest
**Lindsay J. Barratt**, Bedford Park
**Jonas Bergstrom**, Stockholm
**Ori S. Better**, Haifa
**Roland C. Blantz**, San Diego
**Adalbert Bohle**, Tubingen
**Jean-Philippe Bonjour**, Berne
**Vittorio Bonomini**, Bologna
**Barry M. Brenner**, Boston
**Neal S. Bricker**, Los Angeles
**Hans R. Brunner**, Lausanne
**J. S. Cameron**, London
**Anthony R. Clarkson**, Adelaide
**Jack W. Coburn**, Los Angeles
**Ramzi Cotran**, Boston
**William G. Couser**, Seattle
**Hugh E. de Wardener**, London
**Evert J. Dorhout Mees**, Utrecht
**Jean Dormont**, Clamart
**R. Dzurik**, Bratislava
**Laurence E. Earley**, Philadelphia
**Bryan T. Emmerson**, Brisbane
**Marilyn G. Farquhar**, New Haven
**Thomas F. Ferris**, Minneapolis
**Eli A. Friedman**, Brooklyn
**Gerhard Giebisch**, New Haven
**Carmelo Giordano**, Naples
**Richard J. Glassock**, Los Angeles
**Jared J. Grantham**, Kansas City
**J. P. Grünfeld**, Paris
**Robert A. Gutman**, Durham
**Renée Habib**, Paris
**Jean Hamburger**, Paris
**Lee W. Henderson**, San Diego
**Robert H. Heptinstall**, Baltimore
**Klaus Hierholzer**, Berlin
**Norman K. Hollenberg**, Boston
**Malcolm A. Holliday**, San Francisco
**Nishio Honda**, Hamamatsu
**Rex L. Jamison**, Stanford
**Colin I. Johnston**, Melbourne
**D. N. S. Kerr**, Newcastle-upon-Tyne
**Fredrik Kiil**, Oslo
**Priscilla Kincaid-Smith**, Melbourne
**Saulo Klahr**, St. Louis
**Horst Klinkmann**, Rostock
**Franklyn G. Knox**, Rochester, Minn.
**Juha P. Kokko**, Dallas
**Franciszek Kokot**, Katowice
**W. Kriz**, Heidelberg
**Kiyoshi Kurokawa**, Los Angeles
**Neil A. Kurtzman**, Chicago
**Paul H. Lambert**, Geneva
**Jacob Lemann, Jr.**, Milwaukee
**David Z. Levine**, Ottawa
**Guy Lemieux**, Montreal
**Manuel Martinez-Maldonado**, San Juan
**Shaul G. Massry**, Los Angeles
**Joel Menard**, Paris
**Alfred F. Michael**, Minneapolis
**Paul Michielsen**, Louvain
**John F. Moorhead**, London
**François Morel**, Paris
**L. Gabriel Navar**, Birmingham
**T. J. Neale**, Wellington
**Alphonse Nizet**, Liege
**Karl D. Nolph**, Columbia
**Jack Orloff**, Bethesda
**Tadeusz Orlowski**, Warsaw
**D. Keith Peters**, London
**Mordecai M. Popovtzer**, Jerusalem
**Jaime Borrero Ramirez**, Medellin
**Gabriel Richet**, Paris
**Jose L. Rodicio**, Madrid
**George E. Schreiner**, Washington, D.C.
**Robert W. Schrier**, Denver
**Donald W. Seldin**, Dallas
**Fred L. Shapiro**, Minneapolis
**David P. Simpson**, Madison
**Jay H. Stein**, San Antonio
**Liliane Striker**, Seattle
**Wadi N. Suki**, Houston
**Roger A. L. Sutton**, Vancouver
**Richard L. Tannen**, Ann Arbor
**Klaus Thurau**, Munich
**C. Craig Tisher**, Gainesville
**Bruno Truniger**, Lucerne
**Karl J. Ullrich**, Frankfurt
**Heinz Valtin**, Hanover
**Pierre Verroust**, Paris
**Herman Villarreal**, Mexico, D.F.
**Mackenzie Walser**, Baltimore
**Clark D. West**, Cincinnati
**Guillermo Whittembury**, Caracas
**Curtis B. Wilson**, La Jolla
**Douglas R. Wilson**, Toronto

### Manuscript Editor
**Brenna Nichols**, Nashville

### Editorial Assistants
**Jon Erickson**, Nashville
**Sharon D. Lee**, Durham
**André Ulmann**, Paris


Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1984 by International Society of Nephrology

# Author Index For Volume 26


Abboud HE: *see* Sedor et al ..... 144
Abdelhamid S (abst) ..... 518
Abdulmassih Z (abst) ..... 553, 579, 580, 589
Abomelha M (abst) ..... 237
Abouna GM (abst) ..... 629, 640
Abrahams M (abst) ..... 895
Absi M (abst) ..... 237
Accogli M (abst) ..... 576
Adam WR (abst) ..... 236
Adamiec R (abst) ..... 601
Adams BA (abst) ..... 236
Adler S: *see* Madaio et al ..... 397
Adler S, Baker P, Pritzl P, Couser WG: Detection of terminal complement components in experimental immune glomerular injury ..... 830
Adler WH: *see* Bender et al ..... 436
Adu D (abst) ..... 531, 629, 629
Aebischer P (abst) ..... 531
Agishi T (abst) ..... 531
Agnes E (abst) ..... 495
Aguilar L (abst) ..... 546
Ainscow J (abst) ..... 236
Ait-Slimane B (abst) ..... 569
Ajzen H (abst) ..... 533, 634, 634
Akiba T (abst) ..... 534
Akiyama N (abst) ..... 649
Aksoy A (abst) ..... 584
Al-Bander H (abst) ..... 231
Albano V (abst) ..... 599
Albertazzi A (abst) ..... 518, 531, 532, 532
Alberth M (abst) ..... 532
Alcazar JM (abst) ..... 506, 508
Alcazar J (abst) ..... 647
Alciturri L (abst) ..... 532, 533
Alevizou-Terzaki V (abst) ..... 613
Alexandre GPJ (abst) ..... 649
Alexiewicz J (abst) ..... 535
Alexopoulos E (abst) ..... 485, 654
Alfani D (abst) ..... 647
Alfano G (abst) ..... 548
Alfarone C (abst) ..... 496
Alfonso L (abst) ..... 576, 576, 577
Alfrey AC (abst) ..... 234
Alfrey AC: *see* Sedman et al ..... 201
Algaba F (abst) ..... 221
Aljama P (abst) ..... 219, 222
Aljama P (abst) ..... 485, 575
Allain P (abst) ..... 549
Allegri L (abst) ..... 485
Allen GG (abst) ..... 231
Allman M (abst) ..... 230
Alonso M (abst) ..... 220
Alperin R (abst) ..... 607
Alpert MA (abst) ..... 591
Alsina J (abst) ..... 218, 218, 218, 219, 220
Altmann P (abst) ..... 533, 544
Altmeyer P (abst) ..... 501
Altomonte C (abst) ..... 492
Altunkova I (abst) ..... 614
Alvarez de Lara M (abst) ..... 630
Alvarez F (abst) ..... 485
Alvarez F (abst) ..... 222
Amato G (abst) ..... 492, 493, 498, 636
Amendola G (abst) ..... 486, 486
Amiel C (abst) ..... 225
Amiel C: *see* Blanchet et al ..... 430
Amiel C: *see* Nitenberg et al ..... 744
Amos N: *see* Rees et al ..... 444
Anandan JV (abst) ..... 550
Anaya F (abst) ..... 585, 604, 629, 630, 657
Anaya M (abst) ..... 577
Ançoa MS (abst) ..... 533
Ancona G (abst) ..... 650, 651
Anderson S: *see* Brater et al ..... 183
Anderson WP (abst) ..... 232
Andrassy K (abst) ..... 509
Andres E (abst) ..... 219, 222
Andres E (abst) ..... 575
Andres P (abst) ..... 575
Andres P (abst) ..... 219
Andresen H (abst) ..... 639
Andreu J (abst) ..... 505
Andreú J (abst) ..... 219, 222, 222
Andreu L (abst) ..... 578, 579
Andreucci VE (abst) ..... 486, 486, 491, 492, 492, 549
Andrew J (abst) ..... 246
Andrews J (abst) ..... 243
Ang KS (abst) ..... 512, 624
Angelina C (abst) ..... 488
Antic S (abst) ..... 521
Antignac C (abst) ..... 630
Antonelli A (abst) ..... 491, 522
Antonelli F (abst) ..... 585
Antoni D (abst) ..... 570
Antoniewicz K (abst) ..... 535
Antonucci C (abst) ..... 499, 621
Antos M (abst) ..... 566
Aperia A: *see* Pettersson et al ..... 122
Aprile M (abst) ..... 576, 576, 576, 577
Arbelaez M: *see* Olgaard et al ..... 791
Arduini U (abst) ..... 499, 621
Arendsen D (abst) ..... 897
Argiles A (abst) ..... 648
Ariano MG (abst) ..... 491
Arisi L (abst) ..... 544
Arjkova E (abst) ..... 653
Arnfred J (abst) ..... 518
Arnold EP (abst) ..... 240
Arnolda L (abst) ..... 232, 235
Aroldi A (abst) ..... 614
Arrizabalaga P (abst) ..... 505
Arrizabalaga P (abst) ..... 222, 222
Arroyo V: *see* Pérez-Ayuso et al ..... 72
Arvieux C (abst) ..... 569
Ascher NL (abst) ..... 632
Ashcroft R (abst) ..... 582
Athéa N (abst) ..... 779
Atik H (abst) ..... 496

Atkins RC (abst) . 228, 234, 238, 238, 238, 241, 244, 245, 245
Attardi A (abst) . 533
Attman PO (abst) . 645
Aubia J (abst) . 614
Auciello A (abst) . 549
Aurell M (abst) . 645
Ausiello C (abst) . 605, 654
Avanzi C (abst) . 487
Avioli L: *see* Olgaard et al . 791
Aviram A (abst) . 534, 534, 616
Australasian Society of Nephrology Abstracts, Surfers Paradise, Australia, February 29–March 2, 1984 . 228
Aymard M (abst) . 650
Aynedjian HS: *see* Bank et al . 275
Azar S: *see* Raij et al . 137

Baba M (abst) . 534
Bachetoni A (abst) . 647
Bachs M (abst) . 579
Bacic F (abst) . 534
Baczyk K (abst) . 535, 535, 535, 551
Badamus CA (abst) . 557
Baddeley H: *see* Craswell et al . 319
Badr M (abst) . 517
Badzio T (abst) . 510
Bagni B (abst) . 558
Bahlmann J (abst) . 628
Bailey RR (abst) . 240, 242, 242, 243
Baker P: *see* Adler et al . 830
Bakkaloglu A (abst) . 485
Bakker WW (abst) . 368
Balager G (abst) . 218
Balcells A (abst) . 218, 220, 221
Balcke P (abst) . 530, 535, 567, 596, 641
Baldamus CA (abst) . 536, 595
Balderson GA (abst) . 228
Balducchi JP (abst) . 542, 779
Balfe JW (abst) . 494
Ballanti P (abst) . 586
Ballardie FW (abst) . 630
Ballarín JA (abst) . 220, 221
Balletta MM (abst) . 486, 486
Balmès M (abst) . 598
Balogh L (abst) . 572
Balslöv JT (abst) . 490
Baltes LA: *see* Zager et al . 689
Bandinelli M (abst) . 538
Bandini S (abst) . 593
Bandino D (abst) . 605
Bandres S (abst) . 590
Bank N, Aynedjian HS: Failure of changes in intracapillary pressures to alter proximal fluid reabsorption . 275
Baptista AL (abst) . 898
Barani R (abst) . 544
Barata JD (abst) . 536
Baratelli L (abst) . 618
Barbiano di Belgiojoso G (abst) . 539, 624
Barbiano G (abst) . 488
Barbour GL: *see* Gutman et al . 459
Barceló P (abst) . 220, 221, 221, 222
Bardare M (abst) . 560
Bariety J (abst) . 633
Bariety J (abst) . 225
Bariety J: *see* Nochy et al . 85
Barillari M (abst) . 617
Barnaba V (abst) . 647
Barnabei R (abst) . 599
Barnes JN (abst) . 611
Baronti R (abst) . 498
Barratt LJ (abst) . 231
Barres D: *see* Nochy et al . 85
Barril G (abst) . 630
Barrio V (abst) . 657
Barrios J (abst) . 590
Barsotti G (abst) . 498
Barthe PH (abst) . 489, 541
Bartoli E (abst) . 486, 614, 615, 615, 615
Bártová V (abst) . 572
Baruffaldi M (abst) . 560
Basayannis E (abst) . 588
Basile A (abst) . 618
Basolo B (abst) . 509
Basso T: *see* Rizzoni et al . 52
Bastos M (abst) . 486
Bastrenta F (abst) . 569
Bataille P (abst) . 496, 508, 515
Batchelor JR: *see* Rees et al . 444
Battaner E (abst) . 220
Batlle DC (abst) . 536
Bauer H (abst) . 654
Bauer K (abst) . 518
Baufeld H (abst) . 602
Baumelou A (abst) . 779
Bazzato G (abst) . 498, 503, 536, 537, 636
Bean AR (abst) . 242
Bean C (abst) . 241
Bear JC: *see* Churchill et al . 190
Becaus I (abst) . 522
Bechstein PB (abst) . 557
Beck D (abst) . 489
Beck FX (abst) . 232
Becker G (abst) . 234
Becker G (abst) . 486
Becker P (abst) . 897
Becker U (abst) . 537
Beck-Nielsen H (abst) . 512
Bedani PL (abst) . 558
Bedini R (abst) . 496
Behringer D (abst) . 487
Behringer D (abst) . 240
Beiles JR (abst) . 897
Beilin LJ (abst) . 242
Bekaert AB: *see* Van de Vyver et al . 451
Bekaert AB (abst) . 606
Bekaert A (abst) . 606
Belghiti D (abst) . 780
Belin L (abst) . 554
Belli LS (abst) . 542, 647
Belli L (abst) . 647
Bellinghieri G(abst) . 495, 537, 537, 595, 615
Bellio P (abst) . 591
Bello I (abst) . 506, 508
Bellomo R: *see* Holdsworth et al . 162
Belovezhdov N (abst) . 614
Beltramello G (abst) . 617
Benarbia S (abst) . 538
Bender BS, Curtis JL, Nagel JE, Chrest FJ, Kraus ES, Briefel GR, Adler WH: Analysis of immune status of hemodialyzed adults: Association with prior tranfusions . 436
Bene MC (abst) . 227
Benea G (abst) . 599

Benevent D (abst) ..... 225
Benhamou PY (abst) ..... 552, 552, 569
Bennet SE (abst) ..... 516
Bennett-Jones DN (abst) ..... 538
Bennhold I (abst) ..... 568
Benoît G (abst) ..... 538
Benyahia A: *see* Blanchet et al ..... 430
Berardinelli L (abst) ..... 487, 616, 630, 631
Berden JHM (abst) ..... 366
Beretta C (abst) ..... 616
Berg KJ (abst) ..... 487
Berg Rvd (abst) ..... 367
Bergadá E (abst) ..... 579, 579
Berger BE, Cogan MG, Sebastian A: Reduced glomerular filtration and enhanced bicarbonate reabsorption maintain metabolic alkalosis in humans ..... 205
Bergesio F (abst) ..... 538
Berglund J (abst) ..... 616
Bergman P (abst) ..... 528
Bergmann P (abst) ..... 602
Bergrem H (abst) ..... 631
Bergström J (abst) ..... 551, 571
Berisa F (abst) ..... 541
Berkley BB (abst) ..... 235
Berl T: *see* Kim et al ..... 384
Berland Y (abst) ..... 539
Berman IC (abst) ..... 552
Bernardi D (abst) ..... 538
Bernheim J (abst) ..... 509, 567
Bernini L (abst) ..... 538
Berstrand A (abst) ..... 509
Berthelot JM (abst) ..... 576
Berthoux FC (abst) ..... 497, 497, 561
Berthoux F (abst) ..... 620
Bertoli M (abst) ..... 488, 494, 510
Bertoli S (abst) ..... 488, 539
Bertoni E (abst) ..... 538
Beruard M (abst) ..... 548
Besbas N (abst) ..... 485
Bessa A (abst) ..... 594
Bettelheim H (abst) ..... 641
Bettinelli A (abst) ..... 560, 586
Betuel H (abst) ..... 631, 650
Beus I (abst) ..... 566
Beraud JJ (abst) ..... 544
Bhakdi S (abst) ..... 225
Bhattacharya P (abst) ..... 632
Bianchi C (abst) ..... 519
Bianchi P (abst) ..... 543
Bianchi R (abst) ..... 524
Bianco A (abst) ..... 510
Biasioli S (abst) ..... 539, 539, 589, 590
Biddle N (abst) ..... 234
Bilgin N (abst) ..... 562, 562, 637
Biljanovic L (abst) ..... 554
Billiouw JM (abst) ..... 540, 607, 607
Binswanger U (abst) ..... 509, 622
Biolchini A (abst) ..... 560
Birbara T (abst) ..... 247
Bird G (abst) ..... 571
Birembaut P (abst) ..... 780
Bishop GA (abst) ..... 237
Bishop VA (abst) ..... 240, 243
Bizollon C (abst) ..... 507
Bizzarri D (abst) ..... 594, 594
Blake E (abst) ..... 242, 243
Blair-West JR (abst) ..... 236
Blanchet F: *see* Nitenberg et al ..... 744
Blanchet F (abst) ..... 225
Blanchet F, Kanfer A, Cramer E, Benyahia A, Georges R, Méry JP, Amiel C: Relative contribution of intrinsic lung dysfunction and hypoventilation to hypoxemia during hemodialysis ..... 430
Blantz RC: *see* Tucker et al ..... 112
Blasco R (abst) ..... 223
Bleiber R (abst) ..... 613
Blockx PP: *see* Van de Vyver et al ..... 451
Blockx PPG (abst) ..... 606
Blohmé I (abst) ..... 645
Blum M (abst) ..... 534
Blumenkrantz M (abst) ..... 229
Blumenkrantz MJ: *see* Gutman et al ..... 459
Bodini U (abst) ..... 507
Boer P: *see* Geers et al ..... 324
Boero R (abst) ..... 508
Bogaard T (abst) ..... 632, 632, 646, 646
Bogicevic M (abst) ..... 521
Bohle A (abst) ..... 620
Böhnert U (abst) ..... 608
Boken R (abst) ..... 229
Bolton ND: *see* Gerig et al ..... 308
Bolton WK: *see* Gerig et al ..... 308
Bomalaski JS: *see* Goldstein et al ..... 733
Bommer G (abst) ..... 488
Bommer J (abst) ..... 488, 540, 581, 599
Bommer J, Gemsa D, Waldherr R, Kessler J, Ritz E: Plastic filing from dialysis tubing induces prostanoid release from macrophages ..... 331
Bonadio M (abst) ..... 488
Bonadonna A (abst) ..... 581
Bonal J (abst) ..... 579, 579
Bonalumi U (abst) ..... 540, 540
Bonnano D (abst) ..... 549
Bone JM (abst) ..... 513, 655
Bonechi I (abst) ..... 538
Boner G (abst) ..... 512, 653
Bonfiglio M (abst) ..... 546
Bönner G (abst) ..... 489, 489
Bonneville M (abst) ..... 658
Bono F (abst) ..... 489
Bonsdorff Mv (abst) ..... 565
Bonucci E (abst) ..... 586
Bony C (abst) ..... 570
Boone L (abst) ..... 606
Boquet E (abst) ..... 221, 222
Bordoni V (abst) ..... 636
Borghettti A (abst) ..... 499, 621
Borghi M (abst) ..... 50
Borghi M: *see* Usberti et al ..... 351
Borin D (abst) ..... 539, 539, 589, 590
Boros Gy (abst) ..... 541
Borsato N (abst) ..... 520, 617
Borzone E (abst) ..... 540, 540
Bosch J (abst) ..... 595, 614
Bosch R (abst) ..... 515
Bosshard S (abst) ..... 650
Botella J (abst) ..... 519, 541
Botey A (abst) ..... 218, 222
Botha JR (abst) ..... 897, 898, 898, 899
Bouissou F (abst) ..... 489, 541
Boulas J (abst) ..... 228
Boulpaep EL: *see* Hirsch et al ..... 798

Bouncristiani U (abst) ..... 543
Bourbigot B (abst) ..... 490, 564
Bourquelot P (abst) ..... 541, 562
Bovio G (abst) ..... 593
Boyce NW (abst) ..... 245
Boyle P (abst) ..... 240
Boyle P: *see* Craswell et al ..... 319
Bozoviz M (abst) ..... 526
Bradley BA (abst) ..... 636, 636
Bradley JA (abst) ..... 542
Bragantini L (abst) ..... 590
Brahm M (abst) ..... 490
Bramwell SP (abst) ..... 542
Branca GF (abst) ..... 486, 614
Brandinelli Geri A (abst) ..... 538
Brando B (abst) ..... 542, 647
Branger B (abst) ..... 542, 542, 598, 779
Brater DC, Day B, Burdette A, Anderson S: Bumetanide and furosemide in heart failure ..... 183
Braun J (abst) ..... 543
Brautbar N, Tabernero-Romo J, Coats J, Massry SG: Impaired myocardial lipid metabolism in phosphate depletion ..... 18
Bręborowicz A, Knapowski J: Augmentation of peritoneal dialysis clearance with procaine ..... 392
Breborowicz A (abst) ..... 543
Breithaupt H (abst) ..... 588
Brendolan A (abst) ..... 539, 539, 589, 590
Breutzmann D (abst) ..... 563
Briefel GR: *see* Bender et al ..... 436
Briganti M (abst) ..... 635
Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: A new perspective (Editorial Review) ..... 375
Briggs JD (abst) ..... 542, 545, 566, 635
Brocard JF (abst) ..... 538
Bröcker M (abst) ..... 597
Brocklebank JT (abst) ..... 647
Brodde OE (abst) ..... 551
Broggi L (abst) ..... 647
Brouard R (abst) ..... 779
Brown DJ (abst) ..... 234
Brown T: *see* Dominguez et al ..... 404
Brownjohn AM (abst) ..... 612, 612
Broyer M (abst) ..... 630
Brun C (abst) ..... 490
Bruno F (abst) ..... 630
Brunois JP (abst) ..... 490
Brunois JP (abst) ..... 226
Brunori G (abst) ..... 644
Brusa M (abst) ..... 633
Bruss J (abst) ..... 897
Bryer A (abst) ..... 899
Brynger H (abst) ..... 645
Bucht H (abst) ..... 509
Budde C (abst) ..... 575
Buder, HW (abst) ..... 512
Buendia E (abst) ..... 218, 220
Bukvic R (abst) ..... 527
Buller HR (abst) ..... 611
Buoncristiani U (abst) ..... 554, 554
Burdette A: *see* Brater et al ..... 183
Burdiel IG (abst) ..... 219
Burdiel LG (abst) ..... 575
Burger CH (abst) ..... 232
Burke JR (abst) ..... 240
Burnatowska-Hledin MA: *see* Kaiser et al ..... 269
Burnier M (abst) ..... 610, 658
Burrows L (abst) ..... 595, 631
Burshtein A (abst) ..... 653
Busarac D (abst) ..... 587
Busnach G (abst) ..... 542, 647
Butler JL (abst) ..... 230
Butter K (abst) ..... 533, 544
Buyssens N: *see* Van de Vyver et al ..... 451
Buzio C (abst) ..... 533
Buzzi F (abst) ..... 510
Buzzigoli G (abst) ..... 524

Cabili S (abst) ..... 616
Caggetta F (abst) ..... 576
Caglar S (abst) ..... 616
Calabrese G (abst) ..... 560
Calcagni G (abst) ..... 546
Calderaro V (abst) ..... 549
Calemard E (abst) ..... 549, 570
Calitri V (abst) ..... 584
Callís L (abst) ..... 223, 224, 224
Calvani M (abst) ..... 496
Calzavara P (abst) ..... 520, 527, 617
Cam G (abst) ..... 512, 624
Cambi V (abst) ..... 489, 544
Camerini C (abst) ..... 504
Cameron JS (abst) ..... 506, 506, 538, 649, 656, 656
Camilleri JP: *see* Nochy et al ..... 85
Campbell D (abst) ..... 234
Campbell M (abst) ..... 495
Camps J: *see* Perez-Ayuso et al ..... 72
Camussi G (abst) ..... 602
Canafax DM (abst) ..... 632
Canal R (abst) ..... 631
Canaud B (abst) ..... 544, 598
Canavese C (abst) ..... 584, 584
Candi P (abst) ..... 594
Candiano G (abst) ..... 618, 620
Candolfi E (abst) ..... 639
Cannata JB (abst) ..... 544, 545, 545, 545
Cantaluppi A (abst) ..... 545, 598
Cantarovitch D (abst) ..... 631
Cantù P (abst) ..... 620
Capasso G (abst) ..... 493
Capodicasa G (abst) ..... 492, 493, 498, 636
Cappellari PL (abst) ..... 510
Cappelli P (abst) ..... 518, 531
Capsa D (abst) ..... 604
Capsoni A (abst) ..... 618
Capuano A (abst) ..... 549
Capuano F (abst) ..... 498, 636
Caralps A (abst) ..... 218, 218, 220
Caraps A (abst) ..... 219
Carayon A (abst) ..... 495
Cardella C (abst) ..... 634
Cardellach F (abst) ..... 220
Carella C (abst) ..... 492, 493, 498, 636
Carlier M-B: *see* Giuliano et al ..... 838
Carmines PK: *see* Rosivall et al ..... 263
Carobi C (abst) ..... 543
Carone FA: *see* Kanwar et al ..... 35
Carone FA: *see* Peterson et al ..... 411
Carozzi S (abst) ..... 622, 632, 641
Carrasco A (abst) ..... 218
Carrasco D (abst) ..... 219, 220
Carrera F (abst) ..... 546

Carrera M (abst) ..... 546
Carrio J (abst) ..... 219
Carvalho F (abst) ..... 506
Casciani CU (abst) ..... 546, 585, 605, 654
Cascone C (abst) ..... 520, 527, 617
Casedei-Maldini M (abst) ..... 594
Cassani D (abst) ..... 618
Cassidy MJD (abst) ..... 492, 546, 897
Castelao AM (abst) ..... 218, 218, 220
Castellani A (abst) ..... 547, 547
Castellanos J (abst) ..... 566
Castello F (abst) ..... 223, 224, 224
Castelnovo C (abst) ..... 545, 598, 614
Castillo D (abst) ..... 575
Casuscelli di Tocco A (abst) ..... 537
Catalano C (abst) ..... 495, 557
Catalán R (abst) ..... 566
Catania B (abst) ..... 488
Caterson RJ (abst) ..... 229, 229, 236
Cattell WR (abst) ..... 559
Catto G (abst) ..... 644
Cattran DC (abst) ..... 547
Cattran D (abst) ..... 634
Cavalli PL (abst) ..... 548
Cavicchioni C (abst) ..... 548
Cecchetti V (abst) ..... 586
Cecchin E (abst) ..... 618
Celeris P (abst) ..... 553
Cerri M (abst) ..... 524
Cerulli N (abst) ..... 519
Chachati A (abst) ..... 548
Chacón JA (abst) ..... 533, 559
Chacón J (abst) ..... 532
Challoner-Hue L: *see* Steele et al ..... 719
Chamorro A (abst) ..... 220
Chan Y-K: *see* Gutman et al ..... 459
Chan YL (abst) ..... 229, 234
Chanard J (abst) ..... 227
Chanard J (abst) ..... 490
Channon SM (abst) ..... 555, 588
Chapuis-Cellier C (abst) ..... 633
Chapuy MC (abst) ..... 490, 548
Charhon SA (abst) ..... 490, 548
Charhon S (abst) ..... 539
Charles BG (abst) ..... 237
Charlesworth J (abst) ..... 245
Charpentier B (abst) ..... 538, 635
Charra B (abst) ..... 549, 570
Chatterjee S (abst) ..... 632, 632, 646, 646
Chavassieux PM (abst) ..... 490, 548
Chen TC: *see* Dominquez et al ..... 404
Cheung HS: *see* Maierhofer et al ..... 752
Cheung K (abst) ..... 236
Chevalier JY (abst) ..... 607
Chevet D (abst) ..... 226
Chiaramont S (abst) ..... 590
Chiaramonte S (abst) ..... 539, 539, 589
Chiarini C (abst) ..... 519, 553, 594
Child A (abst) ..... 233
Chmura A (abst) ..... 652
Cho C (abst) ..... 585
Choisy H (abst) ..... 227
Chong G (abst) ..... 648, 648
Chrest FJ: *see* Bender et al ..... 436
Christensen M (abst) ..... 589
Christiani K (abst) ..... 505
Christiansen C (abst) ..... 589
Christl HL (abst) ..... 518
Chung TG (abst) ..... 593
Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH: Prognosis of adult onset polycystic kidney disease re-evaluated ..... 190
Cianchiaruso B (abst) ..... 549
Cianchioni C (abst) ..... 549
Cibin D (abst) ..... 600
Ciccarelli M (abst) ..... 613
Cieciura L (abst) ..... 626
Cigarrán S (abst) ..... 585
Cimadevilla R (abst) ..... 544
Cinaz P (abst) ..... 621
Cinti P (abst) ..... 647
Ciociaro D (abst) ..... 524
Ciuti R (abst) ..... 538
Civardi F (abst) ..... 487
Civati G (abst) ..... 549, 647
Clague MB (abst) ..... 561
Clasen W (abst) ..... 617
Clavel JP (abst) ..... 590
Cledes J (abst) ..... 490, 550, 564
Clerico A (abst) ..... 524
Clifford D (abst) ..... 896
Clinton C (abst) ..... 897
Coates JH (abst) ..... 234
Coats J: *see* Brautbar et al ..... 18
Coburn JW: *see* Gutman et al ..... 459
Coca A (abst) ..... 218, 220, 221
Cocchi F (abst) ..... 635
Cochat P (abst) ..... 493
Cochran M (abst) ..... 234, 234
Cocks M (abst) ..... 235
Coelho RA (abst) ..... 506
Coffrini E (abst) ..... 499, 621
Cogan MG: *see* Berger et al ..... 205
Cohen J (abst) ..... 896, 896
Coli E (abst) ..... 503, 536, 537, 636
Collart F (abst) ..... 555, 602, 602, 603
Collier F (abst) ..... 520
Collins A (abst) ..... 563
Collura C (abst) ..... 495
Colon S (abst) ..... 493, 493
Colussi G (abst) ..... 491, 491, 574, 614
Company X (abst) ..... 546
Comparini L (abst) ..... 593
Conesa D (abst) ..... 626
Conesa J (abst) ..... 223
Conger JD: Nephron heterogeneity in ischemic acute renal failure ..... 422
Conrad KP: Renal hemodynamics during pregnancy in chronically catheterized, conscious rats ..... 24
Consolo F (abst) ..... 537, 537, 595, 615
Conte G (abst) ..... 491, 492, 492
Conté JJ (abst) ..... 556
Conti P (abst) ..... 494
Contu B (abst) ..... 614
Cook DB (abst) ..... 651
Cook DJ (abst) ..... 895
Cooper I (abst) ..... 566
Copercini B (abst) ..... 507
Copper SG (abst) ..... 242
Coppo R (abst) ..... 509
Corbacho L (abst) ..... 221
Cordonnier D (abst) ..... 509

Coriatt D (abst) ..... 489
Corlianò C (abst) ..... 576, 576, 576, 577
Cornud F (abst) ..... 226
Corradi A (abst) ..... 489
Corradi B (abst) ..... 574
Corsi M (abst) ..... 515
Cortesini R (abst) ..... 647, 657
Corvaja E (abst) ..... 617
Corvol P: *see* Nochy et al ..... 85
Cosci P (abst) ..... 574
Cosma PO (abst) ..... 581
Cossu G (abst) ..... 617
Costa G (abst) ..... 595
Costa J (abst) ..... 898
Costa J: *see* Pérez-Ayuso et al ..... 72
Costa M (abst) ..... 587
Costantini S (abst) ..... 586
Costanza G (abst) ..... 550
Cosyns JP (abst) ..... 633, 649
Cottino R (abst) ..... 547
Coumian P (abst) ..... 576
Couper I (abst) ..... 550
Courel MA (abst) ..... 585
Couroucé AM (abst) ..... 598
Couser WG: *see* Adler et al ..... 830
Couser WG: *see* Madaio et al ..... 397
Cowley D (abst) ..... 240
Cozzari M (abst) ..... 543
Craig ID (abst) ..... 609
Cramer E (abst) ..... 225
Cramer E: *see* Blanchet et al ..... 430
Craswell P (abst) ..... 240
Craswell P (abst) ..... 487
Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW: Chronic renal failure with gout: A marker of chronic lead poisoning ..... 319
Creazzo G (abst) ..... 557
Crewe EB (abst) ..... 229
Cristian R (abst) ..... 604
Cristinelli L (abst) ..... 597, 644
Crombie Y (abst) ..... 898
Cross RB (abst) ..... 232, 235
Cruz C (abst) ..... 550, 582
Cruz JM (abst) ..... 219, 220
Csongor J (abst) ..... 529
Cuesta V (abst) ..... 544, 545, 545
Cunningham J (abst) ..... 533, 544, 611
Curley J (abst) ..... 531
Curtis FK: *see* Gutman et al ..... 459
Curtis JL: *see* Bender et al ..... 436
Curtis Morris R Jr (abst) ..... 231
Cuzzocrea G (abst) ..... 491, 522
Czarnecki R (abst) ..... 535, 535
Czyzewski K (abst) ..... 551

Dadah SK (abst) ..... 629
D'Agostino CD (abst) ..... 551
Daha MR (abst) ..... 366
Daha MR: *see* Valentijn et al ..... 760
Dal Canton A: *see* Usberti et al ..... 351
Dal Canton A (abst) ..... 491, 492, 492, 549
Dal Col A (abst) ..... 542
Dalet F (abst) ..... 221, 222
Dalhoff K (abst) ..... 520
Dall'Aglio PP (abst) ..... 485
Dall'Argine P (abst) ..... 618
D'Amicone M (abst) ..... 584
D'Angelo A (abst) ..... 519
Danielsson A (abst) ..... 551, 571
d'Apice A (abst) ..... 241
Darai G (abst) ..... 488
Darby C: *see* Madaio et al ..... 397
Dard S (abst) ..... 226
Darnell A (abst) ..... 505, 505, 622, 623
Darnell A (abst) ..... 222
Dascola G (abst) ..... 485
da Silva J (abst) ..... 896
Date A (abst) ..... 240
Dathan R (abst) ..... 495
Daudon M (abst) ..... 226
Daugaard H (abst) ..... 583
Daul A (abst) ..... 504, 551, 659
David S (abst) ..... 544, 618
Davidman M: *see* Houser et al ..... 176
Davies DJ (abst) ..... 239
Davies PG (abst) ..... 899
Davies RM (abst) ..... 552
Davis D (abst) ..... 585
Davison AM (abst) ..... 610
Dawborn JK (abst) ..... 234
Day B: *see* Brater et al ..... 183
Dean MPG (abst) ..... 899
Dean P (abst) ..... 650, 651
Deane N (abst) ..... 552, 552, 611
De Blasi V (abst) ..... 576, 576, 577
Debroe M (abst) ..... 603
De Broe ME (abst) ..... 606, 606, 607
De Broe ME: *see* Van de Vyver et al ..... 451
De Broe ME: *see* Giulinao et al ..... 838
De Carolis C (abst) ..... 585
Dechelette E (abst) ..... 552, 569
Dechenne C (abst) ..... 548, 548
Decker G (abst) ..... 609
De Cubber A (abst) ..... 540
Dedeman S (abst) ..... 562
Deeg M (abst) ..... 489
De Ferrari E (abst) ..... 574
De Ferrari ME (abst) ..... 491, 491
De Francisco AM (abst) ..... 492, 523
de Frémont JF (abst) ..... 495, 508
de Fremont JF (abst) ..... 553, 553, 579, 603, 603
Degli Esposti E (abst) ..... 519, 553, 594
de Heer E (abst) ..... 366
de Groc F (abst) ..... 779
Deinhardt D (abst) ..... 488
de Jong PE (abst) ..... 367
de Jong PE (abst) ..... 627
De Keersmaecker W: *see* Van de Vyver et al ..... 451
de Keijzer MH (abst) ..... 367
Dekkers WT (abst) ..... 570
De Korwin J (abst) ..... 227
Del Canale S (abst) ..... 499, 621
Del Chicca MG (abst) ..... 524
Del Favero E (abst) ..... 647
Delfino G (abst) ..... 618, 620
Deligiannis A (abst) ..... 553
De Ligny B (abst) ..... 227
Delin K (abst) ..... 554
Delitala G (abst) ..... 617
Delmez J: *see* Kettner et al ..... 66
Delons S (abst) ..... 549

Del Rio G (abst) ..... 220, 221
Del Rosso G (abst) ..... 532, 532
De Luca G (abst) ..... 548
De Luca M (abst) ..... 520, 617
De Luca M (abst) ..... 527
Delz E (abst) ..... 637
De Maio A (abst) ..... 618
De Marchi S (abst) ..... 618
De Mia M (abst) ..... 554
de Miguel A (abst) ..... 519, 541
Demontis R (abst) ..... 508, 553, 580
Denton KM (abst) ..... 232
de Oliveira AA (abst) ..... 896
De Paoli EV (abst) ..... 599
De Paoli Vitali E (abst) ..... 599
Deray G (abst) ..... 779
Derfler K (abst) ..... 520
Derkx FHM (abst) ..... 368
Derom F (abst) ..... 607
De Roose J (abst) ..... 607
de Rooy L (abst) ..... 895
De Roy G (abst) ..... 602
Derzsiová K (abst) ..... 648
Desailly I (abst) ..... 495
De Santo NG (abst) ..... 492, 493, 498, 636
Deschodt G (abst) ..... 542, 779
DeSchryver-Kecskemeti K: *see* Lefkowith et al ..... 10
De Simone V (abst) ..... 492, 498, 636
De Smyter J (abst) ..... 516
De Sole P (abst) ..... 579
Despotovic N (abst) ..... 526, 526
Deteix P (abst) ..... 493, 493, 633
Deteix P (abst) ..... 225, 226
Deulofeu R (abst) ..... 546
Deutsch E (abst) ..... 575
De Vecchi A (abst) ..... 633
De Vetter L (abst) ..... 555
De Villa LF (abst) ..... 494, 647
Dewar J (abst) ..... 897
de Zeeuw D (abst) ..... 367
de Zeeuw D (abst) ..... 523, 524, 527
Dhaene M (abst) ..... 528, 606
D'Haese P: *see* Van de Vyver et al ..... 451
D'Haese P (abst) ..... 606, 606
D'Iddio S (abst) ..... 496, 515
Dieperink H (abst) ..... 493
Diéval J (abst) ..... 589
Djukanovic Lj (abst) ..... 554, 587
Dkhissi H (abst) ..... 515, 553, 579, 589, 597
Di Landro D (abst) ..... 488, 494, 510, 613
Di Minno G (abst) ..... 492
Di Paolo B (abst) ..... 521, 531, 532, 532
Di Paolo N (abst) ..... 533, 543, 554, 554
Disney APS (abst) ..... 247
Di Spigno C (abst) ..... 492
Di Stefano E (abst) ..... 521
Djaldetti M: *see* Weinstein et al ..... 741
Dobbie J (abst) ..... 550
Docci D (abst) ..... 555
Dolkart RE (abst) ..... 571
Dominguez JH, Pitts TO, Brown T, Puschett DB, Schuler F, Chen TC, Puschett JB: Prostaglandin $E_2$ and parathyroid hormone: Comparisons of their actions on the rabbit proximal tubule ..... 404
Donadio C (abst) ..... 519
Donati D (abst) ..... 618
Donckerwolcke RAMG (abst) ..... 515
Dondi M (abst) ..... 519
Donker AJM (abst) ..... 510, 514, 531, 627, 656, 658
Donker AJM (abst) ..... 366, 367, 368
Donnelly PK (abst) ..... 555
Donovsky L (abst) ..... 568
Dorhout Mees EJ: *see* Geers et al ..... 324
Dorhout Mees EJ: *see* Koomans et al ..... 848
Dörtlemez H (abst) ..... 584
Dörtlemez O (abst) ..... 584
Doss Sh (abst) ..... 623
Dossetor JB (abst) ..... 633
Dougados M (abst) ..... 779
Douglas SD: *see* Goldstein et al ..... 733
Dowling JP (abst) ..... 245
Downing N (abst) ..... 564
Drachman R (abst) ..... 630
Dragicevic P (abst) ..... 587
Draibe A (abst) ..... 533, 594
Draibe SA (abst) ..... 634
Dratwa M (abst) ..... 555, 602, 602, 603
Drazniowsky M (abst) ..... 555
Dreikorn K (abst) ..... 638, 641, 651, 651
Drew P (abst) ..... 544
Dreyer L (abst) ..... 899
Driedger AA (abst) ..... 609
Drif M (abst) ..... 569
Drinovec J (abst) ..... 503
Droz D: *see* Ganeval et al ..... 1
DuBose TD Jr (abst) ..... 231
Dudczak R (abst) ..... 502, 520, 578, 578
Dueymes JM (abst) ..... 556
Dugdale L (abst) ..... 233
Duggin GG (abst) ..... 228, 228, 230, 233, 235, 236, 237, 279
Duheille J (abst) ..... 227
Dulaney JT, Hatch FE Jr: Peritoneal dialysis and loss of proteins: A review (Editorial Review) ..... 253
Dulka E (abst) ..... 513
Dumovic B (abst) ..... 600, 625, 625
Dun G (abst) ..... 550
Dunn M (abst) ..... 623
Duranti E (abst) ..... 494, 594, 594
Durutovic R (abst) ..... 625
Dutch Society of Nephrology Abstracts, Leiden, The Netherlands, April 28, 1984 ..... 366
du Toit E (abst) ..... 625
du Toit E (abst) ..... 900
Duursma SA (abst) ..... 515
Dwenger A (abst) ..... 628
Dzikova S (abst) ..... 525

Eaton A (abst) ..... 538
Ebel H (abst) ..... 642
Eberle P (abst) ..... 511
Edefonti A (abst) ..... 560, 560, 586
Edward N (abst) ..... 644
Egbring R (abst) ..... 653
Egfjord M (abst) ..... 583
Eggert W (abst) ..... 613
Egidi F (abst) ..... 633
Egido J (abst) ..... 223, 223, 223
Egitto M (abst) ..... 617
Ehringer H (abst) ..... 522
Eigler FW (abst) ..... 654
Eisenhauer T (abst) ..... 641
Eke FU (abst) ..... 494

Eldeleklioglu S (abst) ..... 563
Elema JD (abst) ..... 369
Eliahou HE (abst) ..... 500
El-Haieg MO (abst) ..... 517
Elinder G: *see* Pettersson et al ..... 122
Ellis HA (abst) ..... 897
Ellis HA (abst) ..... 492, 546
Ellison DH, Velázquez HE, Wright FS: Osmotic activity of dimethyl sulfoxide in the renal distal tubule (Technical Note) ..... 471
Emiliani G (abst) ..... 635
Engeset J (abst) ..... 644
El-Said W (abst) ..... 557
El-Sheemy (abst) ..... 623
ElYafi S (abst) ..... 650
English PB (abst) ..... 236
Enia G (abst) ..... 495, 557
Enriquez R (abst) ..... 519
Epstein FH: *see* Brezis et al ..... 375
Era K (abst) ..... 531
Erben J (abst) ..... 557
Ernst W (abst) ..... 557, 595
Errasti P (abst) ..... 219
Ersoy F (abst) ..... 485
Escobar EM (abst) ..... 577
Escobedo JM (abst) ..... 219
Escuín F (abst) ..... 223
Eskubi N (abst) ..... 532
Espinel E (abst) ..... 558, 566
Espinosa J (abst) ..... 532, 533, 559
Esposito A (abst) ..... 486, 486
Esposito C (abst) ..... 492
Esser J (abst) ..... 897
Esterman A (abst) ..... 240
Etheredge SB (abst) ..... 231, 236
European Dialysis and Transplant Association-European Renal Association Abstracts, Florence, Italy, September 23–26, 1984 ..... 483
Evangelista B (abst) ..... 654
Evangelista M (abst) ..... 531
Evans J (abst) ..... 586
Evans SM (abst) ..... 234
Evers J (abst) ..... 489

Fabbri A (abst) ..... 635
Fabiani F (abst) ..... 491
Fabris A (abst) ..... 539, 539, 589, 590
Faedda R (abst) ..... 486, 614, 615, 615, 615
Fairley K (abst) ..... 486
Fairley KF (abst) ..... 242
Fakir M (abst) ..... 780
Falk E (abst) ..... 515
Falkenstein D (abst) ..... 634, 634
Faller B (abst) ..... 225
Fanetti G (abst) ..... 554
Fanfani G (abst) ..... 511
Fanti P: *see* Malluche et al ..... 869
Farina V (abst) ..... 537
Farinelli A (abst) ..... 558, 599
Farndon JR (abst) ..... 492, 529, 897
Farnsworth RH (abst) ..... 242
Farrell PC (abst) ..... 234, 243, 244, 245, 245
Fassbinder W (abst) ..... 501, 557, 595
Fasset RG (abst) ..... 229, 241
Fauchald P (abst) ..... 655
Faugere M-C: *see* Malluche et al ..... 869
Faure G (abst) ..... 227
Favre H (abst) ..... 226
Favre H (abst) ..... 573, 573, 591, 619
Fawcett S (abst) ..... 558
Fazzelari N (abst) ..... 229
Fearon DT: *see* Hakim et al ..... 194
Fede C (abst) ..... 495
Federman DD: The articulation of Adam's rib with the lower urinary tract (Nephrology Forum) ..... 476
Feest TG (abst) ..... 558, 619
Feldman JL (abst) ..... 225
Feldman L (abst) ..... 898
Feldman R (abst) ..... 585
Fellay G (abst) ..... 531
Felthuis W (abst) ..... 649, 650
Fenton S (abst) ..... 634
Fenton SSA (abst) ..... 547
Feriani M (abst) ..... 539, 539, 589, 590
Ferlin G (abst) ..... 520
Fernández A (abst) ..... 577, 584
Fernandez E (abst) ..... 221
Fernandez J (abst) ..... 519, 541, 541
Ferrari ME (abst) ..... 544
Ferreira C (abst) ..... 559
Fiaccadori E (abst) ..... 499, 621
Fidler V (abst) ..... 366
Fiegel P (abst) ..... 518
Fiers HA (abst) ..... 570
Fiévet P (abst) ..... 495, 497, 515
Figueiredo JF (abst) ..... 634, 634, 634
Filippich LJ (abst) ..... 236
Finco D: *see* Olgaard et al ..... 791
Fine RN (abst) ..... 493
Fine S (abst) ..... 493
Finet M (abst) ..... 508
Fink MJ (abst) ..... 608
Fiselier T, Monnens L, Lameire N, van Munster P, Peer P, Leusen I, Lijnen P: Effects of angiotensin II blockade in the canine puppy under different salt-intake ..... 823
Fish A: *see* Houser et al ..... 176
Fisher JW (abst) ..... 504
Fishman P: *see* Weinstein et al ..... 741
Fitz AE (abst) ..... 496
Flatmark A (abst) ..... 631, 655
Fleming LW (abst) ..... 559
Fleming SJ (abst) ..... 559
Flendrig JA (abst) ..... 366
Fletcher PI (abst) ..... 235
Fleuren GJ (abst) ..... 369
Florio R (abst) ..... 631
Flotta S (abst) ..... 491
Foguer P (abst) ..... 553
Fohrer P (abst) ..... 553, 579, 603
Font J (abst) ..... 218, 220
Fontana L (abst) ..... 585
Fonteyne E (abst) ..... 522
Foote J (abst) ..... 495
Forbes SM (abst) ..... 246
Formica M (abst) ..... 636
Fortezza P (abst) ..... 546
Fortuny G (abst) ..... 223, 224, 224
Forwell MA (abst) ..... 635
Forzani F (abst) ..... 507
Fosso A (abst) ..... 498
Fotino M (abst) ..... 631

Foulkes S (abst) ..... 588
Fourcade J (abst) ..... 779
Fournié GJ (abst) ..... 556
Fournier A (abst) ..... 495, 496, 497, 508, 515, 553, 579, 580, 589, 597, 603, 603, 603
Fracasso AM (abst) ..... 511
Fracasso A (abst) ..... 536, 537
Francis DMA (abst) ..... 555
Francisco L (abst) ..... 229
Frank J (abst) ..... 505
Franz HE (abst) ..... 654
Frascarelli M (abst) ..... 496
Frattini G (abst) ..... 618
Freddo L (abst) ..... 488
Fredj G (abst) ..... 779
Freeman RB (abst) ..... 524, 623
Freeman RM (abst) ..... 496
French Society of Nephrology Abstracts, Paris, France, February 1, 1984 ..... 225
French Society of Nephrology Abstracts, Paris, France, May 7, 1984 ..... 779
Freyschuss U (abst) ..... 551
Friedman D (abst) ..... 540, 540
Fries D (abst) ..... 538, 635
Fries J (abst) ..... 627
Frischauf H (abst) ..... 502, 520
Fritzsche H (abst) ..... 581
Frizzi V (abst) ..... 538
Fröhling PT (abst) ..... 496, 511
Fuiano G (abst) ..... 491, 492
Fujita T: *see* Hamazaki et al ..... 81
Funari C (abst) ..... 560
Furci L (abst) ..... 624
Furlong T (abst) ..... 229, 229, 234, 243
Furman KI (abst) ..... 895
Fusaroli M (abst) ..... 635, 635
Fuss M (abst) ..... 528
Fyhrquist F (abst) ..... 514

Gabás J (abst) ..... 218
Gabriel R (abst) ..... 619
Gaesa J (abst) ..... 222
Gaggiotti E (abst) ..... 554
Gagnadoux MF (abst) ..... 630
Gaiger E (abst) ..... 523
Galard R (abst) ..... 566
Galati A (abst) ..... 576
Galato R (abst) ..... 539, 560
Galeotti R (abst) ..... 599
Gallego JL (abst) ..... 519, 541
Gallery EDM (abst) ..... 232, 241
Gallet A (abst) ..... 225
Galli F (abst) ..... 593
Galvani E (abst) ..... 650, 651
Galy Cl (abst) ..... 497, 508
Gamba PG (abst) ..... 613
Gandhi VC: *see* Gutman et al ..... 459
Ganeval G, Noel L-H, Preud'homme J-L, Droz D, Grünfeld J-P: Light chain deposition disease: Its relation with AL-type amyloidosis (Editorial Review) ..... 1
Ganten D (abst) ..... 557
Garabédian M (abst) ..... 597
García M (abst) ..... 546
Garcia Alonso A (abst) ..... 559
Garcia-Alfageme A (abst) ..... 533, 559
García-Hoyo R (abst) ..... 223
García-Pérez J (abst) ..... 220
Garcia-Robles R (abst) ..... 494, 647
Gardini F (abst) ..... 489
Gardner P (abst) ..... 608
Garner MG (abst) ..... 235
Garre M (abst) ..... 490
Garrett WJ (abst) ..... 242
Garrido MC (abst) ..... 219
Garriou R (abst) ..... 658
Garvey MA (abst) ..... 552
Gary J (abst) ..... 226
Gasparotto ML (abst) ..... 494, 510
Gasparovic V (abst) ..... 619
Gastaldi L (abst) ..... 618
Gaucher P (abst) ..... 227
Gault MH: *see* Churchill et al ..... 190
Gaur SS, Nancollas GH: Kinetics of crystal growth in urine (Technical Note) ..... 767
Gauthier C, Nguyen-Simonnet H, Vincent C, Revillard J-P, Pellet MV: Renal tubular absorption of $\beta$2 microglobulin ..... 170
Gautschi K (abst) ..... 622
Gavendo S (abst) ..... 500
Gaya J (abst) ..... 222
Gaya J: *see* Pérez-Ayuso et al ..... 72
Gee D (abst) ..... 241
Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ: Functional relationships in the nephrotic syndrome ..... 324
Geers AB: *see* Koomans et al ..... 848
Geisen HP (abst) ..... 641
Geisler W (abst) ..... 547
Gekle D (abst) ..... 627
Geleris P (abst) ..... 588
Gelpi C (abst) ..... 220, 221
Gemsa D: *see* Bommer et al ..... 331
Genin C (abst) ..... 497, 497, 561, 620
Georges R (abst) ..... 225
Georges R: *see* Blanchet et al ..... 430
Georgilis C (abst) ..... 621
Gerig JS, Bolton ND, Swabb EA, Scheld WM, Bolton WK: Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics ..... 308
Germanò G (abst) ..... 546
Gerstoft J (abst) ..... 490
Gessler U (abst) ..... 499, 543
Gessler W (abst) ..... 639
Getino MA (abst) ..... 220
Geusa AL (abst) ..... 562
Gevenois PA (abst) ..... 606
Ghais Z (abst) ..... 633
Ghiggeri GM (abst) ..... 618, 620
Ghio L (abst) ..... 560, 560, 586
Ghione S (abst) ..... 538
Ghiringhelli P (abst) ..... 560
Ghoneim M (abst) ..... 513
Ghysen J (abst) ..... 649
Giacchino F (abst) ..... 636
Giampietro O (abst) ..... 526
Gianarakis N (abst) ..... 237
Giangrande A (abst) ..... 620
Giani M (abst) ..... 560, 560, 586
Giannoni A (abst) ..... 498
Giannopoulos Z (abst) ..... 498
Giannotti P (abst) ..... 488
Gianopoulos Z (abst) ..... 637

Giardino O (abst) ..... 605
Gié S (abst) ..... 226
Gilge U (abst) ..... 499
Gilks WR (abst) ..... 636, 636
Gilli G (abst) ..... 497
Gil-Vernet S (abst) ..... 218, 218, 219
Gimsing P (abst) ..... 601
Gioffrè F (abst) ..... 537
Giorcelli G (abst) ..... 515
Giordano C (abst) ..... 492, 493, 498, 636
Giouticas S (abst) ..... 588
Giovannetti S (abst) ..... 498
Girard JF (abst) ..... 225
Giraudo G (abst) ..... 502
Girdano R (abst) ..... 586
Giuliano RA, Paulus GJ, Verpooten GA, Pattijn VM, Pollet DE, Nouwen EJ, Laurent G, Carlier M-B, Maldague P, Tulkens PM, De Broe ME: Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats ..... 838
Gjurasin M (abst) ..... 619
Glabman S (abst) ..... 595
Glasgow EF (abst) ..... 238, 244
Gleim GW, Kao-Lo G, Maude DL: Pressure natriuresis and prostaglandin secretion by perfused rat kidney . 683
GlezPosadas JM (abst) ..... 528
Glöckner WM (abst) ..... 620
Glynn EM (abst) ..... 235
Gnudi A (abst) ..... 544, 618
Gnutzmann KH (abst) ..... 637
Gobe G (abst) ..... 232
Godon JP (abst) ..... 548, 548
Goia F (abst) ..... 547
Gokce O (abst) ..... 562
Goldberg A: *see* Kettner et al ..... 66
Goldman M (abst) ..... 528, 606
Goldstein J (abst) ..... 656
Goldstein CW, Bomalaski JS, Zurier RB, Neilson EG, Douglas SD: Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients . 733
Gollogly RK (abst) ..... 236
Golomb J (abst) ..... 534
Gomez C (abst) ..... 506
Gomez J (abst) ..... 485
Gómez J (abst) ..... 219
Gómez P (abst) ..... 223
Gonella M (abst) ..... 560
Goñi M (abst) ..... 219
Gonthier R (abst) ..... 497, 561, 620
Gonzalez FM (abst) ..... 561
Gonzalez J (abst) ..... 223
Goodship THJ (abst) ..... 523, 561, 582
Goodwin FJ (abst) ..... 611
Goodwin F (abst) ..... 553, 544
Göppinger S (abst) ..... 575
Gordge MP (abst) ..... 591, 592
Gore SM (abst) ..... 636
Gotloib L (abst) ..... 591
Gottschalk F (abst) ..... 518
Gougoux A (abst) ..... 587
Graben N (abst) ..... 504, 551, 561, 658
Graf H (abst) ..... 568
Grala T (abst) ..... 535
Grammer L (abst) ..... 582
Grande J (abst) ..... 625
Grande J (abst) ..... 223
Gracia J (abst) ..... 220
Granérus G (abst) ..... 645
Granier A (abst) ..... 562
Graninger W (abst) ..... 530
Granoleras C (abst) ..... 542
Granvuillemin (abst) ..... 539
Gray RW: *see* Maierhofer et al ..... 752
Graziani G (abst) ..... 545, 614
Grcevska L (abst) ..... 525
Greco S (abst) ..... 520
Greenwood RN (abst) ..... 559
Grekas D (abst) ..... 498, 498, 637
Grégoire I (abst) ..... 597
Gremo L (abst) ..... 602
Gretz N (abst) ..... 505
Gribnau F (abst) ..... 367
Griffanti F (abst) ..... 540, 540
Grigg R (abst) ..... 241
Grillo S (abst) ..... 491
Grimaldi F (abst) ..... 618
Grime B (abst) ..... 240
Grino JM (abst) ..... 218, 218, 219, 220
Gritzmann N (abst) ..... 567
Grond J (abst) ..... 369
Grönhagen-Riska (abst) ..... 514
Grosoli M (abst) ..... 593
Gross J (abst) ..... 517, 613
Grossi C (abst) ..... 562
Groufsky A (abst) ..... 242
Gruer LD (abst) ..... 531
Grundmann R (abst) ..... 637, 638
Grünfeld J-P: *see* Ganeval et al ..... 1
Grusendorf M (abst) ..... 488
Grutta d'Auria C (abst) ..... 507
Grutta d'Auria C: *see* Usberti et al ..... 351
Grzegorzewska A (abst) ..... 535, 551
Guardia I (abst) ..... 223
Guarena C (abst) ..... 508
Guariglia A (abst) ..... 499, 621
Guarner F (abst) ..... 220
Guarriello L (abst) ..... 491
Guastoni C (abst) ..... 549
Guder WG, Ross BD: Enzyme distribution along the nephron (Editorial Review) ..... 101
Guenel J (abst) ..... 639
Guerra L (abst) ..... 545
Guerrero R (abst) ..... 485
Guerrero R (abst) ..... 222
Guiberteau R (abst) ..... 225
Guillen M (abst) ..... 220
Guillodo MP (abst) ..... 564
Guillou PJ (abst) ..... 610, 647
Guiter J (abst) ..... 648
Gunnarsson B (abst) ..... 571
Gursoy G (abst) ..... 562
Guth R (abst) ..... 654
Gutman RA, Blumenkrantz MJ, Chan Y-K, Barbour GL, Gandhi VC, Shen FH, Tucker T, Murawski BJ, Coburn JW, Surtis FK: Controlled comparison of hemodialysis and peritoneal dialysis: Veterans Administration multicenter study ..... 459
Gutsche HU (abst) ..... 516, 637
Guyda H (abst) ..... 580
Guzzardi R (abst) ..... 519
Gyftaki E (abst) ..... 613
Györy AZ (abst) ..... 232, 232, 232, 241

Gzlez-Revaldería J (abst) ..... 650

Haajman JJ: *see* Valentijn et al ..... 760
Haas M (abst) ..... 523, 524
Haberal M (abst) ..... 562, 562, 637
Habib M (abst) ..... 623, 623
Habicht G (abst) ..... 899
Hachicha J (abst) ..... 226
Hadj Aissa A (abst) ..... 226, 502, 507
Hagberg J: *see* Kettner et al ..... 66
Hahn W (abst) ..... 608
Haimovitz C (abst) ..... 653
Hajek P (abst) ..... 567
Hajkova B (abst) ..... 551
Hakim RM, Fearon DT, Lazarus JM: Biocompatibility of dialysis membranes: Effects of chronic complement activation ..... 194
Halabi G (abst) ..... 610
Halilbasic A (abst) ..... 526
Hall BM (abst) ..... 228, 228, 230, 230, 233, 235, 237
Hall M (abst) ..... 520, 638, 640
Halloran P (abst) ..... 634
Hamazaki T, Nakazawa R, Tateno S, Shishido H, Isoda K, Hattori Y, Yoshida T, Fujita T, Yano S, Kumagai A: Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients.. 81
Hamet M (abst) ..... 226
Hammer M (abst) ..... 507
Hammond TG (abst) ..... 243
Hammouche M (abst) ..... 635
Hampel G (abst) ..... 499
Hampl H (abst) ..... 563, 574
Hancock WW (abst) ..... 228, 238
Hannah MC (abst) ..... 233
Hansen HE (abst) ..... 512, 518
Hardie IR (abst) ..... 228, 237, 237
Hardonk MJ (abst) ..... 368
Hardy M (abst) ..... 644
Harper PA, Robinson JM, Hoover RL, Wright TC, Karnovsky MJ: Improved methods for culturing rat glomerular cells (Technical Note) ..... 875
Harries RHC (abst) ..... 239
Harrington J: Metabolic alkalosis (Nephrology Forum) .. 88
Harris DCH (abst) ..... 229, 230, 239
Harris JP (abst) ..... 228
Harris K (abst) ..... 638
Harrison J (abst) ..... 547
Hart A (abst) ..... 655
Harter H: *see* Kettner et al ..... 66
Hartley B (abst) ..... 506, 549
Hartmann A: *see* Langberg et al ..... 128
Harvey CE: *see* Hutchinson et al ..... 44
Harvey GK (abst) ..... 235
Hasanoglu A (abst) ..... 621
Hasanoglu E (abst) ..... 563, 621
Hassani W (abst) ..... 569
Hasslacher C (abst) ..... 499
Hatch FE Jr: *see* Dulaney et al ..... 253
Hattori Y: *see* Hamazaki et al ..... 81
Hatzigeorgiou G (abst) ..... 621
Haubenstock A (abst) ..... 535
Haughey DB (abst) ..... 563
Haunschild J (abst) ..... 499
Hauser I (abst) ..... 595
Hawkins T (abst) ..... 658
Hayslett JP: *see* Hirsch et al ..... 798
Heale WF (abst) ..... 234
Heathcote K (abst) ..... 230
Heaton A (abst) ..... 555, 563
Heazlewood A (abst) ..... 246
Heazlewood VJ: *see* Craswell et al ..... 319
Hedaya M (abst) ..... 632
Heidbreder E (abst) ..... 499
Heidland A (abst) ..... 499, 565
Heine H (abst) ..... 499
Heinker W (abst) ..... 564
Helin H (abst) ..... 621
Hellfritsch U (abst) ..... 505
Hellmann C (abst) ..... 517
Hellström I (abst) ..... 500
Hemphill G (abst) ..... 563
Henderson I (abst) ..... 550
Henderson IS (abst) ..... 564, 583
Henderson-Smart D (abst) ..... 233
Henning HV (abst) ..... 503
Henny CP (abst) ..... 611
Henrich WL: *see* Velez et al ..... 59
Hernandez M (abst) ..... 632
Hernández RM (abst) ..... 577
Hernando L (abst) ..... 626
Hernando L (abst) ..... 223
Herrera J (abst) ..... 544, 545, 545
Hersdorffer CS (abst) ..... 897
Herve JP (abst) ..... 490, 550, 564
Hervé M (abst) ..... 495, 580
Hervé MA (abst) ..... 597, 603, 603
Herzog D (abst) ..... 500
Hess B (abst) ..... 509
Hess T (abst) ..... 622
Hesse U (abst) ..... 637, 638
Hicks J (abst) ..... 506
Higgs A (abst) ..... 900
Hildebrandt HH (abst) ..... 641
Hillis AN (abst) ..... 655
Hinglais N (abst) ..... 633
Hinglais N (abst) ..... 225
Hirose H, Udo K, Kojima M, Takahashi Y, Miyakawa Y, Miyamoto K, Yoshizawa, Mayumi M: Deposition of hepatitis B e antigen in membranous glomerulonephritis: Identification by $F(ab')^2$ fragments of monoconal antibody ..... 338
Hirsch D, Kashgarian M, Boulpaep EL, Hayslett JP: Role of aldosterone in the mechanism of potassium adaptation in the initial collecting tubule ..... 798
Hirschl M (abst) ..... 522
Hishida A: *see* Kobayashi et al ..... 808
Hiwatari M (abst) ..... 231
Hjelle JT: *see* Peterson et al ..... 411
Hjelte MB (abst) ..... 571
Hjøllund E (abst) ..... 512
Hocken AG (abst) ..... 235
Hoedemaeker PJ (abst) ..... 369
Hoenich NA (abst) ..... 558, 564, 571, 612
Hoenich N (abst) ..... 555
Hogg RJ (abst) ..... 247
Hoitsma AJ (abst) ..... 366
Holdsworth SR (abst) ..... 238, 238, 239, 241, 244, 245, 245
Holdsworth SR, Bellomo R: Differential effects of steroids on leukocyte-mediated glomerulonephritis in the rabbit ..... 162
Holzer H (abst) ..... 565, 586
Homburg A (abst) ..... 617

Honda N: *see* Kobayashi et al ..... 808
Honkanen E (abst) ..... 565
Hooke DH (abst) ..... 238
Hoorntje SJ (abst) ..... 570
Hoover RL: *see* Harper et al ..... 875
Hoppe D (abst) ..... 608
Hörl WH (abst) ..... 499, 565
Hornak H (abst) ..... 624
Hornych A (abst) ..... 779
Horsch R (abst) ..... 638, 641
Hortling L (abst) ..... 565
Horvath JS (abst) ..... 228, 228, 230, 233, 235, 237
Hosokawa S (abst) ..... 500, 565
Hourmant M (abst) ..... 638
Houser M, Zimmerman B, Davidman M, Smith C, Fish A: Idiopathic hypercalciuria associated with hyperreninemia and high urinary prostaglandin E ..... 176
Howden B (abst) ..... 236, 237
Howden B (abst) ..... 645, 645
Hoyer J (abst) ..... 521, 639
Hruby Z (abst) ..... 500
Huarte E (abst) ..... 223
Hulstaert CE (abst) ..... 368
Hulter HN: Hypophosphaturia impairs the renal defense against metabolic acidosis ..... 302
Humphreys MH (abst) ..... 231
Hunt JS (abst) ..... 242
Hurst A (abst) ..... 586
Husserl F (abst) ..... 504
Hust W (abst) ..... 574
Hutchison BG (abst) ..... 231
Hutchinson TA, Thomas DC, Lemieux JC, Harvey CE: Prognostically controlled comparison of dialysis and renal transplantation ..... 44
Huyghebaert M-F: *see* Nitenberg et al ..... 744

Iacovoni P (abst) ..... 546
Iaina A (abst) ..... 500, 501
Iandolo R (abst) ..... 549
Ibarra M (abst) ..... 218
Ibels LS (abst) ..... 230, 239, 241, 243, 244
Idatte JM (abst) ..... 576
Iellamo D (abst) ..... 495, 557
Ignjatovic V (abst) ..... 566
Ihle B (abst) ..... 486
Ihle BU (abst) ..... 234
Ikonomovski J (abst) ..... 587
Ilacqua N (abst) ..... 537
Ilic S (abst) ..... 521, 566, 577
Imai T (abst) ..... 500, 565
Imbs D (abst) ..... 601
Imperiali P (abst) ..... 594, 594
Ingelmo M (abst) ..... 218, 220, 221
Innocenti D (abst) ..... 538
Ireland H (abst) ..... 591, 592
Irschik H (abst) ..... 568
Isaacson LC (abst) ..... 895, 899
Isdale JM (abst) ..... 898
Isemer FE (abst) ..... 651
Ishida Y (abst) ..... 534
Ishigami M (abst) ..... 501
Isles CG (abst) ..... 545
Isles CG (abst) ..... 900, 900, 900, 901
Isoda K: *see* Hamazaki et al ..... 81
Ivanovic D (abst) ..... 619
Ivanovski N (abst) ..... 525
Ivic MA (abst) ..... 654
Iwanaga S (abst) ..... 612
Izumi N (abst) ..... 601

Jablonski P (abst) ..... 236, 237
Jablonski P (abst) ..... 645, 645
Jackson AE (abst) ..... 238
Jackson B (abst) ..... 232, 233
Jacob ET (abst) ..... 527
Jacob GK ..... 240
Jacobs C (abst) ..... 598
Jacobsen BK (abst) ..... 642
Jacobson J (abst) ..... 625, 898
Jacobson JE (abst) ..... 639
Jacobson SH (abst) ..... 501
Jadric S (abst) ..... 534
Jahn H (abst) ..... 521, 639
Jakubowski H (abst) ..... 559
Jakubowski HD (abst) ..... 654
Janev J (abst) ..... 568
Janicka L (abst) ..... 604, 604
Janicks L (abst) ..... 569
Jankowska H (abst) ..... 604, 604
Janssen F (abst) ..... 520, 638, 639
Janssen S (abst) ..... 368
Janushkevitch TN (abst) ..... 626
Jardí R (abst) ..... 558
Jaschonek K (abst) ..... 575
Jaszczuk-Jarosz B (abst) ..... 626
Jaudon MC (abst) ..... 590
Javit O (abst) ..... 547
Jean-Jacques M (abst) ..... 644
Jeantet A (abst) ..... 602
Jedeiken R (abst) ..... 567
Jeren T (abst) ..... 566
Jeren-Strujic B (abst) ..... 566
Jervell J (abst) ..... 631
Jessen H (abst) ..... 643, 659
Jilderda JF (abst) ..... 527
Jilg W (abst) ..... 488
Jing-Dou L (abst) ..... 607
Jirka J (abst) ..... 528, 640, 640
Jofre R (abst) ..... 629
Jofré R (abst) ..... 585
John P (abst) ..... 629
Johnson AOC (abst) ..... 900, 900
Johnson J (abst) ..... 230
Johnson JJ (abst) ..... 228
Johnson JR (abst) ..... 228
Johnston CI (abst) ..... 231, 231, 232, 235
Johny KV (abst) ..... 640
Jonasson R (abst) ..... 616
Jones SP (abst) ..... 504
Joven J (abst) ..... 558, 566
Jörgensen F (abst) ..... 490
Jörgensen HE (abst) ..... 490
Joyeux H (abst) ..... 544
Julian BA: *see* McLean et al ..... 855
Jullien C (abst) ..... 648
Junco E (abst) ..... 585, 604
Jungbluth H (abst) ..... 622
Jungers P (abst) ..... 779
Junor B (abst) ..... 550
Junor BJR (abst) ..... 544, 566, 635
Juquel JP (abst) ..... 570
Jureidini KJ (abst) ..... 247

Jurkowitz MS: *see* Zager et al ..... 689
Just HO (abst) ..... 567

Kabata J (abst) ..... 511
Kachel HG (abst) ..... 501
Kaiser L, Schwartz KA, Burnatowska-Hledin MA, Mayor GH: Microcytic anemia secondary to intraperitoneal aluminum in normal and uremic rats ..... 269
Kakuk Gy (abst) ..... 529
Kala AR (abst) ..... 564
Kalicharan D (abst) ..... 368
Kalima L (abst) ..... 603
Källenius G (abst) ..... 501
Kallivretakis N (abst) ..... 580, 580
Kallmeyer JC (abst) ..... 895
Kaltwasser JP (abst) ..... 536
Kaminska Z (abst) ..... 652
Kaneko I (abst) ..... 531
Kanfer A (abst) ..... 225
Kanfer A: *see* Blanchet et al ..... 430
Kanwar YS, Carone FA: Reversible changes of tubular cell and basement membrane in drug-induced renal cystic disease ..... 35
Kao-Lo G: *see* Gleim et al ..... 683
Kaplan S (abst) ..... 594
Kapuler S (abst) ..... 500
Karagöz F (abst) ..... 616
Karamehmet M (abst) ..... 637
Karges HE (abst) ..... 653
Kariv N (abst) ..... 509
Karnovsky MJ: *see* Harper et al ..... 875
Kaschube I (abst) ..... 511
Kashgarian M: *see* Hirsch et al ..... 798
Katz F (abst) ..... 600
Kauffman RH: *see* Valentijn et al ..... 760
Kawaguchi H (abst) ..... 649
Kazatchkine M (abst) ..... 633
Kazatchkine M (abst) ..... 225
Keane W: *see* Raij et al ..... 137
Keavey PM (abst) ..... 658
Kechrid C (abst) ..... 635
Keefer CL (abst) ..... 236
Keeton GR (abst) ..... 897, 899
Kelleher SP: *see* Conger et al ..... 422
Keller F (abst) ..... 526, 595, 622
Kemp E (abst) ..... 493
Kerr DNS (abst). 492, 546, 555, 558, 561, 563, 571, 588, 612, 651, 655, 897
Keshaviah P (abst) ..... 563
Kesse-Elias M (abst) ..... 613
Kessel M (abst) ..... 563, 574
Kesselhut J (abst) ..... 230
Kessler J: *see* Bommer et al ..... 331
Kessler J (abst) ..... 540
Kessler M (abst) ..... 227
Kettner A, Goldberg A, Hagberg J, Delmez J, Harter H: Cardiovascular and metabolic responses to submaximal exercise in hemodialysis patients ..... 66
Khader AA (abst) ..... 237
Khalifa AM (abst) ..... 551
Khasabov NN (abst) ..... 623
Khosropour R (abst) ..... 502
Kidawa Z (abst) ..... 626
Kien T (abst) ..... 639
Kiersztejn M (abst) ..... 502
Kiil F: *see* Langberg et al ..... 128
Kim JK, Summer SN, Berl T: The cyclic AMP system in the inner medullary collecting duct of the potassium-depleted rat ..... 384
Kincaid-Smith P (abst) ..... 233, 234, 239, 241, 243, 245, 486
Kindler J (abst) ..... 617
Kinnaert P (abst) ..... 528, 638, 640, 657
Kirjakov Z (abst) ..... 568, 568
Kirkendol PL (abst) ..... 561
Kirubakaran MG (abst) ..... 240
Kirwin P (abst) ..... 239
Kishimoto T (abst) ..... 601, 612
Klahr S: *see* Olgaard et al ..... 791
Klaus D (abst) ..... 570
Klein B: *see* Weinstein et al ..... 741
Kletter K (abst) ..... 502, 520
Klinkmann H (abst) ..... 511
Klooker P (abst) ..... 599
Kluger G (abst) ..... 499
Knapowski J (abst) ..... 543, 551
Knapowski J: *see* Bręborowicz et al ..... 392
Kobayashi S, Nagase M, Honda N, Hishida A: Glomerular alterations in uranyl acetate-induced acute renal failure in rabbits ..... 808
Kobryn A (abst) ..... 652
Kocandrle V (abst) ..... 521, 640
Koch HG (abst) ..... 488
Kociszewska M (abst) ..... 652
Koene RAP (abst) ..... 366
Köhler H (abst) ..... 529, 617
Kojima M: *see* Hirose et al ..... 338
Kokko JP (abst) ..... 231
Kokot F (abst) ..... 502, 502, 569
Kolmos HJ (abst) ..... 567
Komarnicki M (abst) ..... 535
Konopacki J (abst) ..... 616
Koolen MI (abst) ..... 367
Koomans HA: *see* Geers et al ..... 324
Koomans HA, Geers AB, Dorhout Mees EJ: Plasma volume recovery after ultrafiltration in patients with chronic renal failure ..... 848
Koopmans P (abst) ..... 367
Kopeé W (abst) ..... 500
Kopp KF (abst) ..... 567
Koppensteiner R (abst) ..... 522
Kopper L (abst) ..... 513
Kopsa H (abst) ..... 535, 567, 575, 641
Korda A (abst) ..... 233
Korpela M (abst) ..... 621
Korzets Z (abst) ..... 567
Kosicka T (abst) ..... 522
Köstering H (abst) ..... 596
Kostic S (abst) ..... 566, 577, 600, 608, 609
Koudstaal J (abst) ..... 369
Koumantakis G (abst) ..... 241
Kovarbasic B (abst) ..... 566
Kovarik J (abst) ..... 568
Kovithavongs T (abst) ..... 633
Kowalczyk J (abst) ..... 652
Kozlovskaya LV (abst) ..... 623
Kraev Z (abst) ..... 568, 568
Kramer P (abst) ..... 596, 641
Kramer W (abst) ..... 611
Krane K (abst) ..... 550
Kraus ES: *see* Bender et al ..... 436
Krause R (abst) ..... 568
Kreisberg J: *see* Matthys et al ..... 153

Kremer GD (abst) ..... 657
Kremer Hovinga TK (abst) ..... 367
Kreusser W (abst) ..... 564, 638, 641
Krier C (abst) ..... 564
Kronzon I (abst) ..... 552
Krouri A (abst) ..... 569
Kruse-Thams KH (abst) ..... 505
Ksiazek A (abst) ..... 569, 569
Kubes L (abst) ..... 557
Kuczera M (abst) ..... 502
Kuehn-Freitag G (abst) ..... 596
Kuentz F (abst) ..... 552, 552, 569
Kumagai A: *see* Hamazaki et al ..... 81
Kumanov Ch (abst) ..... 568
Kumar AS (abst) ..... 629, 640
Kusma G (abst) ..... 629, 640
Kuttenn F (abst) ..... 779

Labeeuw M (abst) ..... 502, 507
Lacour B (abst) ..... 496
Ladefoged J (abst) ..... 502, 642, 642, 648
Lafforgue B (abst) ..... 570
LaGreca G (abst) ..... 539, 539, 590
LaGreca S (abst) ..... 589
Lagrue G (abst) ..... 780
Laidley L (abst) ..... 896
Lakier JB (abst) ..... 582
Lama G (abst) ..... 493
Lambrey G (abst) ..... 553, 603
Lameire N: *see* Fiselier et al ..... 823
Lamperi S (abst) ..... 622, 632, 641
Landini S (abst) ..... 503, 536, 537
Landini V (abst) ..... 498, 546
Lane DA (abst) ..... 591, 592
Lang G (abst) ..... 536
Lang I (abst) ..... 601
Langberg H, Hartmann A, Kiil F: Glomerular filtration rate and plasma pH as determinants of phosphate reabsorption ..... 128
Lange H (abst) ..... 642, 653
Langeveld JPM (abst) ..... 367
Langhoff E (abst) ..... 502, 583, 642, 642, 642
Lapierre L (abst) ..... 587
Larm O (abst) ..... 571
Larsen M (abst) ..... 490
Larsen S (abst) ..... 490
Larsson R (abst) ..... 571
Lattanzi R (abst) ..... 657
Lattes C (abst) ..... 644
Lauer C (abst) ..... 239
Laurent B (abst) ..... 497, 620
Laurent G (abst) ..... 549, 570
Laurent G: *see* Giuliano et al ..... 838
Laurent MC (abst) ..... 780
Laurent P (abst) ..... 497, 620
Lauria F (abst) ..... 645
Lavaud S (abst) ..... 490
Laville M (abst) ..... 493
Laville M (abst) ..... 225
Lawton WL (abst) ..... 496
Lazarus JM: *see* Hakim et al ..... 194
Lazebnik R (abst) ..... 534
Lazic N (abst) ..... 587
Lazowski T (abst) ..... 652
Lazzeri M (abst) ..... 498
Lea EJA (abst) ..... 504
Lecic N (abst) ..... 600
Leclerc JL (abst) ..... 656
Lederle RM (abst) ..... 570
Lee BS (abst) ..... 574
Lee HA (abst) ..... 652
Lefebvre A (abst) ..... 576
Lefkowith JB, Okegawa T, DeSchryver-Kecskemeti K, Needleman P: Macrophage-dependent arachidonate metabolism in hydronephrosis ..... 10
Leflon A (abst) ..... 580
Leflon P (abst) ..... 508, 553, 603, 603, 603
Lefrançois N (abst) ..... 493, 633
LeFrancois N (abst) ..... 225, 226
Legarreta M (abst) ..... 533
Legrain M (abst) ..... 591
Leguy P (abst) ..... 564
Leimenstoll GE (abst) ..... 516, 643, 643, 659
Leimenstoll G (abst) ..... 537, 610
Leitao P (abst) ..... 546
Leitienne P (abst) ..... 493
Lemann J Jr: *see* Maierhofer WJ et al ..... 752
Lemieux JC: *see* Hutchinson et al ..... 44
Lemke R (abst) ..... 570
Lenhard V (abst) ..... 643, 651
Lennes G (abst) ..... 548
Le Pogamp P (abst) ..... 226
Leroy JP (abst) ..... 490
Lessing MPA (abst) ..... 896
Leumann E (abst) ..... 493
Leung ACT (abst) ..... 564, 583
Leunissen KML (abst) ..... 570
Leusen I: *see* Fiselier et al ..... 823
Léveillé M (abst) ..... 587
Levenson JA: *see* London et al ..... 342
Levett D (abst) ..... 571
Levi J: *see* Weinstein et al ..... 741
Levin J (abst) ..... 897
Levin NW (abst) ..... 550, 582
Levrero M (abst) ..... 647
Leyssac PP (abst) ..... 493
Lichtendahl DHE (abst) ..... 599
Liebich H (abst) ..... 575
Light PD (abst) ..... 589
Lijnen P: *see* Fiselier et al ..... 823
Lin J (abst) ..... 644
Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age ..... 861
Lindenau K (abst) ..... 496
Lindholm B (abst) ..... 571
Lindic J (abst) ..... 503
Lindsay RM (abst) ..... 503, 571, 609, 609
Ling N (abst) ..... 580, 580
Linkesch W (abst) ..... 568
Lins LE (abst) ..... 500, 501, 571, 616
Lins RL (abst) ..... 607
Linton AL (abst) ..... 503, 571, 609, 609
Liosi C (abst) ..... 537
Lioté F (abst) ..... 779
Lippa S (abst) ..... 579
Liska M (abst) ..... 640
Little PJ (abst) ..... 237
Ljapcev R (abst) ..... 525
LLorach I (abst) ..... 614
LLorach M (abst) ..... 614
LLoveras J (abst) ..... 614

Lloyd HM: *see* Craswell et al. 319
Lloyd S (abst) 561
Lobdell DD (abst) 572
Löber M (abst) 490
Lockington TJ (abst) 531
Lőcsey L (abst) 529, 572
Lőcsey L (abst) 532
Löffler W (abst) 628
Logering HI (abst) 654
Lojacono L (abst) 644
Lolin S (abst) 526
Lomax-Smith JD (abst) 239
Lonati F (abst) 527, 527
London AM: *see* London et al 342
London GM, Levenson JA, London AM, Simon AC, Safar ME: Systemic compliance, renal hemodynamics, and sodium excretion in hypertension 342
Lopez Novoa JM (abst) 219
López Novoa JM (abst) 626
López Pedret J (abst) 579
López-Pedret J (abst) 578, 578, 579
López-Pedret J (abst) 222, 222, 223
LoPiccolo G (abst) 530, 572
Lopot F (abst) 527, 527
Lorenz P (abst) 519, 541
Lorenzen I (abst) 490
Lorenzo V (abst) 528
Lorieo D (abst) 644
Lornoy W (abst) 522
Lorusso P (abst) 519
Lote CJ (abst) 629
Louis F (abst) 573, 573, 591
Løve Jepsen F (abst) 643
Low E (abst) 240
Lozano A (abst) 221
Lozano L (abst) 223
Lubelza R (abst) 590
Lubrano R (abst) 605
Lucci MS (abst) 231
Luciani A (abst) 618
Ludwig HJ (abst) 639
Ludwig-Koehn H (abst) 503
Lugari R (abst) 524, 618
Luitingh-van der Veen JM (abst) 582
Lule J (abst) 556
Lum GM: *see* Sedman et al 201
Lüneburg M (abst) 637
Luño J (abst) 657
Lupetti S (abst) 560
Lusky A (abst) 501
Lusvarghi E (abst) 624
Lydnyard PM (abst) 550
Lynn KL (abst) 242, 242

Maassen G (abst) 643
Maccarinelli G (abst) 560
Maccarone M (abst) 531, 532
Macdonald G (abst) 245, 247
Maceira B (abst) 220
Macias J (abst) 221
Macias J (abst) 625
Macias JF (abst) 514
MacLeod A (abst) 644
Madaio MP, Salant DJ, Adler S, Darby C, Couser WG: Effect of antibody charge and concentration on deposition of antibody to glomerular basement membrane 397
Madia D (abst) 617
Madsen S (abst) 507, 583, 642, 642
Maeda T (abst) 501
Maekawa M (abst) 601, 612
Maekawa T (abst) 601
Mágel F (abst) 541
Maggiore Q (abst) 495, 557, 586, 613
Maglionico G (abst) 492
Magnussen H (abst) 583
Magyarossy E (abst) 513
Mahieu P (abst) 511
Mahiout A (abst) 563, 574
Mahony JF (abst) 229, 229, 234
Maidment CGH (abst) 504
Maierhofer WJ, Lemann J Jr, Gray RW, Cheung HS: Dietary calcium and serum 1,25-$(OH)_2$-vitamin D concentrations as determinants of calcium balance in healthy men 752
Maiga K (abst) 591
Maioli M (abst) 617
Maiorca R (abst) 504, 597, 644
Maj M (abst) 491
Majelyne WM: *see* Van de Vyver et al 451
Malberti F (abst) 491, 491, 574
Maldague P: *see* Giuliano et al 838
Mallafre JM (abst) 219
Mallamace A (abst) 615
Mallamacé A (abst) 537
Mallamaci F (abst) 613
Malluche HH, Faugere M-C, Fanti P, Price PA: Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis 869
Man NK (abst) 549, 553
Manca N (abst) 597
Mancini P (abst) 586
Mandema E (abst) 368
Mandreoli M (abst) 635
Mandressi A (abst) 614
Mangiarotti G (abst) 584
Man in 't Veld J (abst) 368
Manitius A (abst) 510, 511
Mann H (abst) 574, 574
Mannarino T (abst) 491
Mannella P (abst) 599
Mannhalter C (abst) 575
Manning P (abst) 644
Manno C (abst) 551
Manns M (abst) 529
Mansour M (abst) 513
Marangoni R (abst) 487
Marcén R (abst) 508, 644
Marcuccio F (abst) 549
Mareckova O (abst) 521
Margioris A (abst) 580
Margolius LP (abst) 898
Marié A (abst) 603
Mariné M (abst) 218, 221
Marino IR (abst) 548
Marino O (abst) 488
Marosi L (abst) 520, 522
Marques M (abst) 598
Marsh F (abst) 533, 544
Marsh FP (abst) 611
Marshall VC (abst) 645, 645
Marshall VC (abst) 236, 237, 245
Martegani M (abst) 618

Martens H (abst) ... 575
Martens J (abst) ... 522
Martin E (abst) ... 644
Martin J (abst) ... 514
Martín L (abst) ... 220, 221
Martina G (abst) ... 509
Martinelli F (abst) ... 575, 593
Martinelli G (abst) ... 631
Martinelli GP (abst) ... 645
Martinez E (abst) ... 590
Martinez JM (abst) ... 506
Martínez ME (abst) ... 218
Martinez T (abst) ... 634
Martínez Ara J (abst) ... 218
Martínez-Brotons J (abst) ... 218
Martínez-Malo A (abst) ... 219
Martinez-Vea A (abst) ... 222, 222
Martini PF (abst) ... 602
Martín-Malo A (abst) ... 222, 485, 575
Martins R (abst) ... 559
Martín-Vasallo P (abst) ... 220
Martorell J (abst) ... 220
Marugc K (abst) ... 565
Mascart JY (abst) ... 590
Mascart-Lemone F (abst) ... 555
Masdeu S (abst) ... 566
Masi F (abst) ... 487
Masiak M (abst) ... 601
Masin G (abst) ... 525
Mason J, Torhorst J, Welsch J: Role of the medullary perfusion defect in the pathogenesis of ischemic renal failure ... 783
Mason R (abst) ... 644
Masramon J (abst) ... 614
Masselot JP (abst) ... 576
Massry SG: *see* Brautbar et al ... 18
Mastrangelo F (abst) ... 576, 576, 576, 577
Mastrolitti G (abst) ... 511
Matesanz R (abst) ... 508, 577, 584
Mathe JC (abst) ... 607
Mather A (abst) ... 644
Mathews DC (abst) ... 245
Mathillas O (abst) ... 645
Matlou SM (abst) ... 900
Matthews PG (abst) ... 232
Matthys E, Patel Y, Kreisberg J, Stewart JH, Venkatachalam M: Lipid alterations induced by renal ischemia: Pathogenic factor in membrane damage ... 153
Matturri L (abst) ... 616
Maude DL: *see* Gleim et al ... 683
Maukner P (abst) ... 574
Mauras Y (abst) ... 549
Mauro MM (abst) ... 491, 522
Mavi V (abst) ... 562
Mavrikakis M (abst) ... 621
Mawson P (abst) ... 538
Mayayo T (abst) ... 644
Mayor GH: *see* Kaiser et al ... 269
Mayr HU (abst) ... 577
Mayumi M: *see* Hirose et al ... 338
Mazzarella V (abst) ... 585
Mazzuca A (abst) ... 594
McCabe R (abst) ... 644
McClure J (abst) ... 229
McDermott D (abst) ... 246
McGinley E (abst) ... 234, 238
McGiven AR (abst) ... 242
McGonigle RJS (abst) ... 504
McGrath B (abst) ... 232, 235
McGurk J (abst) ... 563
McIntosh M (abst) ... 566
McKenna BA (abst) ... 524, 623
McLean RH, Wyatt RJ, Julian BA: Complement phenotypes in glomerulonephritis: Increased frequency of homozygous null C4 phenotypes in IgA nephropathy and Henoch-Schönlein purpura ... 855
McManamon PJ: *see* Churchill et al ... 190
McMaster P (abst) ... 629, 629
McWhinnie DL (abst) ... 542
Megevand M (abst) ... 226
Mehamha H (abst) ... 590
Mehls O (abst) ... 497
Mehta RL (abst) ... 646
Meihaus J (abst) ... 229
Meijer S (abst) ... 366, 368, 368
Meijer S (abst) ... 510, 524, 528, 656, 658
Meisinger V (abst) ... 568
Melby JC: Primary aldosteronism (Nephrology Forum) ... 769
Melin JP (abst) ... 490
Meloni C (abst) ... 546, 585
Memmos D (abst) ... 652
Memoli B (abst) ... 491
Menard J: *see* Nochy et al ... 85
Mendez R (abst) ... 632, 632, 632, 632, 646, 646, 646, 646
Menta R (abst) ... 489
Mercuriali F (abst) ... 646
Merdjan H (abst) ... 779
Méry JP (abst) ... 225, 226
Méry JP: *see* Blanchet et al ... 430
Meshiah D (abst) ... 596
Messina A (abst) ... 239
Mestdagh J (abst) ... 522
Mestre M (abst) ... 218, 220
Metaxas P (abst) ... 588
Metreweli C (abst) ... 237
Metz U (abst) ... 504
Meunier PJ (abst) ... 490, 548
Meyer GJ (abst) ... 505, 516
Meyer KH (abst) ... 529, 627
Meyers AM (abst) ... 896, 897, 897, 898, 898, 898, 899, 900
Michael J (abst) ... 531, 629, 629
Michalik R (abst) ... 653
Michel C (abst) ... 523
Michel F (abst) ... 542
Micossi P (abst) ... 598
Miescher PA (abst) ... 619
Miettinen A (abst) ... 514, 514
Mignon F (abst) ... 523
Mignot P (abst) ... 225
Migone L (abst) ... 485
Milcent T (abst) ... 490
Milcent T (abst) ... 227
Miguel Alonso JL (abst) ... 218
Milenkovic M (abst) ... 566, 577
Miljkovic P (abst) ... 600
Miller J (abst) ... 608
Miller NL: *see* Sedman et al ... 201
Miller PFW (abst) ... 647
Miller T: Pyelonephritis: The role of cell-mediated immunity defined in a congenitally athymic rat ... 808
Millet VG (abst) ... 508
Milne FJ (abst) ... 896, 896, 896, 897, 900, 900

Milosavljevic Lj (abst) ..... 600
Mimram A (abst) ..... 495
Minar E (abst) ..... 522, 530, 578, 578
Minetti L (abst) ..... 491, 491, 539, 542, 549, 574, 624, 647
Mioli V (abst) ..... 498, 636
Mion C (abst) ..... 544, 577, 598, 598, 648, 648, 779
Miralles J (abst) ..... 625
Miranda B (abst) ..... 494, 647
Mirapeix E (abst) ..... 505, 578
Mirapeix E (abst) ..... 220, 222, 223
Mircescu G (abst) ..... 604
Mittelstaedt GV (abst) ..... 505
Miyakawa Y: *see* Hirose et al ..... 338
Miyamoto K: *see* Hirose et al ..... 338
Mjåland S (abst) ..... 610
Modan M (abst) ..... 501
Möhring K (abst) ..... 581
Molenaar JC (abst) ..... 367
Molet B (abst) ..... 639
Moll JL (abst) ..... 219, 220
Molzahn M (abst) ..... 526, 596, 622
Mombelloni S (abst) ..... 504
Monaco PI (abst) ..... 605
Monari C (abst) ..... 657
Monetti N (abst) ..... 519
Monnens LAH (abst) ..... 367
Monnens L: *see* Fiselier et al ..... 823
Montanari A (abst) ..... 635
Montemurro NE (abst) ..... 562
Monti G (abst) ..... 635
Monti L (abst) ..... 598
Montinaro AM (abst) ..... 576, 576, 577
Montoliu J (abst) ..... 505, 546, 578, 578, 579, 579, 622, 623
Montoliu J (abst) ..... 221, 222, 222, 223
Monzón A (abst) ..... 219
Moore PA: *see* Peterson et al ..... 411
Mooy MC (abst) ..... 611
Mora J (abst) ..... 220, 221
Morachiello P (abst) ..... 536, 537
Morales JM (abst) ..... 494, 506, 508
Moran J (abst) ..... 230, 244, 246
More I (abst) ..... 566
Moreau JF (abst) ..... 658
Moreira P (abst) ..... 587
Morelle V (abst) ..... 522
Morelli E (abst) ..... 498
Moreno A (abst) ..... 544
Moreno E (abst) ..... 485
Moreno E (abst) ..... 219, 222
Morgan J: *see* Churchill et al ..... 190
Mori R (abst) ..... 579
Morinière P (abst) ..... 579, 580, 589, 603, 603
Morinière P (abst) ..... 553, 603
Morita T (abst) ..... 612
Morosetti M (abst) ..... 546, 585
Morrison ND (abst) ..... 235
Mortensen E (abst) ..... 518
Morzycka M (abst) ..... 652
Mota A (abst) ..... 220
Mottola G (abst) ..... 498, 636
Mountokalakis T (abst) ..... 506, 580, 580
Mourad G (abst) ..... 648, 648
Mouton A (abst) ..... 562
Movilli E (abst) ..... 504
Mudaliar MY (abst) ..... 247
Mukhin NA (abst) ..... 623, 626
Mulder AW (abst) ..... 570
Mulder C (abst) ..... 582
Mulder J (abst) ..... 524
Mulder NH (abst) ..... 368
Mulero JF (abst) ..... 590
Mulinari RA (abst) ..... 594
Müller G (abst) ..... 575
Müller-Hermelink K (abst) ..... 643
Müller-Wiefel DE (abst) ..... 580
Munaretto G (abst) ..... 581
Mundo A (abst) ..... 557
Muolo A (abst) ..... 650, 651
Murawski BJ: *see* Gutman et al ..... 459
Murphy BF (abst) ..... 233, 242, 2a107
Musialik D (abst) ..... 522
Mustafa A (abst) ..... 517
Mustonen J (abst) ..... 621
Myburgh J (abst) ..... 898, 898, 900
Mydlik M (abst) ..... 523, 648

Nagase M: *see* Kobayashi et al ..... 808
Nagel JE: *see* Bender et al ..... 436
Nagy Z (abst) ..... 513
Naicker S (abst) ..... 895
Naidoo K (abst) ..... 899
Naito H (abst) ..... 593
Najarian JS (abst) ..... 632
Nakagawa S (abst) ..... 534
Nakao A: *see* Shimizu et al ..... 785
Nakazawa R: *see* Hamazaki et al ..... 85
Nancollas GH: *see* Gaur et al ..... 767
Napoli M (abst) ..... 576, 576, 577
Nardi L (abst) ..... 595
Naret C (abst) ..... 549
Narins RG: Mild hypertension: A therapeutic dilemma (Nephrology Forum) ..... 881
Naso A (abst) ..... 494, 510
Naumovic T (abst) ..... 526, 526
Navar LG: *see* Rosivall et al ..... 263
Navas J (abst) ..... 508
Navratil H (abst) ..... 648
Neale TJ, Woodroffe AJ, Wilson CB: Spontaneous glomerulonephritis in rabbits: Role of a glomerular capillary antigen ..... 701
Needleman P: *see* Lefkowith et al ..... 10
Neild GH (abst) ..... 538
Neilson EG: *see* Goldstein et al ..... 733
Nelson JF (abst) ..... 236
Neri M (abst) ..... 524
Nesti E (abst) ..... 538
Neuweiler W (abst) ..... 581
Nevins TE (abst) ..... 581
Neyer U (abst) ..... 581
Nguyen-Simonnet H: *see* Gauthier et al ..... 170
Niall J (abst) ..... 230, 246
Nicholls A (abst) ..... 582
Nicolotti V (abst) ..... 544, 618
Niedermayer W (abst) ..... 505, 516, 537, 610, 637, 643, 643, 659
Nielsen B (abst) ..... 487, 601
Nielsen L (abst) ..... 583, 648
Nielsen M (abst) ..... 515
Nielubowicz J (abst) ..... 652
Nieto J (abst) ..... 647
Nikolaides P (abst) ..... 498
Nikolakakis NI (abst) ..... 523, 582
Ninane V (abst) ..... 606

Ninin D (abst) ..... 897, 898
Nishimoto K (abst) ..... 601
Nishimura M (abst) ..... 649
Nishio T (abst) ..... 500, 565
Nitenberg A, Huyghebaert M-F, Blanchet F, Amiel C: Analysis of increased myocardial contractility during sodium acetate infusion in humans ..... 744
Niwa M (abst) ..... 612
Noack C (abst) ..... 517
Nochy D (abst) ..... 225
Nochy D, Bariety J, Camilleri JP, Barres D, Corvol P, Menard J: Diminished number of renin-containing cells in kidney biopsy samples from hypertensive women immediately postpartum: An immunomorphologic study (Technical Note) ..... 85
Nöel L-H: *see* Ganeval et al ..... 1
Nolan PI (abst) ..... 231
Nolasco F (abst) ..... 506, 506, 649
Nonaka M (abst) ..... 500
Nonaka T: *see* Shimizu et al ..... 785
Nordon R (abst) ..... 244
Norstedt B (abst) ..... 500
Norstedt E (abst) ..... 500
Nouwen EJ: *see* Giuliano et al ..... 838
Novinga TKK (abst) ..... 367
Nozaki H (abst) ..... 649
Nuzzi F (abst) ..... 492, 493, 498, 636
Nuzzo V (abst) ..... 576

Ockhuizen Th (abst) ..... 523, 524
Odell RA (abst) ..... 234
Oe PL (abst) ..... 582, 605
Offerman JJG (abst) ..... 368
Offermann G (abst) ..... 596, 622
Ogawa H (abst) ..... 593
Ogg CS (abst) ..... 506, 538, 656
Oh HK (abst) ..... 582
Ohgke H (abst) ..... 583
Oka H: *see* Shimizu et al ..... 785
Okegawa T: *see* Lefkowith et al ..... 10
Okumura T (abst) ..... 565
Olame A (abst) ..... 523
Oldenburg B (abst) ..... 247
Olgaard K, Finco D, Schwartz J, Arbelaez M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E: Effect of 24, 25$(OH)_2D_3$ on PTH levels and bone histology in dogs with chronic uremia ..... 791
Olgaard K (abst) ..... 507, 583, 642, 642, 642
Olier P (abst) ..... 521
Oliva JA (abst) ..... 219
Oliveira L (abst) ..... 559
Olmeo NA (abst) ..... 615, 615, 615
Olmer M (abst) ..... 539
Olmos A (abst) ..... 558, 566
Olmos M (abst) ..... 219
Olsson P (abst) ..... 571
O'Malley M (abst) ..... 230
Omar OF (abst) ..... 629
Oner Z (abst) ..... 562, 637
Onieva J (abst) ..... 221, 222
Ono K (abst) ..... 583
Opelz G (abst) ..... 643, 651
Oppermann F (abst) ..... 557
Orange G (abst) ..... 583
Orange GV (abst) ..... 564
Orfila A (abst) ..... 614
Orhaner B (abst) ..... 485
Orkiszewska A (abst) ..... 652
Orlowski T (abst) ..... 652
Ornt DB (abst) ..... 646
Orofino L (abst) ..... 577, 584
Ørskov H (abst) ..... 512
Orte L (abst) ..... 577, 584
Ortega O (abst) ..... 223
Ortuño J (abst) ..... 577, 584
Ortuño J (abst) ..... 508, 644, 650
Ortuno MT (abst) ..... 506
Osipova IN (abst) ..... 626
Ota K (abst) ..... 531
Ottavioli JN (abst) ..... 780
Otte J (abst) ..... 520
Otten B (abst) ..... 229
Otting U (abst) ..... 517
Otubo O (abst) ..... 649
Oulès R (abst) ..... 483, 483, 483, 542, 542, 598, 779
Owen JP (abst) ..... 492, 546
Ozen B (abst) ..... 562
Ozogul Y (abst) ..... 562
özturk M (abst) ..... 563
özüer M (abst) ..... 584

Paar D (abst) ..... 654
Pabico RC (abst) ..... 524, 623
Pacitti A (abst) ..... 584, 584
Padovano I (abst) ..... 595
Paganelli E (abst) ..... 485
Paidlik A (abst) ..... 642
Pak KY (abst) ..... 244
Palla R (abst) ..... 524, 524
Pallardó L (abst) ..... 219, 220
Palma JL (abst) ..... 584
Palmieri P (abst) ..... 532
Panadero J (abst) ..... 220
Panayiloutou H (abst) ..... 897, 898
Pandin M (abst) ..... 539
Pankiewicz T (abst) ..... 567
Pantchev P (abst) ..... 568
Pantovic R (abst) ..... 600, 625, 625
Pantucek M (abst) ..... 557
Panzer S (abst) ..... 578
Papadimitriou M (abst) ..... 485, 553, 588, 652
Pappani A (abst) ..... 494
Parada J (abst) ..... 494, 647
Paraskevakou H (abst) ..... 621
Paravicini M: *see* Stahl et al ..... 30
Parkinson IS (abst) ..... 555
Parlongue F (abst) ..... 648
Parmeggiani A (abst) ..... 618
Parmentier M (abst) ..... 246
Parnham AJ (abst) ..... 529
Parsons F (abst) ..... 588
Parsoo I (abst) ..... 895
Parvin SP (abst) ..... 638
Pasciucco A (abst) ..... 616, 630
Pascoe MD (abst) ..... 625, 895, 895
Pascual R (abst) ..... 219
Paskalidou E (abst) ..... 553
Passerini P (abst) ..... 614
Pasternack A (abst) ..... 621
Pata C (abst) ..... 491
Patel Y: *see* Matthys et al ..... 153
Pathouli C (abst) ..... 506

Patteron D (abst) ..... 234
Patterson R (abst) ..... 582
Pattyn VM: *see* Giuliano et al ..... 838
Paulus GJ: *see* Giuliano et al ..... 838
Pavanello L (abst) ..... 613
Pavlovic N (abst) ..... 609
Payne RH: *see* Churchill et al ..... 190
Paz R (abst) ..... 559
Pea B (abst) ..... 547, 547
Peacock M (abst) ..... 507
Pearson JE (abst) ..... 561
Pearson S (abst) ..... 564
Pecchini F (abst) ..... 507, 560
Pecchini F: *see* Usberti et al ..... 351
Pecoraro C: *see* Usberti et al ..... 351
Peddie BA (abst) ..... 240, 242, 243
Pedersen O (abst) ..... 512
Pedrotti M (abst) ..... 539
Peer G (abst) ..... 534, 534
Peer P: *see* Fiselier et al ..... 823
Pehrsson K (abst) ..... 616
Pélissier C (abst) ..... 779
Pellet MV: *see* Gauthier et al ..... 170
Peña L (abst) ..... 221
Pennec Y (abst) ..... 564
Pepper P (abst) ..... 247
Peral V (abst) ..... 544, 545, 545
Perazzini L (abst) ..... 558
Perego A (abst) ..... 549
Pérez J (abst) ..... 221
Perez MD (abst) ..... 590
Perez R (abst) ..... 485
Pérez R (abst) ..... 219
Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, Rivera F, Rodés J: Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis ..... 72
Pérez Fontán M (abst) ..... 223
Perez Garcia A (abst) ..... 585
Perez Garcia R (abst) ..... 604
Pérez García R (abst) ..... 629, 657
Perez Landeral J (abst) ..... 545
Pérez Pérez AJ (abst) ..... 585
Perez-Garcia R (abst) ..... 630
Perin N (abst) ..... 494, 510
Perlmutter N (abst) ..... 520
Perkins R (abst) ..... 247
Pernicka E (abst) ..... 540
Perricone R (abst) ..... 585
Perrino ML (abst) ..... 542
Persijn GG (abst) ..... 649, 650
Persson AEG: *see* Wahlberg et al ..... 294
Petek W (abst) ..... 586
Peters DK: *see* Rees et al ..... 444
Petersen J (abst) ..... 585
Peterson DR, Hjelle JT, Carone FA, Moore PA: Renal handling of plasma high density lipoprotein ..... 411
Petitjean P (abst) ..... 639
Petrella E (abst) ..... 593
Petrie JJB (abst) ..... 228, 230, 237, 237
Petrovic J (abst) ..... 554
Pettersson BA, Aperia A, Elinder G: Pathophysiological changes in rat kidneys with partial ureteral obstruction since infancy ..... 122
Pfab R (abst) ..... 567
Philip T (abst) ..... 493
Phippard AF (abst) ..... 235
Phipparel A (abst) ..... 233
Piatti PM (abst) ..... 650
Piazza A (abst) ..... 605, 654
Piazza V (abst) ..... 593
Picardi L (abst) ..... 593
Picca M (abst) ..... 560, 560, 560, 586
Piccinini M (abst) ..... 593
Piccoli G (abst) ..... 580, 510, 636
Piepsz A (abst) ..... 520
Piera C (abst) ..... 546
Pierre D (abst) ..... 225
Piers DA (abst) ..... 528
Piers-Becht GPM (abst) ..... 510
Pietrzak I (abst) ..... 535
Piette Y (abst) ..... 587
Pincherle G (abst) ..... 586
Pinggera WF (abst) ..... 568
Pinto J (abst) ..... 546
Piñol J (abst) ..... 590
Pirich K (abst) ..... 530
Piron M (abst) ..... 607
Pirson Y (abst) ..... 649
Pisani F (abst) ..... 654
Piskorzynska U (abst) ..... 510
Pitts TO: *see* Dominguez et al ..... 404
Pizzarelli F (abst) ..... 507, 586
Pizzi C (abst) ..... 646
Plante GE (abst) ..... 513
Platsakis C (abst) ..... 506, 580, 580
Platts M (abst) ..... 582
Platz P (abst) ..... 642
Plebani AM (abst) ..... 560
Plener U (abst) ..... 628
Ploeg R (abst) ..... 649, 650
Pocheville M (abst) ..... 538
Poggio F (abst) ..... 593
Pogglitsch H (abst) ..... 565, 586
Poignet JL (abst) ..... 549
Pokorná I (abst) ..... 523
Polak A (abst) ..... 552
Polenakovic M (abst) ..... 525, 525
Poli F (abst) ..... 646
Poli L (abst) ..... 657
Politi L (abst) ..... 519
Pollack AJ (abst) ..... 243
Pollet DE: *see* Giuliano et al ..... 838
Pommer W (abst) ..... 596
Ponce P (abst) ..... 587
Pons JM (abst) ..... 546
Ponticelli C (abst) ..... 545, 614, 633
Pontin A (abst) ..... 625, 898
Pontin AR (abst) ..... 639
Pontoriero G (abst) ..... 491, 491
Popp-Snijders C (abst) ..... 582
Posen S (abst) ..... 229, 234
Posner B (abst) ..... 580
Post KG (abst) ..... 526
Potgeiter CD (abst) ..... 897
Pouliquen M (abst) ..... 648
Pourrat JP (abst) ..... 556
Pouteil-Noble C (abst) ..... 633, 650
Power D (abst) ..... 644
Pozet N (abst) ..... 502, 507
Pozet N (abst) ..... 226
Pozza G (abst) ..... 598

Pozzato M (abst) ..... 636
Pozzetti G (abst) ..... 498
Pozzoli E (abst) ..... 630
Praga M (abst) ..... 494, 506, 508, 647
Pras M (abst) ..... 616
Pratas J (abst) ..... 559
Pratesi G (abst) ..... 560
Prati E (abst) ..... 597
Prati GF (abst) ..... 650, 651
Prát V (abst) ..... 521
Precht K (abst) ..... 512
Predergast J (abst) ..... 230
Preibsch W (abst) ..... 602
Preiksaitis J (abst) ..... 633
Prejac M (abst) ..... 566
Preud'homme J-L: *see* Ganeval et al ..... 1
Pribylincová V (abst) ..... 648
Price J: *see* Craswell et al ..... 319
Price PA: *see* Malluche et al ..... 869
Prieto C (abst) ..... 632, 647
Prieto M (abst) ..... 219, 220
Primo G (abst) ..... 656
Pritzl P: *see* Adler et al ..... 830
Proppe D (abst) ..... 597
Proud G (abst) ..... 555
Provoost AP (abst) ..... 367
Prud'homme M (abst) ..... 587
Pruna A (abst) ..... 496, 508
Prutchansky A (abst) ..... 538
Pryor JS (abst) ..... 587
Psarakos K (abst) ..... 652
Puddey IB (abst) ..... 242
Pugsley DJ (abst) ..... 229, 240
Purroy A (abst) ..... 219, 220
Puschett DB: *see* Dominguez et al ..... 404
Puschett JB: *see* Dominguez et al ..... 404
Pussell B (abst) ..... 243
Pynsent PB (abst) ..... 587

Quarello F (abst) ..... 508
Queirolo C (abst) ..... 618, 620
Quereda C (abst) ..... 508, 584, 644, 650
Quinn JM (abst) ..... 228

Rabinovitch M (abst) ..... 512
Racelis D (abst) ..... 645
Radaelli L (abst) ..... 488, 539, 624
Radl MC: *see* Valentijn et al ..... 760
Radlovic O (abst) ..... 587
Radmilovic A (abst) ..... 554, 587
Radovanovic LJ (abst) ..... 587
Rae D (abst) ..... 236
Ragni R (abst) ..... 602
Rahman H (abst) ..... 588
Raidis C (abst) ..... 588
Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats ..... 137
Raiteri M (abst) ..... 616, 631
Raman GV (abst) ..... 597
Rambausek M (abst) ..... 488, 509, 540
Ramey W (abst) ..... 644
Ramée MP (abst) ..... 512
Ramos A (abst) ..... 536
Ramos E (abst) ..... 589
Ramos JI (abst) ..... 541
Ramos JM (abst) ..... 563
Ramos J (abst) ..... 519
Ramos OL (abst) ..... 533, 594, 634
Ramos O: Malignant hypertension: The Brazilian experience (Nephrology Forum) ..... 209
Ramsden C (abst) ..... 647
Ramzy M (abst) ..... 623, 623
Ranabaldo C (abst) ..... 495
Randerson DH (abst) ..... 244, 246
Raneri G (abst) ..... 615
Rao MM (abst) ..... 247
Rathaus M (abst) ..... 509
Ravenscroft PJ (abst) ..... 237
Ravetto C (abst) ..... 620
Rawer P (abst) ..... 588
Raymakers JA (abst) ..... 515
Raymond P (abst) ..... 570
Rayón M (abst) ..... 219
Read DJ (abst) ..... 588, 610
Rebaiz K (abst) ..... 780
Rebeschini M (abst) ..... 488
Recchia G (abst) ..... 650, 651
Reed WP (abst) ..... 589
Rees AJ (abst) ..... 630, 659
Rees AJ, Peters DK, Amos N, Welsh KI, Batchelor JR: The influence of HLA-linked genes on the severity of anti-GBM antibody-mediated nephritis ..... 444
Reggio A (abst) ..... 537
Reif MC, Troutman SL, Schafer JA: Sustained response to vasopressin in isolated rat cortical collecting tubule ..... 725
Reinhardt U (abst) ..... 575
Reisin E (abst) ..... 561
Reitter B (abst) ..... 525
Rekola S (abst) ..... 509
Remezy M (abst) ..... 489, 541
Renaud H (abst) ..... 589
Reneltová I (abst) ..... 521, 640, 640
Reni F (abst) ..... 499, 621
RennaMolajoni E (abst) ..... 647
Rennert OM (abst) ..... 504
Ress K (abst) ..... 575
Reuben R (abst) ..... 506, 649
Revaldería JG (abst) ..... 584
Revert L (abst) ... 505, 505, 546, 578, 578, 579, 579, 622, 623
Revert L (abst) ..... 222, 222, 222, 223
Revillard J-P: *see* Gauthier et al ..... 170
Revúsová V (abst) ..... 624
Rey R (abst) ..... 542
Reznícek J (abst) ..... 624, 648
Ribeiro AB (abst) ..... 594
Ricart MJ (abst) ..... 219
Ricciardi B (abst) ..... 615
Richelsen B (abst) ..... 512
Richet G: John Putnam Merrill: 1917 to 1984 (In Memoriam) ..... 98
Rick R (abst) ..... 232
Rickers H (abst) ..... 589
Rickles FR (abst) ..... 228
Rieger J (abst) ..... 596
Riess Ch (abst) ..... 509
Rigby RJ (abst) ..... 230, 236, 237, 237, 246
Righetto F (abst) ..... 536, 537
Rimola A: *see* Pérez-Ayuso et al ..... 72
Ringoir S (abst) ..... 540, 607, 607
Risler T (abst) ..... 575

Ritz E (abst) ..... 487, 488, 499, 509, 540, 581, 599, 600, 641
Ritz E (abst) ..... 240
Ritz E: *see* Bommer et al ..... 331
Rivera F (abst) ..... 223
Rivera F: *see* Pérez-Ayuso et al ..... 72
Rivetta V (abst) ..... 560
Rivolta E (abst) ..... 630, 633
Rizzelli S (abst) ..... 576, 576, 576, 577
Rizzoni GF (abst) ..... 613
Rizzoni G, Basso T, Setari M: Growth in children with chronic renal failure on conservative treatment ..... 52
Rizzuto G (abst) ..... 522
Robert F (abst) ..... 631
Roberts CG (abst) ..... 244
Roberts M (abst) ..... 229
Roberts M (abst) ..... 582
Robinette JB: *see* Conger et al ..... 422
Robinson JM: *see* Harper et al ..... 875
Robinson MF (abst) ..... 236
Roccatello D (abst) ..... 509
Rocchi L (abst) ..... 496
Rodés J: *see* Pérez-Ayuso et al ..... 72
Rodger RSC (abst) ..... 523, 582, 651
Rodicio JL (abst) ..... 494, 506, 508, 647
Rodin G (abst) ..... 634
Rodrigo MJ (abst) ..... 558
Rodrigues I (abst) ..... 546
Rodriquez C (abst) ..... 545
Rodríguez JL (abst) ..... 220, 221
Rodriguez L (abst) ..... 533, 559, 585
Rodriguez R (abst) ..... 545
Rodríguez Carmona A (abst) ..... 218, 223
Rogers JR (abst) ..... 228
Rohde A (abst) ..... 641
Röhl L (abst) ..... 564, 638, 641, 651
Rolino C (abst) ..... 509
Roma J (abst) ..... 219
Romagnoli GF (abst) ..... 488, 494, 510, 613
Romanini PL (abst) ..... 507
Romano C (abst) ..... 507
Romano G (abst) ..... 492
Rombolà G (abst) ..... 491, 491
Ronco C (abst) ..... 539, 539, 589, 590
Ronco P (abst) ..... 523
Rongved G (abst) ..... 590
Roos JC: *see* Geers et al ..... 324
Rorive G (abst) ..... 548
Rosati C (abst) ..... 508
Rose W (abst) ..... 624
Rosen S: *see* Brezis et al ..... 375
Rosenberg AR (abst) ..... 242
Rosenfeld J (abst) ..... 512
Rosenthal E (abst) ..... 561
Rosic B (abst) ..... 525
Rosic D (abst) ..... 526
Rosic J (abst) ..... 526, 526
Rosivall L, Carmines PK, Navar LG: Effects of renal arterial angiotensin I infusion on glomerular dynamics in sodium replete dogs ..... 263
Rosman JB (abst) ..... 510, 514
Ross BD: *see* Guder et al ..... 101
Rössler W (abst) ..... 651, 651
Rossmann P (abst) ..... 640, 640
Rostin M (abst) ..... 489
Rotellar E (abst) ..... 590
Roth HJ (abst) ..... 505
Roth P (abst) ..... 608
Rother K (abst) ..... 575
Rotondo S (abst) ..... 595, 615
Rottembourg J (abst) ..... 590, 591
Roullet JB (abst) ..... 496
Rousselie F (abst) ..... 591
Rovati C (abst) ..... 539, 624
Rowinski W (abst) ..... 652
Rubiés-Prat J (abst) ..... 566
Ruder MA (abst) ..... 591
Rudge C (abst) ..... 538
Rudge CJ (abst) ..... 656
Ruedin P (abst) ..... 573, 573, 591
Ruffatti A (abst) ..... 488, 494, 510
Ruilope L (abst) ..... 494, 647
Ruilope LM (abst) ..... 506, 508
Ruiz T (abst) ..... 533, 559
Rupprecht E (abst) ..... 624
Rupprecht H (abst) ..... 543
Rus M (abst) ..... 503
Russel G (abst) ..... 240
Russell GI (abst) ..... 516, 638
Russo D (abst) ..... 492, 492
Rutgeerts L (abst) ..... 528, 608
Rutkowski B (abst) ..... 510, 511
Ryan GB (abst) ..... 239
Ryckelynck JP (abst) ..... 225, 225
Ryder LP (abst) ..... 642
Rylance PB (abst) ..... 591, 529

Saatçi U (abst) ..... 485
Sabagh T (abst) ..... 237
Sabater J (abst) ..... 508, 650
Sabater R (abst) ..... 218, 218, 220
Sabatier JC (abst) ..... 497, 497, 561, 620
Sabbadini G (abst) ..... 618
Sabbatini M (abst) ..... 492
Saccaggi A (abst) ..... 560, 586
Sack K (abst) ..... 520, 639
Sadler JH (abst) ..... 589
Safar ME: *see* London et al ..... 342
Saines D (abst) ..... 243
Sainte-Laudy J (abst) ..... 778
Saito A (abst) ..... 593, 593
Saito T (abst) ..... 244
Sakelariou G (abst) ..... 553
Sakellariou G (abst) ..... 485, 652
Salant DJ: *see* Madaio et al ..... 397
Salatic M (abst) ..... 526
Salerni B (abst) ..... 644
Salerno A (abst) ..... 538
Salihmoghedda S (abst) ..... 229
Salkie M (abst) ..... 633
Salomone M (abst) ..... 584
Salva M (abst) ..... 541
Salvadeo A (abst) ..... 593
Salvadori M (abst) ..... 533, 538, 575, 593
Salvi G (abst) ..... 555
Sama C (abst) ..... 581
Samhan (abst) ..... 640
Samney S (abst) ..... 623
Samoshenkova L (abst) ..... 652, 653
Sanchez JJ (abst) ..... 574
Sanchez-Garcia M (abst) ..... 494
Sanchez-Ibarrola A (abst) ..... 219
Sanchez Sicilia L (abst) ..... 218, 223

SánchezTomero JA (abst) ..... 514
Sancho E (abst) ..... 222
Sancho H (abst) ..... 485
Sancho J (abst) ..... 647
Sancho J (abst) ..... 223, 223, 223
Sandilands GP (abst) ..... 635
Sandrini S (abst) ..... 597, 644
Sandroni S (abst) ..... 524
Sanna M (abst) ..... 486
Santo LE (abst) ..... 634
Santopietro A (abst) ..... 486, 486
Santoro A (abst) ..... 519, 553, 594
Santos JR (abst) ..... 536
Sanz-Guajardo D (abst) ..... 519, 541
Sanz-Medel A (abst) ..... 545
Sanz-Moreno C (abst) ..... 519
Saragoça MA (abst) ..... 533, 594
Sarrias X (abst) ..... 218
Sasdelli M (abst) ..... 494, 594, 594
Satta A (abst) ..... 486, 614, 615, 615, 615
Saunders LD (abst) ..... 901
Savazzi G (abst) ..... 544
Savdie E (abst) ..... 229, 229, 246
Savica V (abst) ..... 495, 537, 537, 595, 615
Savitsky SN (abst) ..... 626
Sawanishi K (abst) ..... 500, 565
Sbrana A (abst) ..... 524
Scalamogna A (abst) ..... 545
Scalamogna M (abst) ..... 646
Scandurra R (abst) ..... 519
Scanferla F (abst) ..... 536, 537
Scapellato L (abst) ..... 613
Schaar H (abst) ..... 511
Schafer JA: *see* Reif et al ..... 725
Schäfer R (abst) ..... 499
Schäfer RM (abst) ..... 565
Schalekamp MADH (abst) ..... 368
Schaller K-H (abst) ..... 499
Schanzer H (abst) ..... 595, 631, 645
Schärer K (abst) ..... 497, 525, 580, 628
Schätzle-Schuler G (abst) ..... 567
Scheld WM: *see* Gerig et al ..... 308
Scheler F (abst) ..... 596
Schelling JL (abst) ..... 658
Schena FP ..... 511, 551
Shepers P (abst) ..... 511
Scheuermann EH (abst) ..... 536, 557, 595
Schiby G (abst) ..... 500
Schindhelm K (abst) ..... 243, 244
Schmicker R (abst) ..... 496, 511
Schmidt H (abst) ..... 536
Schmidt M (abst) ..... 595
Schmidt P (abst). 518, 520, 522, 530, 535, 567, 575, 578, 596, 641
Schmitt R (abst) ..... 521
Schmitz O (abst) ..... 512
Schneider-Waterberg M (abst) ..... 899
Schoel R (abst) ..... 643
Schoeppe W (abst) ..... 536, 557, 595, 608
Schohn D (abst) ..... 521
Scholler P (abst) ..... 651
Schollmeyer P (abst) ..... 655
Schollmeyer P: *see* Stahl et al ..... 30
Scholz D (abst) ..... 521
Scholz M (abst) ..... 654
Scholze J (abst) ..... 512
Schorderet D (abst) ..... 531
Schouten JA (abst) ..... 582
Schoutens A (abst) ..... 528
Schrader J (abst) ..... 596
Schraffordt Koops H (abst) ..... 368
Schröder CH (abst) ..... 367
Schröder JM (abst) ..... 620
Schuler F: *see* Dominguez et al ..... 404
Schultz E (abst) ..... 900, 901
Schultze G (abst) ..... 622
Schulz E (abst) ..... 520
Schustak A (abst) ..... 596
Schütterle G (abst) ..... 588, 611
Schwartz J: *see* Olgaard et al ..... 791
Schwartz KA: *see* Kaiser et al ..... 269
Schwartz S (abst) ..... 558
Schwarz A (abst) ..... 526, 596
Scida S (abst) ..... 522
Scoggins BA (abst) ..... 233
Scolari F (abst) ..... 597
Scolari S (abst) ..... 644
Scoppa F (abst) ..... 493
Scorza D (abst) ..... 539
Scott DF (abst) ..... 245
Searle M (abst) ..... 597, 652
Sebastian A: *see* Berger et al ..... 205
Sebert JL (abst) ..... 579, 597, 603, 603
Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC: Aluminum loading in children with chronic renal failure ..... 201
Sedor JR, Abboud HE: Actions and metabolism of histamine in glomeruli and tubules of the human kidney .. 144
Seedat YK (abst) ..... 895
Segaert M (abst) ..... 528, 529, 608
Segagni S (abst) ..... 593
Seggie J (abst) ..... 898, 898, 899, 899
Segoloni GP (abst) ..... 584, 636
Seignalet J (abst) ..... 648, 648
Seiler KU (abst) ..... 597, 610
Seim KE (abst) ..... 588
Seitz R (abst) ..... 653
Seldin DW (abst) ..... 231
Self B (abst) ..... 632
Selgas R (abst) ..... 218
Selig SE (abst) ..... 232
Sellars L (abst) ..... 546, 651
Sellem C (abst) ..... 493
Sellin D (abst) ..... 521
Selwood N (abst) ..... 636, 636
Selwood NH (abst) ..... 484, 484, 484
Senf L (abst) ..... 602
Serban I (abst) ..... 500
Servadio C (abst) ..... 653, 653
Sessa A (abst) ..... 488
Setari M: *see* Rizzoni et al ..... 52
Setoain J (abst) ..... 546
Seymour AE (abst) ..... 239
Shahwan ML (abst) ..... 517
Shaldon S (abst) ..... 542
Shapira Z (abst) ..... 653, 653
Sharma HM: *see* Zager et al ..... 689
Sharman VL (abst) ..... 652
Shastry JCM (abst) ..... 240
Shaw A (abst) ..... 897
Sheil AGR (abst) ..... 228, 228, 229, 237
Shen FH: *see* Gutman et al ..... 459

Shif B (abst) ..... 653
Shiigai T (abst) ..... 534
Shimizu K, Nakao A, Nonaka T, Oka H: Identification of vasopressin and determination of its corticomedullary levels in rat kidney tissue ..... 785
Shinaberger J (abst) ..... 608
Shishido H: *see* Hamazaki et al ..... 81
Shmueli D (abst) ..... 653, 653
Shock NW: *see* Lindeman et al ..... 861
Shohat B (abst) ..... 653
Shohat J (abst) ..... 512
Sibbald WJ (abst) ..... 503, 571, 609, 609
Sibert A (abst) ..... 226
Sieberth HG (abst) ..... 617, 620
Sigulem D (abst) ..... 634
Silk D (abst) ..... 246
Silva J (abst) ..... 546
Silva P: *see* Brezis et al ..... 375
Silva SG (abst) ..... 629
Simansky D (abst) ..... 527
Simmons RL (abst) ..... 549
Simó R (abst) ..... 590
Simões JD (abst) ..... 634
Simon AC: *see* London et al ..... 342
Simon N (abst) ..... 598
Simon P (abst) ..... 512, 624
Simoncello P (abst) ..... 527
Simoni GA (abst) ..... 540, 540
Simova N (abst) ..... 525
Sinaiko A: *see* Houser et al ..... 176
Sirchia G (abst) ..... 646
Sisca R (abst) ..... 522
Skála I (abst) ..... 521
Skillen AW (abst) ..... 588
Slapak M (abst) ..... 652
Slatopolsky E: *see* Olgaard et al ..... 791
Slaviero G (abst) ..... 598
Slavov Tch (abst) ..... 568
Sleijfer DT (abst) ..... 368
Slingeneyer A (abst) ..... 598, 598, 779
Slooff M (abst) ..... 366
Slooff MH (abst) ..... 658
Slooff MJH (abst) ..... 599, 656, 657
Sluiter W (abst) ..... 366
Sluiter WJ (abst) ..... 510, 528, 627
Smeby LC (abst) ..... 610
Smeyers J (abst) ..... 602, 602, 603
Smit JA (abst) ..... 900
Smith C: *see* Houser et al ..... 176
Smits PJH (abst) ..... 599
Smogorzewski M (abst) ..... 652
Snitch P (abst) ..... 236
Sobh M (abst) ..... 513
Sobh MA (abst) ..... 513
Sobrado JA (abst) ..... 585
Sochnev A (abst) ..... 652, 653
Sodi A (abst) ..... 533, 538, 575, 593
Sofi A (abst) ..... 537
Soggia G (abst) ..... 615, 615, 615
Sohar E (abst) ..... 616
Solbiati L (abst) ..... 620
Soliman A (abst) ..... 654
Solski J (abst) ..... 569
Somigli M (abst) ..... 533
Sommer G (abst) ..... 567
Sonnekus MI (abst) ..... 898
Sorba GB (abst) ..... 617
Sorrentino F (abst) ..... 492
Soulillou JP (abst) ..... 639, 658
South African Renal Society Abstracts, Pretoria, South Africa, March 7–9, 1984 ..... 895
Spagnoli G (abst) ..... 605, 654
Spanish Society of Nephrology Abstracts, Oviedo, Spain, October 12–15, 1984 ..... 218
Spencer E (abst) ..... 643
Spencer PC (abst) ..... 246, 246
Spira M (abst) ..... 229
Spisni C (abst) ..... 532
Spitz B (abst) ..... 567
Splendiani G (abst) ..... 599
Spohn B (abst) ..... 654
Sponer G (abst) ..... 489
Spotti D (abst) ..... 598
Squerzanti R (abst) ..... 599
Squiccimarro E (abst) ..... 551
Squifflet JP (abst) ..... 649
Srugies S (abst) ..... 561
Stahl RAK, Paravicini M, Schollmeyer P: Angiotensin II stimulation of prostaglandin $E_2$ and 6-keto $F_{1\alpha}$ formation by isolated human glomeruli ..... 30
Stalteri A (abst) ..... 550, 572
Stamenkovic M (abst) ..... 526, 526, 527
Stammler G (abst) ..... 599
Stantchev I (abst) ..... 568
Stanziale P (abst) ..... 486, 486
Stark JH (abst) ..... 900
Starke IF (abst) ..... 900
Starklint H (abst) ..... 493
Stec F (abst) ..... 577, 598
Steele TH, Challoner-Hue L: Renal interactions between norepinephrine and calcium antagonists ..... 719
Stefanovic V (abst) ..... 521, 566, 600, 654
Steiner G (abst) ..... 547
Steinhauer HB (abst) ..... 655
Stella M (abst) ..... 551
Stenberg A: *see* Wahlberg et al ..... 294
Stephen MS (abst) ..... 228
Stepien M (abst) ..... 511
Steplewski Z (abst) ..... 244
Sterz F (abst) ..... 565, 586
Stevens BJ (abst) ..... 234
Stevens ME (abst) ..... 513, 655
Stewart JH (abst) ..... 229, 229
Stewart JH: *see* Matthys et al ..... 153
Stewart K (abst) ..... 644
Stewart WK (abst) ..... 559
Stibbe W (abst) ..... 596
Stiller S (abst) ..... 574
St-Louis G (abst) ..... 587
Stoeppler M (abst) ..... 487
Stoeppler N (abst) ..... 240
Stolear JC (abst) ..... 606
Stoppa ML (abst) ..... 510
Stornello M (abst) ..... 613
Stragier A (abst) ..... 605, 605
Strahinjic S (abst) ..... 600, 608, 609, 654
Strahinjic V (abst) ..... 600
Straniero A (abst) ..... 519
Stratta P (abst) ..... 584
Strauch M (abst) ..... 505, 609
Stroemsaether CE (abst) ..... 655
Strom T: Immunosuppressive agents in renal transplanta-

tion (Nephrology Forum) ... 353
Strong WR (abst) ... 237
Stroucken H (abst) ... 896
Strumpf C (abst) ... 600
Stummvoll HK (abst) ... 568
Sturani A (abst) ... 519, 553, 594
Sturman G (abst) ... 247
Suárez C (abst) ... 578
Suarez E (abst) ... 544, 545, 545
Suárez C (abst) ... 223
Subías R (abst) ... 579
Sücker A (abst) ... 567
Sugimoto H (abst) ... 648
Sumithran E (abst) ... 244
Summer SN: *see* Kim et al ... 384
Surachno S (abst) ... 611
Surian M (abst) ... 491, 491, 574
Susa S (abst) ... 600, 625, 625
Susanna F (abst) ... 520, 527, 617
Sutherland DER (abst) ... 632
Suzuki T (abst) ... 531, 531
Svejgaard A (abst) ... 642
Svenson SB (abst) ... 501
Swabb EA: *see* Gerig et al ... 308
Swainson CP (abst) ... 242
Swanepoel CR (abst) ... 625, 898, 899
Symvoulidou D (abst) ... 506
Szabó T (abst) ... 529
Szalay L (abst) ... 513
Szczepaniak A (abst) ... 535
Szepesházy K (abst) ... 513
Szepietowski T (abst) ... 601
Szewczyk Z (abst) ... 500, 601
Sziedat A (abst) ... 503
Szpirt W (abst) ... 601
Szutowicz A (abst) ... 511

Tabernero JM (abst) ... 221, 514, 625
Tabernero-Romo J: *see* Brautbar et al ... 18
Taccone-Gallucci M (abst) ... 585, 605
Taddei M (abst) ... 586
Tahiri Y (abst) ... 553, 579, 580
Tait J (abst) ... 240
Takác M (abst) ... 648
Takagi T (abst) ... 593
Takahashi I (abst) ... 649
Takahashi S (abst) ... 612
Takahashi Y: *see* Hirose et al ... 338
Takák M (abst) ... 523
Takeda Y (abst) ... 649
Takeuchi J (abst) ... 534
Taljaard D (abst) ... 898, 899
Talseth T (abst) ... 487
Tamburro ML (abst) ... 657
Tanaka H (abst) ... 601
Tanaka K: *see* Tsumagari et al ... 712
Tanaka S (abst) ... 612
Tancredi M (abst) ... 599
Tande D (abst) ... 550
Tange J (abst) ... 645, 645
Tange J (abst) ... 236, 237
Tanghe W (abst) ... 529
Tan Tjiong HL (abst) ... 368
Tapson JS (abst) ... 655
Taraba I (abst) ... 601
Tarantino A (abst) ... 633
Tarchini A (abst) ... 498, 636
Tareyeva IE (abst) ... 626, 626
Tarkowska A (abst) ... 604, 604
Tateno S: *see* Hamazaki et al ... 81
Taube D (abst) ... 538, 656, 656
Taylor RMR (abst) ... 555
Teatini U (abst) ... 549
Tegzess AM (abst) ... 656, 657, 658
Tegzess A (abst) ... 366
Teitelbaum S: *see* Olgaard et al ... 791
Tejedor A (abst) ... 626
Telleria J (abst) ... 532
ten Cate H (abst) ... 611
ten Cate JW (abst) ... 611
Tepper T (abst) ... 527
Terrat JC (abst) ... 549
Teruel JL (abst) ... 644, 650
ter Wee PM (abst) ... 510, 514
Tesio F (abst) ... 618
Testa A (abst) ... 491
Tetta C (abst) ... 602
Thatcher R (abst) ... 233, 243
Thayse C (abst) ... 606
The TH (abst) ... 658
Thea A (abst) ... 602
Thick M (abst) ... 656, 656
Thieler H (abst) ... 602
Thien T (abst) ... 367
Thienpont L (abst) ... 522
Thoenes GH (abst) ... 620
Thoenes W (abst) ... 627
Thomas BJ: *see* Craswell et al ... 319
Thomas BW: *see* Craswell et al ... 319
Thomas C (abst) ... 367
Thomas DC: *see* Hutchinson et al ... 44
Thomas H (abst) ... 606
Thomas MAB (abst) ... 230, 241, 243, 244
Thome F (abst) ... 547
Thomsen AC (abst) ... 490
Thomson NM (abst) ... 234, 238, 241, 245, 245
Thomson PD (abst) ... 898
Thoua Y (abst) ... 656
Thumwood CM (abst) ... 239
Thurau K (abst) ... 232
Tielemans C (abst) ... 555, 602, 602, 603
Tiggeler RGWL (abst) ... 366
Tikkanen I (abst) ... 514, 514
Tiller DJ (abst) ... 228, 228, 230, 233, 235, 237
Tillis T (abst) ... 580
Tipping PG (abst) ... 238, 238
Tisdall S (abst) ... 563
Tjanetou C (abst) ... 613
Tobin JD: *see* Lindeman et al ... 861
Tolani M (abst) ... 497, 515, 553, 603, 603, 603
Tolis G (abst) ... 580, 580
Tollu D (abst) ... 490, 550
Tolon M (abst) ... 583
Tomikawa S (abst) ... 649
Tomoyoshi T (abst) ... 500
Tondriaux A (abst) ... 515
Tongio M (abst) ... 639
Tonini G (abst) ... 644
Tonner E (abst) ... 542
Torhorst J: *see* Mason et al ... 283
Törnroth T (abst) ... 514, 514
Torrabadella P (abst) ... 585, 604, 629, 630, 657

Torras A (abst) ..... 505, 622, 623
Torras A (abst) ..... 222
Torre F (abst) ..... 537, 537
Torres A (abst) ..... 528, 575
Torres A (abst) ..... 219
Toscani S (abst) ..... 618
Tóth E (abst) ..... 572
Tóth T (abst) ..... 541
Totis O (abst) ..... 527
Toulemonde F (abst) ..... 589
Toulon J (abst) ..... 561
Toupance O (abst) ..... 490
Toupance O (abst) ..... 227
Touraine JL (abst) ..... 633, 650
Tourkantonis A (abst) ..... 498, 498, 637
Toussaint C (abst) ..... 656, 657
Touyz RM (abst) ..... 900
Traeer J (abst) ..... 493
Traeger J (abst) ..... 225, 226, 493, 502, 507, 631, 633, 650
Tramonti G (abst) ..... 519
Tranaeus A (abst) ..... 571
Treille M (abst) ..... 542
Treissede D (abst) ..... 542, 542
Trevisan M (abst) ..... 539
Trijbels JMF (abst) ..... 367
Trinchieri A (abst) ..... 614
Triolo L (abst) ..... 579
Trnacevic S (abst) ..... 526
Trombetti E (abst) ..... 553, 594
Trounson W (abst) ..... 558
Troutman SL: *see* Reif et al ..... 725
Trovati A (abst) ..... 657
Trznadel K (abst) ..... 626
Tsakalides J (abst) ..... 498
Tsakalos N (abst) ..... 498
Tsifoutis S (abst) ..... 652
Tsobanelis T (abst) ..... 652
Tsumagari T, Tanaka K: Effects of fibrinogen degradation products on glomerular mesangial cells in culture ... 712
Tucker BJ, Blantz RC: Effect of furosemide administration on glomerular and tubular dynamics in the rat . 112
Tucker T: *see* Gutman et al ..... 459
Tulkens PM: *see* Giuliano et al ..... 838
Tuoni M (abst) ..... 524
Turano A (abst) ..... 597
Turci F (abst) ..... 555
Turgan C (abst) ..... 616
Turney JH (abst) ..... 531, 612, 612, 629
Tvedegaard E (abst) ..... 507, 515
Twardowski Z (abst) ..... 569
Twardowski ZJ (abst) ..... 604, 604
Tytgat J (abst) ..... 529
Tzafetas I (abst) ..... 637

Uccello F (abst) ..... 492
Udo K: *see* Hirose et al ..... 338
Ugur Y (abst) ..... 485
Umeda M (abst) ..... 612
Umimoto K (abst) ..... 601
Urbaniak S (abst) ..... 644
Ursea N (abst) ..... 604
Urso M (abst) ..... 494
Urti DA (abst) ..... 538
Usberti M (abst) ..... 549
Usberti M, Grutta d'Auria C, Borghi M, Pecchini F, Pecoraro, Dal Canton A: Usefulness of hypnosis for renal needle biopsy in children (Technical Note) ..... 351
Uszycka-Karcz M (abst) ..... 627
Utzinger B (abst) ..... 570
Uzan M (abst) ..... 549, 570

Vacha GM (abst) ..... 515
Vagelli G (abst) ..... 560
Vagnoli E (abst) ..... 594, 594
Valderrábano F (abst) ..... 585, 604, 629, 630, 657
Válek A (abst) ..... 572
Valentijn RM, Radl J, Haajman JJ, Vermeer BJ, Weening JJ, Kauffman RH, Daha MR, van Es LA: Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy ..... 760
Valentini W (abst) ..... 599
Valeri M (abst) ..... 605, 654
Valvo E (abst) ..... 613
vanBallegooie E (abst) ..... 627
van Brummelen P (abst) ..... 367
van Dalen W (abst) ..... 895
van der Berg R (abst) ..... 3a8
van der Groen G (abst) ..... 516
van der Hem GK (abst) ..... 366, 367, 368, 368, 524, 527
van der Hoven A (abst) ..... 897
van der Jagt E (abst) ..... 658
van der Merwe A (abst) ..... 897
van der Meulen J (abst) ..... 582, 605
van der Slikke L (abst) ..... 366
van der Slikke LB (abst) ..... 656, 658
van der Woude F (abst) ..... 366, 510
van der Woude FJ (abst) ..... 656, 658
Van de Vyver F (abst) ..... 603
Van de Vyver FL (abst) ..... 606, 606, 606
Van de Vyver FL, Vanheule AA, Majelyne WM, D'Haese P, Blockx PP, Bekaert AB, Buyssens N, De Keersmaecker W, De Broe ME: Serum ferritin as a guide for iron stores in chronic hemodialysis patients ..... 451
van Diemen-Steenvoorde R (abst) ..... 515
Vandongen R (abst) ..... 242
Vanel T (abst) ..... 549
van Es LA (abst) ..... 366
van Es LA: *see* Valentijn et al ..... 760
van Geelen JA (abst) ..... 366
Vangeertruyden J (abst) ..... 638
Van Geertruyden J (abst) ..... 640
van Goor H (abst) ..... 369
van Goor Hm (abst) ..... 657
Vanherweghem JL (abst) ..... 528, 606, 656
Vanheule AA: *see* Van de Vyver et al ..... 451
Vanholder R (abst) ..... 540, 607, 607
van Hooff I (abst) ..... 602
Van Leeuwen BH (abst) ..... 233
van Luijk WHJ (abst) ..... 528
van Munster P: *see* Fiselier et al ..... 823
Vanpellicom J (abst) ..... 607
van Rijswijk MH (abst) ..... 368
van Schilfgaarde R (abst) ..... 649, 650
van Son W (abst) ..... 366
van Son WJ (abst) ..... 656, 658
Van Stone J (abst) ..... 591
Van Waeleghem JP (abst) ..... 606
van Wyk HJ (abst) ..... 896
van Ypersele de Strihou C (abst) ..... 516, 605, 605, 649
van Zyl-Smit R (abst) ..... 625, 895
Varanese L (abst) ..... 518

Vardas P (abst) ..... 621
Vargemezis V (abst) ..... 485, 553
Vas A (abst) ..... 546
Vasconez F (abst) ..... 604
Vasmant D (abst) ..... 607
Vazzola A (abst) ..... 631
Vecsei P (abst) ..... 518
Veerkamp JH (abst) ..... 367
Vegeto A (abst) ..... 487, 616, 630, 631
Veitch PS (abst) ..... 638
Velasco F (abst) ..... 575
Velasco F (abst) ..... 219
Velázquez HE: *see* Ellison et al ..... 471
Velez RL, Woodward TD, Henrich WL: Acetate and bicarbonate hemodialysis in patients with and without autonomic dysfunction ..... 59
Veljkovic S (abst) ..... 608, 609
Vellar I (abst) ..... 230
Venkatachalam M: *see* Matthys et al ..... 153
Verbanck J (abst) ..... 528, 529, 608
Verbeelen D (abst) ..... 602, 602, 603
Verbrugh HA (abst) ..... 605
Vercellone A (abst) ..... 584, 584, 602, 636
Vereerstraeten P (abst) ..... 656, 657
Vergani L (abst) ..... 488
Verhelst F (abst) ..... 528, 529, 608
Verhoef J (abst) ..... 605
Veriava Y (abst) ..... 896
Verleden G (abst) ..... 528, 608
Vermaercke N (abst) ..... 540
Vermeer BJ: *see* Valentijn et al ..... 760
Verpooten GA: *see* Giuliano et al ..... 838
Verpooten GA (abst) ..... 606
Verreyen M (abst) ..... 606
Vetter K (abst) ..... 496, 511
Vialtel P (abst) ..... 552, 552
Vidanovic M (abst) ..... 526, 526
Vié H (abst) ..... 658
Viglino G (abst) ..... 547
Viguier E (abst) ..... 241
Vila A (abst) ..... 224, 224
Vilaplana E (abst) ..... 224
Vilches J (abst) ..... 221
Vilella R (abst) ..... 222
Vilella R (abst) ..... 505
Viljoen M (abst) ..... 896, 896, 896
Villa G (abst) ..... 593
Villaro J (abst) ..... 219
Vinay P (abst) ..... 587
Vincent C: *see* Gauthier et al ..... 170
Vincent M (abst) ..... 226
Vincent M (abst) ..... 502
Vinhas J (abst) ..... 546
Viola D (abst) ..... 532
Viola E (abst) ..... 560
Virgilio M (abst) ..... 551
Viron B (abst) ..... 523
Visser WJ (abst) ..... 515
Vistelle R (abst) ..... 227
Vitali (abst) ..... 599
Vitali P (abst) ..... 499, 621
Vives JL (abst) ..... 218, 221
Vlachojannis J (abst) ..... 608
Vlassis T (abst) ..... 629
Volpi A (abst) ..... 488
von Alberini B (abst) ..... 608
von Riotte A (abst) ..... 536
Vorderbrügge U (abst) ..... 580
Voshart K (abst) ..... 634
Voudiclaris S (abst) ..... 580
Voudiklari S (abst) ..... 506
Voudiklaris S (abst) ..... 580
Vujic D (abst) ..... 587
Vukusic Z (abst) ..... 608, 609

Wacker S (abst) ..... 525
Wagner L (abst) ..... 596, 609
Wahlberg J, Stenberg A, Wilson DR, Persson AEG: Tubuloglomerular feedback and interstitial pressure in obstructive nephropathy ..... 294
Waiss Z (abst) ..... 596
Walb D (abst) ..... 518
Waldherr R (abst) ..... 509, 588, 598, 651
Waldherr R: *see* Bommer et al ..... 331
Walker JF (abst) ..... 503, 571, 609, 609
Walker RG (abst) ..... 239
Wall D (abst) ..... 237
Waller J (abst) ..... 639
Wallin JD (abst) ..... 504
Wallis JP (abst) ..... 619
Walls J (abst) ..... 516, 638
Wambach G (abst) ..... 489
Warady BA: *see* Sedman et al ..... 201
Ward MK (abst) ..... 897
Ward MK (abst) 492, 523, 546, 555, 555, 561, 563, 564, 582, 588, 612, 651, 655
Warnaar SO (abst) ..... 369
Wartha R (abst) ..... 627
Wass U (abst) ..... 554
Wass V (abst) ..... 538
Wassermann O (abst) ..... 610
Watson M (abst) ..... 651
Waugh J (abst) ..... 237
Wauters JP (abst) ..... 610, 658
Weber M (abst) ..... 529, 627
Weening JJ: *see* Valentijn et al ..... 760
Weinstein T, Fishman P, Klein B, Levi J, Djaldetti M: Effect of cimetidine on granulocyte-macrophage colony by normal and chronic renal failure bone marrow ..... 741
Weissbach S (abst) ..... 505
Wellens F (abst) ..... 656
Wells JV (abst) ..... 239
Welsch J: *see* Mason et al ..... 283
Welsh K (abst) ..... 649, 656
Welsh KI: *see* Rees et al ..... 444
Welsh KI (abst) ..... 656
Wens R (abst) ..... 555, 602, 602, 603
Wenting GJ (abst) ..... 368
Werner E (abst) ..... 536, 608
Werynski A (abst) ..... 571
Westberg G (abst) ..... 645
Westlie L (abst) ..... 590
Weston MJ (abst) ..... 591, 592
Weyde W (abst) ..... 601
Whitby J (abst) ..... 586
White AG (abst) ..... 629, 640
Whitworth JA (abst) ..... 233, 233, 243
Wideröe TE (abst) ..... 610
Wiecek A (abst) ..... 502
Wienand P (abst) ..... 637
Wierusz-Wysocka B (abst) ..... 535

Wijeyesinghe ECR (abst) ..... 529, 654
Wilkinson R (abst) .... 529, 546, 555, 561, 582, 651, 655, 658
Will D (abst) ..... 610
Will EJ (abst) ..... 610
Willebrand Ev (abst) ..... 514
Williams AJ (abst) ..... 516, 611
Williams DG (abst) ..... 506, 538, 656
Williams G (abst) ..... 630, 659
Willis W (abst) ..... 232
Wilmink JM (abst) ..... 611
Wilms H (abst) ..... 655
Wilson CB: *see* Neale et al ..... 701
Wilson DR: *see* Wahlberg et al ..... 294
Wilson L (abst) ..... 550
Windeck R (abst) ..... 561, 659
Winearls CG (abst) ..... 630, 659
Wineman RJ (abst) ..... 552, 552, 611
Wing T (abst) ..... 600
Wingen AM (abst) ..... 628
Winkler E (abst) ..... 641
Winterhalter M (abst) ..... 534
Wizemann V (abst) ..... 611
Woffindin C (abst) ..... 564, 571, 612
Wolf C (abst) ..... 780
Wolf S (abst) ..... 613
Wolff ED (abst) ..... 367
Woloszczuk W (abst) ..... 568
Wone C (abst) ..... 225
Wong WK (abst) ..... 229
Wood C (abst) ..... 241, 245
Wood C (abst) ..... 541
Woodroffe AJ (abst) ..... 239, 243, 245
Woodroffe AJ: *see* Neale et al ..... 701
Woodruffe PWH (abst) ..... 228
Woods RL (abst) ..... 232
Woodward TD: *see* Velez et al ..... 59
Wooton AM (abst) ..... 245
Wootton AM (abst) ..... 243
Wórum I (abst) ..... 529, 572
Wöss E (abst) ..... 581
Wright C (abst) ..... 230, 246
Wright FS: *see* Ellison et al ..... 471
Wright RD (abst) ..... 236
Wright TC: *see* Harper et al ..... 875
Wu A (abst) ..... 238
Wulle G (abst) ..... 575
WürtzenNielsen G (abst) ..... 487
Wyatt RJ: *see* McLean et al ..... 855
Wysocki H (abst) ..... 535

Yabuki S (abst) ..... 501
Yamagami S (abst) ..... 612
Yamashita Y (abst) ..... 593
Yamauchi J (abst) ..... 649
Yanagisawa R (abst) ..... 649
Yañez A (abst) ..... 532, 559
Yano S: *see* Hamazaki et al ..... 81
Yasavul U (abst) ..... 616
Yeniay I (abst) ..... 637
Yogout JF (abst) ..... 523
Yoshida T: *see* Hamazaki et al ..... 81
Yoshizawa H: *see* Hirose et al ..... 338
Youinou P (abst) ..... 490, 550, 564
Young GA (abst) ..... 612, 612
Yussim A (abst) ..... 653, 653

Zabel P (abst) ..... 516, 643, 643, 659
Zacchello G (abst) ..... 613
Zaccuri F (abst) ..... 557
Zager RA, Baltes LA, Sharma HM, Jurkowitz MS: Responses of the ischemic acute renal failure kidney to additional ischemic events ..... 689
Zahn T (abst) ..... 499
Zakar G (abst) ..... 516
Zamora E (abst) ..... 221
Zanaty MA (abst) ..... 517
Zanco P (abst) ..... 617
Zandomeneghi R (abst) ..... 618
Zanon GF (abst) ..... 613
Zaoui P (abst) ..... 552, 552
Zarowitz B (abst) ..... 550
Zástava V (abst) ..... 640
Zawadzki A (abst) ..... 652
Zazgornik J (abst) 520, 522, 530, 535, 567, 575, 578, 578, 596, 641
Zazkornik J (abst) ..... 518
Zdravkovic J (abst) ..... 600
Zech P (abst) ..... 493, 493, 502, 507
Zech P (abst) ..... 225
Zeller WJ (abst) ..... 651
Zemer D (abst) ..... 616
Ziak E (abst) ..... 565, 586
Zick R (abst) ..... 628
Zimácek J (abst) ..... 523
Zimmerman B: *see* Houser et al ..... 176
Ziroyannis P (abst) ..... 613, 621
Zoccali C (abst) ..... 495, 613
Zoellner K (abst) ..... 517, 613
Zogovic J (abst) ..... 625
Zozulinska M (abst) ..... 535
Zuber K (abst) ..... 609
Zuccalà A (abst) ..... 519, 553, 594
Zucchelli P (abst) ..... 519, 553, 594
Zurier RB: *see* Goldstein et al ..... 733
Zurowska A (abst) ..... 627
Zvara V (abst) ..... 624
Zvara Vl (abst) ..... 648
Zwas T (abst) ..... 527

# Subject Index For Volume 26


Abdominal aneurysmectomy
related to renal failure (abst) ... 897
Abdominal surgery
postoperative change in ECF and GFR (abst) ... 502
Aborigine
renal disease in South Australian *a.* (abst) ... 240
Aceio-hydroxamic acid
inhibits infected calculi synthesis (abst) ... 221
Acidification, renal tubular
in idiopathic hypercalciuria (abst) ... 221
Acidosis, distal tubular
longterm follow-up of six patients with (abst) ... 223
Adenine nucleotide
in ischemic acute renal failure ... 689
Adenine phosphoribosyl transferase
complete deficiency of *APRT* in adult (abst) ... 226
β-2 adrenergic blockade
in terminal renal failure (abst) ... 222
ACTH (adrenocorticotropin)
effects on urinary kallikrein excretion (abst) ... 233
Adenylate cyclase
influenced by PTH ... 404
related to cyclic AMP ... 384
Adrenalectomy
in primary aldosteronism, Nephrology Forum on ... 769
Adrenergic activity
in essential hypertension (abst) ... 367
Age
blood pressure and decline of renal function with ... 861
Albumin-citrate
effects on kidney preservation for transplantation (abst) ... 237
Alcohol abuse
reversible tubular dysfunction in (abst) ... 618
Aldosterone
associated with serum potassium in terminal renal failure (abst) ... 222
in Bartter syndrome (abst) ... 241
in dialysis or with essential hypertension (abst) ... 507
role in potassium adaptation in collecting tubule ... 798
Aldosteronism, primary
diagnostic criteria of (abst) ... 518
Nephrology Forum on ... 769
trilostane as treatment for (abst) ... 497
Alkaline phosphatase
related to bone histology in dialysis ... 869
Alkalosis, metabolic
chronic *m. a.*
role of deep proximal nephrons (abst) ... 231
maintained by glomerular filtration and bicarbonate reabsorption ... 205
Nephrology Forum on ... 88
Allergy, food
and idiopathic nephrotic syndrome (abst) ... 780
Allograft, cardiac
prolongation of (abst) ... 645
Allograft, renal
cadaveric *r. a.*
antilymphocyte globulins in (abst) ... 648
B-cold lymphocytotoxin effects on (abst) ... 646
HLA-DR typing in recipients of (abst) ... 646
chronic hepatic disease in (abst) ... 219
conversion to azathioprine to cyclosporin in *r. a.* recipients (abst) ... 659
cyclosporin effects on (abst) ... 632
glomerular C3b receptor loss in (abst) ... 649
interleukin 2 and peripheral blood lymphocytes in *r. a.* recipients (abst) ... 658
monoclonal antibodies for monitoring T-cell subsets in (abst) ... 220
recipient hydration associated with (abst) ... 228
*r. a.* rejection
acute rejection (abst) ... 630
antithymocyte globulin effects on (abst) ... 632
indicators of (abst) ... 655
macrophages, fibrin, and (abst) ... 228
post-transplant bacterial infection and irreversible *r.a.j.* (abst) ... 640
treated with steroids (abst) ... 636
Allotransplantation, renal
minoxidil treatment after (abst) ... 512
suppressor cells in recipients before/after (abst) ... 652
ureteropelvic fibrosis in (abst) ... 218
Alpha methyl dopa
compared with clonidine hydrochloride in hypertensive pregnant women (abst) ... 233
Alport syndrome
hydroxylsylaglycosides in (abst) ... 367
Aluminum
and iron removed by hemodialysis and hemofiltration (abst) ... 549
associated with bone disease (abst) ... 234
*a.* binding by transferrin in plasma of dialysis patients (abst) ... 234
effects in osteomalic versus osteofibrotic bone (abst) ... 622
*a.* gastrointestinal absorption (abst) ... 545
in hemodialysis and CAPD patients (abst) ... 234
in microcytic anemia ... 269
*a.* loading in children with chronic renal failure ... 201
plasma *a.*
increased by 1 α OH vitamin $D_3$ in hemodialysis (abst) ... 580
Aluminum hydroxide
effects on anemia and serum phosphorus (abst) ... 545
Aluminum osteodystrophy
in dialysis patients (abst) ... 234
Amiloride
in primary aldosteronism, Nephrology Forum on ... 769
Aminoglycosides
related to acute renal failure (abst) ... 897
Aminophylline
treatment for glycerol-induced acute renal failure (abst) 245
Amyloidosis
prevented in familial Mediterranean fever (abst) ... 616
Amyloidosis, AL-type
light-chain deposition disease related to, Editorial Re-

view on ..... 1
Amyloidosis, familial nephropathic
with indomethacin responsive fever (abst)..... 619
Amyloidosis, systemic
clinical/immunological features of (abst)..... 623
nephropathy in (abst) ..... 368
Anatomy, left ventricular
during hemodialysis, CAPD, and after renal transplantation (abst) ..... 553
Anemia
in chronic renal failure (abst) ..... 897
microcytic *a.*
aluminum-induced..... 269
renal *a.*
during CAPD and hemodialysis (abst) ..... 608
lympho-monocyte and macrophage defects in (abst) 622
Aneurysm, venous
in vascular access for hemodialysis (abst) ..... 613
Aneurysmectomy, abdominal
related to renal failure (abst)..... 897
Angiography, noncomputerized
with bone subtraction (abst) ..... 576
Angioplasty, percutaneous
transluminal renal effects on renal function (abst) ..... 367
Angiotensin I
effects on glomerular dynamics ..... 263
Angiotensin II
AII blockade
effects on different intakes of sodium chloride ..... 823
effects on prostaglandin $E_2$ and 6-keto-$F_{1\alpha}$ formation . 30
in hemofiltration and hemodialysis (abst)..... 557
in primate pregnancy (abst)..... 235
maintains GFR in experimental renal hypertension (abst) ..... 232
role in blood pressure regulation (abst) ..... 231
Antibiotic
determined by pH in CAPD (abst)..... 895
Antibody
against cytomegalovirus in artificial kidney unit staff/patients (abst)..... 601
anti-endothelial *a.*
in malignant hypertension (abst) ..... 900
anti-lymphocyte *a.*
in lupus nephropathy (abst)..... 220
auto-anti-idiotypic *a.*
role in IgA nephropathy (abst)..... 223
immunoregulatory *a.*
transfusion-induced *a.* (abst)..... 635
monoclonal *a.*
*m. a.* analysis of interstitial infiltrate in glomerulonephritis (abst)..... 238
extracorporeal immunoadsorption system using (abst) ..... 244
hepatitis B e antigen identified by ..... 338
in IgA nephropathy..... 760
used to induce experimental glomerulonephritis (abst) ..... 238
induces injury to glomerular basement membrane (abst) ..... 238
induces murine-SLE (abst) ..... 369
monitor T-cell subsets in renal allograft recipients (abst) ..... 220
*a.* specificity of mesangial IgA deposits in alcoholic liver disease (abst)..... 239
to antigens in spontaneous glomerulonephritis ..... 701
to Tamm-Horsfall urinary glycoprotein (abst)..... 242
Antibody charge
effects on glomerular basement membrane ..... 397
Anticoagulant
in hemodialysis (abst)..... 552
treatment in dense deposit disease (abst)..... 242
Anti-DNA, native
used to detect nephropathy (abst) ..... 220
Antigen
dietary *a.*
in IgA nephropathy (abst) ..... 223
DR *a.*
in normal human kidney (abst)..... 505
localized in normal human kidney (abst) ..... 222
fibrin-related *a.*
in tubular handling (abst)..... 219
glomerular capillary *a.*
role in spontaneous glomerulonephritis ..... 701
hepatitis B core *a.*
antibody to, in hemodialysis (abst) ..... 219
hepatitis B e
in membranous glomerulonephritis ..... 338
Antigonadotropic drugs
in systemic lupus erythematosus (abst) ..... 779
Antiplatelet
treatment in dense deposit disease (abst)..... 242
Arachidonic acid
in hydronephrosis ..... 10
*a. a.* metabolism
stimulated by plastic particles in dialysis tubing..... 331
Arginine vasopressin
effects in cortical collecting tubules..... 725
effects on cyclic AMP ..... 384
identification of ..... 785
Arteriolar $C_3$ disease
study of (abst) ..... 244
Assay
for $^{22}$Na-efflux rate constant (abst) ..... 527
intact hormone *a.*
in parathyroid autograft function (abst) ..... 529
Aspirin
chronic *a.* treatment on hydronephrotic kidney ..... 10
Atenolol
as therapy in malignant hypertension (abst) ..... 900
ATPase
in experimental nephrotic syndrome (abst) ..... 368
Autoimmune disease, experimental renal
plasma exchange in (abst) ..... 243
Autonomic nervous system
associated with acetate and bicarbonate hemodialysis . 59
Azathioprine
compared with cyclosporin A (abst) ..... 228
in cadaveric renal transplantation (abst)..... 366
Azotemia
in ischemic acute renal failure ..... 689
Azotemic osteodystrophy
in dialysis patients (abst)..... 234
Aztreonam
in hemodialysis and peritoneal dialysis..... 308

Baltimore Longitudinal Study on Aging
decline of renal function in ..... 861
Bartter syndrome
and laxative abuse (abst)..... 898
associated with passive sodium permeability (abst)..... 227
cellular electrolyte transport in (abst)..... 241
sodium chloride-losing syndrome in (abst)..... 224

Basement membrane
glomerular *b. m.*
ATPase in (abst) ... 368
binding studies with (abst) ... 245
injured by monoclonal antibody (abst) ... 238
tubular *b. m.*
in renal cystic disease ... 35
Behcet disease
effects on kidney (abst) ... 616
Beta blockers
used in hypertensive women, Technical Note on ... 85
Binding studies
on isolated glomerular basement membrane (abst) ... 245
Biocompatibility
during hemodialysis (abst) ... 571
Biopsy, renal
fine needle aspiration *b.*
in renal transplantation (abst) ... 633
in renal transplantation rejection (abst) ... 521
renal needle *b.*
assessment of (abst) ... 640
hypnosis for *r.n.b.* in children, Technical Note on ... 351
new *b. n.* (abst) ... 638
revealing systemic amyloidosis (abst) ... 368
taken from hypertensive women postpartum, Technical Note on ... 85
ultrasonography used after (abst) ... 226
Blockade, acute autonomic
blood pressure regulation after (abst) ... 231
Blood
and ultrafiltrate (abst) ... 602
*b.* biochemistries
from dialysate levels (abst) ... 246
*b.* concentration
related to anti-GBM antibody ... 397
*b.* flow
in ischemic renal failure ... 283
renal *b. f.* in experimental congestive heart failure (abst) ... 235
*b.* pressure
after renal transplantation (abst) ... 367
and decline of renal function with age ... 861
angiotensin II blockade effects on ... 823
how controlled in hypertension (abst) ... 900
in hemodialysis and CAPD (abst 2) ... 573
role of vasopressin and angiotensin II in *b. p.* (abst) 231
sulindac and indomethacin effects on (abst) ... 242
*b.* reflow
after ischemia ... 153
*b.* solute concentration
method for accurate inference of (abst) ... 572
*b.* transfusion
donor-specific *b. t.* for haplotype matched donors—impact on dialysis (abst) ... 659
donor-specific *b. t.* prior to renal transplantation (abst) ... 219
influence on
kidney graft survival in canines (abst) ... 651
T-lymphocyte subsets in uremia (abst) ... 218
tumor growth (abst) ... 651
in hemodialysis ... 436
in renal transplantation (abst) ... 898
non-A, non-B hepatitis in hemodialysis associated with (abst) ... 598
third party *b. t.* (abst) ... 631
Bone
net *b.* resorption role in calcium balance ... 752
Bone disease
after renal transplantation (abst) ... 229
aluminum-associated *b. d.*
bone scan in (abst) ... 519
associated with aluminum (abst) ... 234
dialysis *b. d.*
polyvalent ions in (abst) ... 235
Bone Gla-protein
in dialysis ... 869
Bone histology
*b.* Gla-protein evaluated ... 869
in chronic uremia ... 791
in patients on maintenance dialysis (abst) ... 229
Bone histomorphometry
in renal osteodystrophy (abst) ... 896
Bone marrow cells
in chronic renal failure ... 741
Bone mass
evaluated in hemodialysis (abst) ... 558
Bromoethylamine hydrobromide
cause of chronic papillary necrosis (abst) ... 232
Bulimia
related to pseudo-Bartter syndrome (abst) ... 898
Bumetanide
and furosemide in chronic heart failure ... 183

Calcification, ectopic
role of PTH in (abst) ... 492
Calcitonin
role in treatment of dialysis/kidney transplanted patients (abst) ... 583
Calcium
*c.* antagonists
and norepinephrine ... 719
*c.* balance ... 752
*c.* ion
correction factors in analysis (abst) ... 523
in urine, Technical Note on ... 767
Calcium oxalate
results of 24-hr urine samples in (abst) ... 509
Calcium oxalate monohydrate
guarded electrode used in, Technical Note on ... 767
Calculi
chemical bases of infected *c.* synthesis (abst) ... 222
infected *c.* synthesis inhibited (abst) ... 221
Cancer
in renal transplantation recipients (abst) ... 898
Cancer, skin
associated with renal transplantation and prednisolone (abst) ... 236
Captopril
and spironolactone effects on idiopathic edema (abst) ... 226
effects on unilateral renal artery stenosis (abst) ... 368
treatment for malignant hypertension, Nephrology Forum on ... 209
Carcinoma, skin
in renal transplantation recipients (abst) ... 898
Cardiac calcifications
and longterm hemodialysis (abst) ... 537
Cardiomyopathy
selenium-deficiency related *c.* (abst) ... 499
uremic *c.*
early signs of (abst) ... 611
Cardiopulmonary bypass
associated with renal function (abst) ... 485

effects on renal function (abst) ..... 222
Cardiovascular activity
in multicenter Veterans Administration study of hemodialysis and peritoneal dialysis ..... 459
Cardiovascular disease
associated with mild hypertension, Nephrology Forum on ..... 881
Cardiovascular/metabolic response
to submaximal exercise in hemodialysis ..... 66
Carnitine
*c.* deficiency
L-*c.* in (abst) ..... 488
L-*c.* in hemodialysis (abst) ..... 515
Carpal tunnel syndrome
in chronic hemodialysis (abst) ..... 564
in hemodialysis (abst) ..... 549, 579
in 10-year home-dialysis patients (abst) ..... 570
Catecholamine
effects on sodium efflux (abst) ..... 614
Catheter
double silicone rubber in-dwelling venous *c.* used for hemoaccess (abst) ..... 595
longterm right atrial *c.* (abst) ..... 555
peritoneal *c.*
4-year experience in Italy (abst) ..... 547
peritoneal dialysis *c.*
experience with (abst) ..... 779
new insertion method (abst) ..... 554
removal of *c.* treatment for fungal peritonitis in CAPD (abst 2) ..... 246
subclavian vein *c.*
noninfectious complications in (abst) ..... 533
Tenckhoff *c.*
as hemoaccess in dialysis (abst) ..... 247
versus Lifecath ® peritoneal implant (abst) ..... 598
Cefoperazone
compared with netilmicin for treatment of urinary tract infection (abst) ..... 242
Cell
bone marrow *c.*
in chronic renal failure ..... 741
epithelial and/or mesangial *c.*
how to culture, Technical Note on ..... 875
glomerular *c.*
improved methods for culturing, Technical Note on 875
glomerular epithelial *c.*
in uranyl acetate-induced acute renal failure ..... 808
glomerular mesangial *c.*
effects of fibrinogen on ..... 712
identified by electron microscope, in glomerulonephritides (abst) ..... 238
Kupffer *c.*
iron stores in ..... 451
lymphocyte *c.* cycle
hemodialysis and apheresis effects on (abst) ..... 542
natural killer *c.*
in hemodialysis ..... 436
proximal tubular *c.*
after gentamicin loading ..... 838
renin-containing *c.*
in hypertensive women postpartum, Technical Note on ..... 85
suppressor *c.*
*s. c.* activity in hemodialysis (abst) ..... 223
tubular *c.*
in renal cystic disease ..... 35
white blood *c.*
in lung dysfunction in hemodialysis ..... 430
Cellulose acetate membrane
role in complement activation ..... 194
Cellulose phosphate
in childhood idiopathic hypercalciuria (abst) ..... 240
Cerebral edema
dimethyl sulfoxide effects on, Technical Note on ..... 471
Chemotaxis
in CAPD ..... 733
Chemotherapy
in hypertension, Nephrology Forum on ..... 881
Chloride/potassium
*c./p.* depletion
associated with metabolic acidosis ..... 205
Chlorothiazide
in childhood idiopathic hypercalciuria (abst) ..... 240
Chromatography
molecular sieving *c.*
used on pre-dialysis sera from hemodialysis patients (abst) ..... 554
Cimetidine
effects on granulocyte-macrophage colony ..... 741
Cirrhosis
renal/hepatic immunohistopathology of (abst) ..... 227
renal prostaglandins in ..... 72
Cisdichlorodiamine platinum
renal excretion of (abst) ..... 236
Cis-platin
renal function changes with (abst) ..... 368
Clometacin
hormonal effects of (abst) ..... 779
Clonidine hydrochloride
compared with alpha methyl dopa in hypertensive pregnant women (abst) ..... 233
Cobra venom factor
effects on proteinuria ..... 830
Collecting duct, inner medullary
cyclic AMP in ..... 384
Complement system
C5b-9 complex
in idiopathic membranous nephropathy (abst) ..... 633
during hemodialysis ..... 194
*c.* fixation in glomerulonephritis and primary hematuria (abst) ..... 220
in experimental immune glomerular injury ..... 830
in Heymann nephritis (abst) ..... 366
*c.* phenotypes
in glomerulonephritis ..... 855
terminal C5b-9 complex of *c.* in idiopathic membranous nephropathy (abst) ..... 225
Computer program
CUSUM
used to compare RDT patients to dialysis schedules (abst) ..... 547
Corticosteroids
compared with antigonadotropic drugs (abst) ..... 779
effects on experimental immune complex glomerulonephritis (abst) ..... 238
in idiopathic and recurrent extracapillary glomerulonephritis (abst) ..... 780
Creatinine clearance
in uranyl acetate-induced acute renal failure ..... 808
Cromoglycate
as treatment in food allergy associated with idiopathic nephrotic syndrome ..... 780

Culture
improved methods for *c.* rat glomerular cells, Technical Note on ... 875
Cuprophan membranes
alternatives to (abst) ... 612
associated with dialysis-eosinophilia (abst) ... 595
role in complement activation ... 194
Cyclic AMP
effects of histamine on ... 144
enzyme activities in nephron related to, Editorial Review on ... 101
in inner medullary collecting duct ... 384
Cyclosporin
and prednisolone
as postoperative course of cadaver kidney grafts (abst) ... 657
effects on
prednisolone metabolism (abst) ... 642
proximal tubular function (abst) ... 637
in cadaveric renal transplant recipients (abst) ... 656
Cyclosporin A
conversion to prednisolone and azathioprine (abst) ... 629
determined in capillary blood (abst) ... 641
effects on
antibody-induced experimental glomerulonephritis (abst) ... 238
cadaveric donor renal transplantation (abst) ... 228
early function of cadaver renal grafts (abst) ... 228
renal transplantation (abst) ... 237
systemic lupus (abst) ... 225
glomerulotubular function in *c. A*-treated rats (abst) ... 493
HLA matching in graft survival with (abst) ... 639
in cadaveric renal transplantation (abst) ... 366
in early postoperative period after transplantation (abst) ... 637
possible inhibitor of renal prostaglandin synthesis (abst) ... 629
Cyproterone acetate
in systemic lupus erythematosus (abst) ... 779
Cyst, renal
in RDT patients (abst) ... 574
Cystinosis
nephropathic *c.*
with massive proteinuria (abst) ... 623
potassium physiopathology in (abst) ... 224
Cystitis, abacterial
microbiological investigations on women with (abst) ... 240

Danazol
in systemic lupus erythematous (abst) ... 779
Death
due to hypertension (abst) ... 901
due to renal failure in maturity onset diabetes mellitus (abst) ... 899
Deferoxamine
bone changes after therapy of (abst) ... 548
effects on secondary hyperparathyroidism (abst) ... 541
*d.* infusion test to predict bone aluminum deposits in hemodialysis patients (abst) ... 539
kinetics of chelation of Al, Zr, and Fe by (abst) ... 234
role in regular dialysis treatment (abst) ... 584
treatment in uremia (abst) ... 536
used to
induce aluminum removal in hemodialysis (abst) ... 579
treat iron overload (abst) ... 568
Dense deposit disease
clinical study of (abst) ... 241
Deposition disease, light-chain
related to AL-type amyloidosis, Editorial Review on ... 1
Diabetes
cardiovascular risk factors in hemodialyzed *d.* patients (abst) ... 600
continuous subcutaneous insulin infusion effects in (abst) ... 627
discovery of latent functional kidney alterations in (abst) ... 615
glycemic profile of *d.* patients on hemodialysis (abst) ... 604
hyperglycemia in (abst) ... 559
insulin-dependent *d.*
radionuclear determination of GFR/RPF in (abst) ... 617
metabolic profiles in CAPD *d.* patients (abst) ... 598
$^{99m}$Tc-DTPA kidney scintigraphy in (abst) ... 521
type I *d.*
blood pressure in (abst) ... 499
vascular access in *d.* patients (abst) ... 581
with chronic renal failure (abst) ... 625
Diabetes insipidus
sodium loading and urinary prostaglandins in (abst) ... 509
Diabetes mellitus, maturity onset
renal function in (abst) ... 899
Dialysate
acetate and succinate mixture in (abst) ... 561
blood biochemistries from *d.* levels (abst) ... 246
custom hemodialysis with bicarbonate *d.* (abst) ... 229
effect on blood volume in dialysis (abst) ... 559
peritoneal *d.*
low white blood cell count in (abst) ... 605
*d.* protein
intraperitoneal sources of, Editorial Review on ... 253
sodium *d.* in hemodialysis ... 59
Dialyser
reutilization of (abst) ... 605
RP 2400 *d.*
reutilization technique for (abst) ... 605
$\beta$-thromboglobulin levels related to (abst) ... 219, 575
Dialysis
acetate *d.*
versus bicarbonate *d.* (abst) ... 570
acetate and bicarbonate *d.*
cerebral blood flow in (abst) ... 581
acetate metabolism in (abst) ... 574
adequacy assessed (abst) ... 572
aluminum binding by transferrin in plasma of *d.* patients (abst) ... 234
bicarbonate *d.*
composition of dialysate fluid in (abst) ... 609
daily recycled *b.* with polyacrilonitrile membranes (abst) ... 543
dialysate stability in five systems of (abst) ... 585
cardiac function in (abst) ... 550
chronic *d.*
drinking behavior in patients on (abst) ... 247
chronic maintenance *d.*
bone Gla-protein in ... 869
clobuzarit half-life extended in (abst) ... 597
compared with renal transplantation ... 44
computer-controlled *d.* (abst) ... 587
double-pump single needle systems compared (abst) ... 564
endogenous opioids in baroreflex dysfunction of (abst) 613
fluoride metabolism and renal osteopathy in (abst) ... 557
hemodialysis
acetate and bicarbonate *h.* autonomic dysfunction in 59

antibody to hepatitis B core antigen in (abst) ..... 219
cause of hypoxemia (abst)..... 225
chronic endotoxemia in (abst)..... 896
chronic *h.* serum ferritin in ..... 451
chronic liver disease in *h.* patients (abst)..... 221
custom *h.* with bicarbonate dialysates (abst)..... 229
effects on aztreonam pharmacokinetics ..... 308
platelet function in chronic uremia (abst)..... 218
hepatitis B vaccination for patients/staff of hospital *h.* center (abst)..... 229
hyperlipidemia in..... 81
lung dysfunction in ..... 430
multicenter Veterans Administration study of peritoneal *d.* and ..... 459
nutritional status of patients on (abst)..... 230
plasma glucose perturbations and dialysate buffer anion in (abst) ..... 246
plasma, red cell, and hair aluminum compared in patients on CAPD and (abst)..... 234
prior transfusions in ..... 436
β-thromboglobulin levels during (abst) ..... 219
two-compartment analysis of *h.* data (abst)..... 895
lymphocyte migration in (abst)..... 604
maintenance *d.*
aluminum and azotemic osteodystrophy in patients on (abst) ..... 234
radiological signs/bone histology in patients on (abst) 229
*d.* membranes
biocompatibility of four *d. m.* (abst) ..... 575
polymorphonuclear neutrophils and cuprophan *d. m.* (abst) ..... 602
peritoneal *d.*
albumin transport in (abst) ..... 604
and loss of proteins, Editorial Review on ..... 253
continuous ambulatory *p. d.* (*CAPD*)
bacteriological filters used in (abst)..... 598
clinical index to predict failure rates (abst) ..... 610
contamination of unused *CAPD* fluid (abst)..... 550
diabetic patients on (abst) ..... 591
double-bag system for handicapped patients on (abst) ..... 537
effects on
histological osteitis fibrosis (abst) ..... 546
peritoneal clearance and ultrafiltration (abst) ... 582
whole body protein turnover (abst)..... 561
exit site infections in patients on (abst) ..... 545
factors of peritonitis (abst) ..... 565
5 years at Johannesburg Hospital (abst)..... 895
5-year evaluation of multicenter survey (345 patients) in France (abst)..... 225
5-year experience in Australia (abst)..... 230
4.5-year experience in Durban, South Africa (abst) 895
fungal peritonitis in (abst 2)..... 245
glucose and ultrafiltration in (abst) ..... 559
glutathione peroxidase and tocopherol in (abst) ... 612
hydrothorax during (abst) ..... 779
iron peritoneal balance and serum ferritin in (abst) 590
metabolism of minerals, vitamin D, glucose, and hormones in (abst)..... 569
micro-organisms in used/unused *CAPD* fluid (abst) 564
new autosterilizing connection system for (abst) . 543
nutritional assessment of patients receiving (abst) 230
1-year nutritional study of (abst) ..... 539
pasteurization of *CAPD* connectors (abst)..... 588
peritoneal fluid pH changes in peritonitis in (abst) 895
peritoneal macrophages in..... 733
peritoneal membrane after 5 years of (abst) ..... 246
plasma, red cell, and hair aluminum compared in patients on hemodialysis and (abst)..... 234
psychological profile of patients on (abst) ..... 569
renal transplantation in patients on (abst) ..... 245
results of training program in (abst) ..... 230
transperitoneal water and solute transport during (abst) ..... 610
treatment for diabetics with endstage renal failure (abst) ..... 652
ultrafiltration in (abst)..... 536
used for patients entering transplantation program (abst) ..... 230
zinc and copper deficiency during (abst) ..... 612
effects on aztreonam pharmacokinetics ..... 308
fluid, *p. d.* opsonizing activity determined (abst) .... 579
furosemide/sodium nitroprusside
effects on (abst)..... 535
intermittent *p. d.*
complications of (abst)..... 541
platelet aggregation in (abst)..... 535
polymorphonuclear neutrophils in (abst) ..... 535
small bowel obstruction in (abst)..... 534
multicenter Veterans Administration study of hemodialysis and..... 459
procaine used in ..... 392
radioactive iodide transport during (abst)..... 604
renal transplantation in black population on (abst) .. 899
pharmacokinetics of amezinium (abst) ..... 610
physical fitness/metabolic profile of two Canadian groups (abst)..... 547
responses to submaximal exercise in ..... 66
satellitte units of *d.* evaluated (abst)..... 586
self-care *d.*
5 years of (abst)..... 575
sensitization to ethyleneoxide through (abst) ..... 554
sexual functioning before and during (abst)..... 566
Tenckhoff catheter as hemoaccess for (abst)..... 247
25OHD levels in patients on (abst) ..... 218
vaccination against hepatitis B in *d.* unit (abst) ..... 223
vibration sensory threshold (abst) ..... 558
Dialysis kinetics
single pool model of (abst) ..... 895
Dialysis membrane
biocompatibility of ..... 194
role in lung dysfunction in hemodialysis ..... 430
Dialysis tubing
prostanoid release caused by ..... 331
Dialyzer
effects on β-endorphin levels (abst)..... 595
used to monitor depuration during hemodialysis (abst) 581
Diazoxide
used in malignant hypertension, Nephrology Forum on 209
Diet
single pool hemodialysis model used to assess (abst) . 895
Diet/exercise
in mild hypertension, Nephrology Forum on ..... 897
Diltiazem
effects on GFR and renal vascular resistance ..... 719
Dimeric IgA1
in IgA nephropathy..... 760
Dimethyl sulfoxide
in renal distal tubule, Technical Note on..... 471
Diuresis
saline-expanded *d.* ..... 275
water *d.*

tissue arginine vasopressin level under ..... 785
Diuretics
effects on interstitial hydraulic pressure ..... 275
used in chronic heart failure ..... 183
used to study salivary secretion (abst) ..... 236
Donor, renal graft
vital selection of (abst) ..... 650
young renal cadaver *d.*
graft survival and surgical damage (abst) ..... 650
Doppler ultrasonic test
to evaluate Palmar arch (abst) ..... 522
DPT (2-amino-4,5-diphenyl thiazole)
used to induce renal cystic disease ..... 35

Edema
idiopathic *e.*
effects of captropril and spironolactone on (abst) .... 226
in nephrotic syndrome ..... 324
Eicosapentaenoic acid
effects on hyperlipidemic hemodialysis patients ..... 81
Electrocardiography, dynamic
in extracorporeal dialysis (abst) ..... 576
Electrolytes
cellular *e.* transport in Bartter syndrome (abst) ..... 241
Electron microscope
used to localize glomerular components (abst) ..... 238
ELISA
for detection of antiglomerular basement membrane antibodies (abst) ..... 529
Enalapril
treatment for hypertension (abst) ..... 243
Encephalopathy
polyvalent ions in (abst) ..... 235
Endartheritis, arterio-venous fistula
antibiotic prophylaxis considered for (abst) ..... 587
Endocytosis
related to lipoprotein reabsorbtion ..... 411
Endothelial fenestrae
in uranyl acetate-induced acute renal failure ..... 808
Endotoxemia, chronic
in hemodialysis (abst) ..... 896
Endotoxin
effects on hydronephrotic kidney ..... 10
Enzyme
angiotensin converting *e.*
associated with renal function deterioration in hypertension (abst) ..... 232
converting *e.* inhibition
effects on rat renal microcirculation (abst) ..... 235
in malignant hypertension, Nephrology Forum on ... 209
*e.* distribution
along nephron, Editorial Review on ..... 101
urinary *e.*
in renal transplantation (abst) ..... 635
Eosinophilia
effects on heparin in dialysis (abst) ..... 594
Epidemiological study
of 250,000 with nephrotic syndrome/glomerulonephritis in France (abst) ..... 512
Erythematosus, systemic lupus
danazol and cyproterone acetate in (abst) ..... 779
heterologous model of (abst) ..... 369
Erythrocyte
in hemodialysis (abst) ..... 555
membrane defects in (abst) ..... 896
*e.* $Na^+/K^+$ transport systems in hypokalemia (abst) ... 227
physical properties of *e.* in renal failure (abst) ..... 896
Exercise
in hemodialysis patients ..... 66
Extracorporeal immunoadsorption system
monoclonal antibodies used in (abst) ..... 244

Fabry disease
immune function and renal transplantation (abst) ..... 618
Fanconi syndrome, adult
vitamin D metabolites and osteomalacia in (abst) ..... 491
Feedback, tubuloglomerular
in obstructive nephropathy ..... 294
Ferritin-antiferritin immune complex disease
experimental model of ..... 137
Fibrin
contact activation system of coagulation associated with glomerular *f.* (abst) ..... 219
effects on glomerular mesangial cells ..... 712
macrophages, human renal allograft rejection, and (abst) ..... 228
Fibrinogen
*f.* degradation products
effects on glomerular mesangial cells ..... 712
effects on glomerular mesangial cells ..... 712
Fibronectin
*f.*, prealbumin, and retinol binding protein in chronic renal failure (abst) ..... 558
Fibrosis
in idiopathic and recurrent extracapillary glomerulonephritis (abst) ..... 780
ureteropelvic *f.*
in renal allograft (abst) ..... 218
Filtration fraction
in nephrotic syndrome ..... 324
index of renal function in SLE (abst) ..... 619
Fish oil
effects on
hyperlipidemic hemodialysis patients ..... 81
renal failure (abst) ..... 504
Fistula, arterio-venous
alternative vascular access for (abst) ..... 589
hemodynamic effects of high flow graft *a.*-v. *f.* (abst) . 582
Furosemide
and bumetanide in chronic heart failure ..... 183
effects on glomerular and tubular dynamics ..... 112

Genes, HLA-linked
effects on nephritis ..... 444
Genitalia, ambiguous
at birth, Nephrology Forum on ..... 476
Gentamicin
used to induce phospholipidosis ..... 838
Globulin, antithymocyte
improves graft survival of steroid resistant rejections (abst) ..... 646
Glomerular basement membrane
antibody charge to ..... 397
Glomerular injury, experimental immune
terminal complement components in ..... 830
Glomerulonephritis
acute post-streptococcal *g.*
serum complement levels in (abst) ..... 485
antibody-induced experimental *g.*
cyclosporin A effects on (abst) ..... 238
associated with hypertension ..... 137
chronic proliferative *g.*

peripheral blood monocyte activation in (abst) ..... 500
complement fixation in (abst) ..... 220
complement phenotypes in ..... 855
experimental immune complex *g.*
corticosteroid effects on (abst) ..... 238
extracapillary *g.*
in renal transplants (abst) ..... 643
focal necrotizing *g.*
teaching hospital experience in New South Wales (abst) ..... 243
histological subgroups in (abst) ..... 490
idiopathic *g.*
reticuloendothelial system in (abst) ..... 511
idiopathic and recurrent extracapillary *g.*
treatment for (abst) ..... 780
idiopathic mesangial *g.*
study of 119 patients with *i.m.g.* in Spain (abst) .... 221
leukocyte-mediated *g.*
steroid effects on ..... 162
lupus *g.*
renal involvement in (abst) ..... 625
membranoproliferative *g.*
associated with cirrhosis (abst) ..... 620
membranous *g.*
clinical/morphological/laboratory parameters (abst). 486
hepatitis B e antigen in. ..... 338
in Zimbabwean children (abst) ..... 899
pure/mixed *m. g.* immunosuppressive treatment for (abst) ..... 615
monoclonal antibody analysis of interstitial infiltrate in (abst) ..... 238
non-IgA primary mesangial proliferative *g.*
symptoms (abst) ..... 485
primary *g.*
in elderly (abst) ..... 488
osmotic nephrosis in (abst) ..... 486
primary and secondary *g.*
macrophage function in (abst). ..... 510
rapidly progressive *g.*
clinical course/prognosis of (abst) ..... 504
mixed IgA/IgG cryoglobulinemia with (abst) ..... 627
with immunological myopathy (abst). ..... 620
rapidly progressive crescentic *g.*
steroid treatment in (abst) ..... 513
severe mesangial IgA *g.*
steroids and plasma exchange in (abst). ..... 497
South African study of *g.* in 324 renal biopsies (abst) .. 899
spontaneous *g.*
glomerular capillary antigen in ..... 701
study of arteriolar $C_3$ disease (abst) ..... 244
Glomerulopathy
cirrhosis of liver and (abst) ..... 623
in renal allografts (abst) ..... 643
mesangial *g.*
in rheumatoid arthritis (abst). ..... 621
Glomerulosclerosis
nodular *g.*
associated with light-chain deposition disease, Editorial Review on ..... 1
Glomerulus
*g.* damage
*g. d.*, hypertension, and mesangial immune injury... 137
*g.* dynamics
angiotensin I infusion effects on. ..... 263
*g.* filtration
role in metabolic alkalosis in humans ..... 205
*g.* filtration rate (GFR)
affected by perfusion pressure ..... 683
and plasma pH as determinants of phosphate reabsorption ..... 128
cis-platin effects on (abst) ..... 368
determined by $^{99m}$Tc-DPTA and plasma samples (abst) ..... 524
during pregnancy ..... 24
furosemide effects on ..... 112
in anti-GBM antibody-mediated nephritis ..... 444
in ischemic acute renal failure ..... 689
in metabolic alkalosis, Nephrology Forum on. ..... 88
in partial ureteral obstruction ..... 122
maintained by angiotensin II (abst) ..... 232
measured by iothalamate (abst) ..... 236
single nephron GFR affected by proximal tubular pressure. ..... 422
histamine in ..... 144
Glucocorticoid
effects on graft prognosis (abst) ..... 642
Gluconeogenesis
in nephron, Editorial Review on ..... 101
Glycerol
in peritoneal dialysis (abst) ..... 571
Glycoprotein
Tamm-Horsfall urinary *g.*
antibodies to (abst) ..... 242
Glycosyl albumin
in diabetic keto-acidotic hyperosmolar states (abst) ... 618
Goodpasture syndrome
following mycoplasma pneumoniae infections (abst) ... 511
Gout
as marker of chronic lead poisoning ..... 319
in chronic renal failure ..... 319
lead excretion in (abst). ..... 240
GP70
in murine SLE-associated glomerulonephritis (abst) ... 369
Granulocyte-macrophage colony
cimetidine effects on. ..... 741
Graft
cadaver renal *g.*
cyclosporin A effects on (abst). ..... 228
report from Australian center on survival of (abst) . 237
renal *g.* survival
of low donor-specific MLC versus HLA-DR matching (abst) ..... 642
total ischemic time and HLA matching on (abst). .... 657
renal *g.* survival factors
analysis of 2531 transplants in United Kingdom and Ireland, 1978-1981 (abst) ..... 636
Granuloma, periglomerular
as marker of vasculitic disorder (abst) ..... 624
Granulomatosis, Wegener
with renal involvement (abst) ..... 241
Growth
in children with chronic renal failure ..... 52

Hantaan virus
cause of nephropathia epidemica (abst) ..... 516
HBsAg
in nephropathy/glomerulonephritis in black/white South Africans (abst) ..... 899
Headache
hemodialysis-induced (abst) ..... 565
Heart
open *h.* surgery

renal function during (abst) ... 222
Heart failure, chronic
bumetanide and furosemide in ... 183
Heart failure, congestive
renal blood flow in experimental *c.h.f.* (abst) ... 235
Hematomas, retroperitoneal
assessed with ultrasonography (abst) ... 226
Hematuria
in IgA nephropathy ... 760
in IgA nephropathy (abst) ... 239
primary *h.*
complement fixation in (abst) ... 220
Hemodiafiltration
closed volume *h.* apparatus (abst) ... 366
evaluation of short-term (abst) ... 553
high flux *h.* (abst) ... 608
protein-permeating *h.*
effects on erythropoiesis (abst) ... 593
Hemodialysate
granulated dry chemicals for (abst) ... 531
Hemodialysis
acetate *h.*
blood lines in biocompatibility study of (abst) ... 542
cellulose acetate hemodialysers in (abst) ... 542
acetate and bicarbonate *h.*
autonomic dysfunction in ... 59
carbon dioxide and ventilatory regulation during (abst) ... 563
effects on
left ventricle (abst) ... 591
plasma calcium fractions (abst) ... 572
anaerobic threshold in (abst) ... 568
anaphylatoxin formation and leucocinetic (abst) ... 574
anemia in (abst) ... 607
antibody to hepatitis B core antigen in (abst) ... 219
autonomic neuropathy in (abst) ... 546
bicarbonate *h.*
technical approach to buffered *b. h.* (abst) ... 532
versus acetate *h.* (abst) ... 607
Biocarbon ® vascular access device for (abst) ... 599
blood access and longterm *h.* (abst) ... 570
blood pressure
control during (abst) ... 545
response to (abst) ... 553
bone mineral loss during (abst) ... 589
cardiovascular risk factors in (abst) ... 538
cardiovascular system during (abst) ... 533
cause of hypoxemia (abst) ... 225
changes in body compartments in (abst) ... 546
changes in T lymphocyte subsets induced by (abst) ... 555
chronic endotoxemia in (abst) ... 896
chronic *h.*
acetate intolerance in (abst) ... 587
aluminum burden in (abst) ... 553
aluminum related to Redy cartridge in (abst) ... 606
aortic/coronary atherosclerosis in (abst) ... 548
changes in copper and zinc (abst) ... 565
dental management of (abst) ... 532
diagnostic errors at autopsy (abst) ... 548
effects on blood coagulation process (abst) ... 575
hypothalamic pituitary adrenal axis in (abst) ... 580
mammographic findings in (abst) ... 567
osteodystrophy in (abst) ... 560
plasma calcium-oxalate product in (abst) ... 560
serum ferritin in ... 451
sonographic diagnosis of renal cystic disease in (abst) ... 608
sympathetic nervous system function (abst) ... 538
vancomycin pharmacokinetics in (abst) ... 550
chronic liver disease (abst) ... 221
cimetidine/pirenzepine therapy in (abst) ... 578
complement system during ... 194
computerization of small *h.* units (abst) ... 531
custom *h.* with bicarbonate dialysates (abst) ... 229
decreasing infection rate in (abst) ... 544
depressive personality reactions in (abst) ... 600
dialysate buffer effects on potassium removal (abst) ... 611
dialysate sodium effects in (abst) ... 569
dietary lipid-lowering treatment (abst) ... 582
drug compliance in (abst) ... 562
early *h.*
acute pulmonary hypertension, leukopenia, and hypoxia in (abst) ... 609
pulmonary vascular tone and right ventricular dysfunction in (abst) ... 609
effects on
aztreonam pharmacokinetics ... 308
platelet function in chronic uremia (abst) ... 218
erythrocytes in (abst) ... 896
ethylene oxide hypersensitivity (abst) ... 582
GHRH/ACTH-RH-induced pituitary responses in (abst) ... 580
granulocyte proteinases during (abst) ... 565
hepatitis B vaccination for patients/staff of hospital *h.* center (abst) ... 229
hepatitis B virus infection in (abst) ... 532
herpetic viruses in (abst) ... 597
high efficiency *h.* (abst) ... 577
hyperlipidemia in ... 81
immunological monitoring after vitamin E supplementation (abst) ... 605
in carpal osteolysis with nephropathy (abst) ... 624
left ventricular function during (abst) ... 588
leukopenia and hypoxemia during (abst) ... 585
low molecular weight heparin in (abst) ... 611
lung dysfunction in ... 430
maintenance *h.*
β-adrenoceptors in (abst) ... 551
autonomic nervous system and hypotension in (abst) 609
cardiac rhythm disturbance in (abst) ... 608
chronic *m. h.* effects on cardiac function (abst) ... 551
hemasite vascular access device for (abst) ... 540
study of 220 patients on *m. h.* with pruritus in Spain (abst) ... 546
multicenter Veterans Administration study of peritoneal dialysis and ... 459
myocardial studies in (abst) ... 520
new *h.*
changes with (abst) ... 590
nutritional status of 50 patients on (abst) ... 230
oncotic/osmotic pressure in plasma of *h.* patients (abst) 570
opsonic deficiency in sera of patients on (abst) ... 542
oral complications in (abst) ... 500
plasma glucose perturbations and dialysate buffer anion in (abst) ... 246
prior transfusions in ... 436
protection against hyperaluminemia in (abst) ... 533
psychologic investigations of *h.*/transplanted patients (abst) ... 572
psychological factors in (abst) ... 577
reconstructive surgery for arterio-venous fistulas in (abst) ... 568

red blood cells and aluminum toxicity in (abst) ..... 603
renal cysts in *h.* patients (abst)..... 537
responses to submaximal exercise in ..... 66
role of convective transport in (abst) ..... 595
rupture of kidney during (abst)..... 562
saphenous vein allografts for (abst)..... 559
septic osteoarthritis in (abst)..... 585
shunt conversion technique, 9-year experience in Spain (abst) ..... 533
silicone particle load in (abst)..... 540
single needle *h.*
Brescia-Cimino fistula survival in (abst)..... 607
single pool *h.* model (abst) ..... 895
subclavian venous stenoses and arterio-venous fistulas in (abst) ..... 562
subclavian venous stenoses in (abst)..... 585
suppressor cell activity in (abst) ..... 223, 578
systolic time intervals before/after (abst) ..... 543
β-thromboglobulin levels during (abst) ..... 219
transvenous serial-xeroangiography for arteriovenous fistulas in (abst) ..... 599
two-compartment analysis of *h.* data (abst)..... 895
upper respiratory infections in (abst) ..... 577
vascular access for (abst)..... 544
vascular access surgery in (abst) ..... 568
versus hemofiltration in chronic renal failure (abst).... 247
vitamin $B_{12}$ and transcobalamins in dialysate/serum of (abst) ..... 613
with heparin-coated hollow fiber dialyzer (abst)..... 571
with prostacyclin alone (abst)..... 591
without heparinization (abst)..... 562
Hemodialysis tubing
diethylhexyl phthalate release into (abst)..... 563
Hemodialyzer
*h.* reprocessing
automatic devices for (abst) ..... 611
Hemodynamics
blood-dialyzer interaction effects on (abst) ..... 551
glomerular *h.*
prostaglandin formation and angiotensin II as related to ..... 30
in hypertension ..... 342
peripheral *h.*
in essential hypertension (abst) ..... 367
related to sodium acetate infusion..... 744
renal *h.*
during pregnancy..... 24
Hemofiltration
continuous arterial-venous *h.*
clinical experience with (abst) ..... 590
self-limited dehydration (abst) ..... 589
Hemasite ® in (abst)..... 487
high efficiency continuous arterio-venous *h.*
new technique (abst)..... 576
in porphyria cutanea tarda (abst)..... 569
microbiological assessment of electrolyte solution for (abst) ..... 577
plasma levels and acid-base balance during (abst)..... 539
post-dilutional *h.* (abst) ..... 584
versus hemodialysis in chronic renal failure (abst)..... 247
without substitution fluid (abst) ..... 549
Hemolysis
chloramine-induced *h.*
in hemodialysis (abst)..... 896
Hemostatic function
in CAPD and hemodialysis (abst) ..... 554
Henoch-Schönlein purpura
homozygous null $C_4$ phenotypes in ..... 855
survey of 100 children (abst)..... 627
Heparin
effects on plasma aldosterone secretion (abst) ..... 534
in hemodialysis and hemofiltration (abst)..... 589
low molecular weight *h.* in hemodialysis (abst) ... 592, 596
Hepatic disease, chronic
in renal allograft patients (abst) ..... 219
Hepatic failure
plasmapheresis and charcoal perfusion (abst)..... 548
Hepatitis B
*h.* B antigenemia
associated with membranous glomerulonephritis in Zimbabwean children (abst) ..... 899
in dialysis center (abst) ..... 600
*h.* B infection
and uremic nervous disease (abst)..... 532
vaccination against (abst)..... 223
vaccinatin given to patients/staff of hemodialysis center (abst) ..... 229
Hepatitis B core antigen
antibody to, in hemodialysis (abst) ..... 219
Hepatitis B e antigen
in membranous glomerulonephritis ..... 338
Hepatocytes
fetal rat *h.* in human uremic serum (abst) ..... 517
Hernia, abdominal
in CAPD, Johannesburg Hospital (abst)..... 895
Heymann nephritis
fine-needle aspiration cytology of (abst)..... 514
hemodynamic/immunological factors in (abst)..... 514
IgG and C5-8 in ..... 830
Histamine
in glomeruli and tubules of human kidney..... 144
Hormones
antidiuretic *h.*
in cirrhosis ..... 72
PTH
in idiopathic hypercalciuria (abst) ..... 221
sex *h.*
influence on lower urinary tract, Nephrology Forum on ..... 476
vasoconstrictor *h.*
effects on experimental congestive heart failure (abst) ..... 235
Hydration
moderate *h.*
used against acute tubular necrosis (abst) ..... 366
recipient *h.*
for early renal allograft function (abst)..... 228
tissue *h.*
in chronic renal failure..... 848
Hydrochlorothiazide
for mild hypertension, Nephrology Forum on..... 881
Hydrolysis
of plasma high density lipoprotein..... 411
Hydronephrosis
in partial ureteral obstruction..... 122
macrophage-dependent arachidonate metabolism in ... 10
Hydrothorax
during peritoneal dialysis (abst)..... 779
Hydroxylsylglycosides
in Alport syndrome (abst) ..... 367
Hypercalciuria
childhood idiopathic *h.*

cellulose phosphate or chlorothiazide in (abst) ..... 240
high fluid intake on drug treatment in (abst) ..... 614
idiopathic *h.*
associated with hyperreninemia and prostaglandin E 176
calcium restriction in (abst) ..... 496
changes in renal tubular acidification in (abst) ..... 221
proximal/distal tubular function in (abst) ..... 491
Hyperemia, medullary
in ischemic renal failure ..... 283
Hyperparathyroidism
parathyroid scintigraphy in (abst) ..... 520
secondary *h.*
associated with anemia in chronic renal failure (abst) 897
ultrasonically guided fine-needle alcoholization in (abst) ..... 620
studied by Thallium Technicium Subtraction Scintiscanning (TTSS) (abst) ..... 897
Hyperpolarization
in cortical collecting tubule ..... 725
Hyperreninemia
associated with idiopathic hypercalciuria and prostaglandin E ..... 176
Hypertension
acute postsinusoidal portal *h.*
renal prostaglandins and urinary sodium excretion in (abst) ..... 220
acute pulmonary *h.*
associated with hemodialysis (abst) ..... 571
aldosterone-renin axis related to (abst) ..... 517
anti*h.* therapy in pregnancy (abst) ..... 232
associated with
angiotensin II in primate pregnancy (abst) ..... 235
decline of renal function with age ..... 861
cause of death (abst) ..... 901
discrimination between essential and secondary *h.* (abst) ..... 221
essential *h.*
genetic marker of (abst) ..... 218
plasma effects on 22Na and 86Rb transport in (abst) 220
prostaglandins in (abst) ..... 367
sodium sensitivity in (abst) ..... 367
experimental renal *h.*
angiotensin II effects on GFR in (abst) ..... 232
*h.*, mesangial immune injury, and progressive glomerular damage ..... 137
in IgA glomerulonephritis (abst) ..... 509
in pregnancy (abst) ..... 233
in pregnancy following renal transplantation (abst) .... 237
in primary aldosteronism, Nephrology Forum on ..... 769
magnesium/calcium/sodium/potassium in Johannesburg black patients with (abst) ..... 900
malignant *h.*
atenolol and nifedipine as therapy for (abst) ..... 900
in black South Africans (abst) ..... 900
in Brazil, Nephrology Forum on ..... 209
tissue typing and anti-endothelial antibodies in (abst) 900
mild *h.*
associated with cardiovascular disease, Nephrology Forum on ..... 881
Australian therapeutic trial on, Nephrology Forum on ..... 881
diet/relaxation therapy in, Nephrology Forum on ... 881
*m.* essential *h.* chlorthalidone effects on serum/urinary electrolytes in (abst) ..... 496
five trials studied, Nephrology Forum on ..... 881
Oslo study of, Nephrology Forum on ..... 881
non-drug *h.* clinic (abst) ..... 900
renal biopsy taken from *h.* women postpartum, Technical Note on ..... 85
renal function deterioration in (abst) ..... 232
renal kallikrein in (abst) ..... 489
renal response to orthostatism in (abst) ..... 502
renovascular *h.*
renal scintigraphy in (abst) ..... 519
studied with renal artery digital subtraction radiology (abst) ..... 233
severe *h.*
ketanserin effects on (abst) ..... 233
systemic compliance, renal hemodynamics and sodium excretion in ..... 342
treated with enalapril (abst) ..... 243
Hypnosis
for renal needle biopsy in children, Technical Note on 351
Hypokalemia
cyclic AMP in ..... 384
erythrocyte $Na^+$ and $K^+$ transport systems in (abst) .. 227
Hypomagnesemia
and hypertension in Johannesburg black patients (abst) 900
Hypoperfusion, renal
medullary thick ascending limb during, Editorial Review on ..... 375
Hypophosphaturia
in metabolic acidosis ..... 302
Hypotension
chronic *h.*
postsynaptic adrenergic receptors in (abst) ..... 222
symptomatic *h.*
during hemodialysis (abst) ..... 593
Hypoventilation
and lung dysfunction effects on hemodialysis-induced hypoxemia (abst) ..... 225
in hemodialysis ..... 430
Hypovolemia
in nephrotic syndrome ..... 324
Hypoxemia
during acetate dialysis (abst) ..... 593
hemodialysis-induced *h.* (abst) ..... 558
in hemodialysis ..... 430
induced by hemodialysis (abst) ..... 225
Hypozincemia
in dialysis (abst) ..... 599

Immune complex, circulating
in IgA nephropathy ..... 760
Immune complex disease
ferritin-antiferritin *i.c.d.*
experimental model of ..... 137
Immunity, cell-mediated
in pyelonephritis ..... 816
Immunoglobulin
IgA deposits, mesangial
in alcoholic liver disease (abst) ..... 239
in C3H/HeJ mice (abst) ..... 497
IgG, anti-GBM
in glomeruli ..... 397
Immunoperoxidase staining
used to localize glomerular components (abst) ..... 238
Immunosuppression
*i.* agents in renal transplantation, Nephrology Forum on ..... 353
treatment in
dense deposit disease (abst) ..... 242

Wegener granulomatosis (abst) ..... 241
Indomethacin
and sulindac effects on renal function and blood pressure (abst) ..... 242
associated with pressure natriuresis ..... 683
role in conversion of arachidonic acid to prostaglandins ..... 30
treatment for idiopathic hypercalciuria ..... 181
Insipidus, experimental diabetes
tubular transport in (abst) ..... 626
Insulin
associated with serum potassium in terminal renal failure (abst) ..... 222
*i.* receptors
in patients with moderate/severe renal in sufficiency (abst) ..... 628
Inulin
clearance of *i.*
procaine effects on, in peritoneal dialysis ..... 392
Ion
models for *i.* transport in early and late distal tubules (abst) ..... 231
polyvalent *i.*
in dialysis bone disease and encephalopathy (abst) . 235
Iothalamate
compensatory renal function and *i.* clearance (abst) ... 236
Iron
in liver ..... 451
*i.* removal
during hemodialysis (abst) ..... 580
*i.* replacement
in hemodialysis (abst) ..... 596
serum ferritin as marker for ..... 451
Iron staining, colloidal
in protein overload nephropathy (abst) ..... 239
Ischemia, renal
Editorial Review on ..... 375
lipid alterations induced by ..... 153
medullary hyperemia after ..... 283
Isosthenuria
in renal ischemia, Editorial Review on ..... 375

Kallikrein
effects of ACTH on urinary *k.* excretion (abst) ..... 233
Kallikrein-kinin system
and prostaglandin in malignant hypertension, Nephrology Forum on ..... 209
Ketanserin
effects on severe hypertension (abst) ..... 233
Kidney, cadaveric donor
surgical damage related to (abst) ..... 649
Kidney disease
in Southern Arabia (abst) ..... 487
Kinin
renal blood flow regulated by (abst) ..... 489
Kupffer cell
*k. c.* iron stores in chronic hemodialysis ..... 451

Lactate dehydrogenase
in rabbit renal cortex (abst) ..... 634
Laxatives
pseudo-Bartter syndrome and (abst) ..... 898
Lead
*l.* excretion
in gout and chronic renal failure, German/Australian study (abst) ..... 240
*l.* poisoning
associated with chronic renal failure with gout in Australia and New Jersey, USA ..... 319
urinary *l.* excretion
in uremia (abst) ..... 487
Leptospirosis
early dialysis in (abst) ..... 504
no mortality in (abst) ..... 507
Lesions
histological *l.*
in nephrotic syndrome ..... 324
minimal *l.*
in nephrotic syndrome ..... 324
Leukopenia, hemodialysis
dialysate temperature effects on (abst) ..... 557
Leukostasis, intrapulmonary
in hemodialysis ..... 430
Levamisole
in minimal change disease (abst) ..... 240
Ligation, unilateral ureteric
in diabetic rats (abst) ..... 621
Limb, medullary thick ascending
in renal ischemia, Editorial Review on ..... 375
Lipid
*l.* alterations
induced by renal ischemia ..... 153
*l.* metabolism
impaired myocardial *l. m.* in phosphate depletion ... 18
serum *l.*
and apoproteins in dialyzed/transplanted patients (abst) ..... 651
role in hyperlipidemic hemodialysis patients ..... 81
Lipoprotein metabolism
in nephron segments ..... 411
Liver disease
alcoholic *l. d.*
antibody specificity of mesangial IgA deposits in (abst) ..... 239
chronic *l. d.*
in hemodialysis patients (abst) ..... 221
Lung disease
associated with nephritis ..... 444
Lupus, systemic
treated with cyclosporin A (abst) ..... 225
L-valine
in rat glomerular cell cultures, Technical Note on ..... 875
Lymphocytes
in pyelonephritis ..... 816
T-*l.*
effects of blood transfusions on T-*l.* in uremia (abst) 218
tonsil *l.*
role in immune regulation of IgA (abst) ..... 223
Lymphoma, kidney
sonographically guided aspiration diagnosis of (abst) . 529
Lymphoproliferation
cyclosporin-induced (abst) ..... 633
Lysosomes
enzymes of *l.* and peroxisomes, Editorial Review on . 101

Macrophages
*m.*-dependent
arachidonate metabolism in hydronephrosis ..... 10
effects of steroids on glomerular *m.* accumulation ..... 162
fibrin, human renal allograft rejection, and (abst) ..... 228
peritoneal *m.*
in CAPD ..... 733

prostanoid release from ..... 331
Magnesium
*m.* metabolism in idiopathic calcium stone formers (abst) ..... 508
Magnesium sulfate
in eclampsia (abst) ..... 515
Maleic acid
used to induce renal tubular disorder (abst) ..... 231
Mannitol
used against acute tubular necrosis (abst) ..... 366
Markers
VHB
chronic liver disease in hemodialysis patients with (abst) ..... 221
Meclofenamate
associated with pressure natriuresis ..... 683
Medulla, renal
in ischemic renal failure ..... 283
Membrane
*m.* damage
in ischemia ..... 153
*m.* erythrocyte
transport of 22Na and 86Rb through (abst) ..... 220
hemodialysis *m.*
substances from pre-use (abst) ..... 612
peritoneal *m.*
after 5 years of CAPD (abst) ..... 246
polyacrylonitrile *m.*
in biofiltration technique (abst) ..... 599
Merrill, John Putnam
in memoriam ..... 98
Mesangial function
in aminonucleoside nephrosis (abst) ..... 369
Mesangial immune injury
model of ..... 137
Mesangiolysis
role of fibrin deposition in ..... 712
Metabolic acidosis
hypophosphaturia effects on ..... 302
Metabolic alkalosis
glomerular filtration and bicarbonate reabsorption maintain *m. a.* ..... 205
Microcirculation, rat renal
affected by prostaglandin $E_2$ and converting enzyme inhibition (abst) ..... 235
$\beta$2-Microglobulin
renal tubular absorption of ..... 170
Microcomputer model
to plan renal services (abst) ..... 552
Microscopy, electron
silver methenamine used in renal *e. m.* (abst) ..... 245
used to localize glomerular components (abst) ..... 238
Mitochrondria
associated with phosphate depletion ..... 18
Monocytes
peripheral blood *m.*
compared to peritoneal macrophages ..... 733
Morbidity
in analgesic-associated nephropathy and endstage renal failure (abst) ..... 596
uremic *m.*
related to BUN or middle molecule clearance? (abst) 606
Multicenter Veterans Administration study
of hemodialysis and peritoneal dialysis ..... 459
Multistix
used to define specific gravity in urine (abst) ..... 897
Muscle
skeletal *m.* buffer
response to acute acid load (abst) ..... 499
Myocardial activity
during sodium acetate infusion ..... 744
Myoglobin
potential uremic toxin (abst) ..... 600

Naloxone
effects on testosterone secretion in dialysis (abst) ..... 534
Natural killer activity
and renal transplantation associated with skin cancer (abst) ..... 236
Necrokidney
outcome of 360 "twin" *n.* (abst) ..... 631
Necrosis
acute tubular *n.*
in cadaveric renal transplantation (abst) ..... 366
avascular *n.*
in renal transplantation patients (abst) ..... 237
chronic renal papillary *n.*
induced by bromoethylamine hydrobromide (abst) .. 232
recovery from ..... 838
Nephrectomy, donor
renal function and blood pressure after (abst) ..... 655
Nephrectomy, unilateral
in study of partial ureteral obstruction ..... 122
Nephritis
anti-GBM antibody-mediated *n.*
HLA-linked gene influence on ..... 444
endstage lupus *n.*
dialysis and transplantation in (abst) ..... 625
Heymann *n.*
IgG and C5-8 in ..... 830
proteinuria related to (abst) ..... 366
lupus *n.*
in males and females (abst) ..... 626
lymphocyte sensibilization in (abst) ..... 626
treated with anticoagulant, corticosteroid, and immunosuppressive drugs (abst) ..... 614
nephrotoxic serum *n.*
plasmapheresis in (abst) ..... 244
Nephrocalcinosis
metabolic disorders in (abst) ..... 624
Nephrolithiasis, active
endocrine abnormalities in (abst) ..... 502
Nephrolithiasis, calcium
distal tubular function (abst) ..... 226
low calcium diet effects on (abst) ..... 494
oral calcium load test for monitoring *c. n.* (abst) ..... 624
Nephrology Forum on
articulations of Adam's rib with lower urinary tract ... 476
immunosuppressive agents in renal transplantation .... 353
malignant hypertension in Brazil ..... 209
metabolic alkalosis ..... 88
mild hypertension: a therapeutic dilemma ..... 875
primary aldosteronism ..... 769
Nephron
affected by partial ureteral obstruction ..... 122
enzyme distribution along, Editorial Review on ..... 101
deep proximal *n.*
role in chronic metabolic alkalosis (abst) ..... 231
*n.* heterogeneity in ischemic acute renal failure ..... 422
lipoprotein metabolism in *n.* segments ..... 411
Nephropathy
analgesic *n.*

value of urinary cytology in (abst) ... 522
chronic interstitial *n.*
associated with lithium nephrotoxicity (abst) ... 239
cyclosporin *n.*
after heart/heart-lung transplantation (abst) ... 656
de novo graft membranous *n.*
etiology/prognosis of (abst) ... 649
diabetic *n.*
glycosylated proteins in (abst) ... 623
diabetic functional *n.*
urinary excretion of albumin (abst) ... 620
endemic *n.*
creatinine phosphokinase in (abst) ... 527
isoenzymes determined in (abst) ... 526
lactate dehydrogenase patterns in (abst) ... 534
nucleotides in erythrocytes in (abst) ... 526
tumor markers in (abst) ... 526
gold *n.*
with minimal glomerular changes (abst) ... 225
Hantaan virus *n.*
in France (abst) ... 490
idiopathic membranous *n.*
terminal C5b-9 complex of complement in (abst) ... 225
IgA *n.*
clinicopathological correlations of (abst) ... 239
homozygous null $C_4$ phenotypes in ... 855
immune regulation of IgA by tonsil lymphocytes in (abst) ... 223
immune response to dietary antigens in (abst) ... 223
macroscopic hematuria in (abst) ... 508
mesangial IgA *n.*
role of β-hemolytic streptococci in (abst) ... 509
phenytoin in treatment of (abst) ... 223
primary IgA *n.* IgA in ... 760
primitive IgA *n.*
diaminodiphenylsulfone-dapsone trial in (abst) ... 493
in systemic amyloidosis (abst) ... 368
lupus *n.*
antilymphocyte antibodies and other immunological parameters (abst) ... 220
obstructive *n.*
tubuloglomerular feedback and interstitial pressure in ... 294
protein overload *n.*
glomerular ultrastructure and colloidal iron staining in (abst) ... 239
reflux *n.*
associated with Tamm-Horsfall urinary glycoprotein (abst) ... 242
urinary red cell morphology to diagnose *n.* (abst) ... 523
Nephrosis
aminonucleoside *n.*
mesangial function and glomerular sclerosis in (abst) 369
Nephrotic syndrome
adult *n. s.*
immunoregulatory treatment in (abst) ... 513
adult-onset minimal change *n. s.*
steroid treatment in (abst) ... 506
experimental *n. s.*
ATPase in (abst) ... 368
functional relationships in ... 324
idiopathic *n. s.*
and food allergy (abst) ... 780
immunosuppressive treatment of (abst) ... 615
interstitial foam cells in (abst) ... 506
plasma fibronectin/fibrinogen levels in (abst) ... 530
renin-angiotensin-aldosterone system in (abst) ... 243
sonographic diagnosis of renal vein thrombosis in (abst) ... 528
Nephrotoxicity
lithium *n.*
associated with chronic interstitial nephropathy (abst) ... 239
Netilmicin
compared with cefoperazone for treatment of urinary tract infection (abst) ... 242
single-dose *n.* in urinary infection (abst) ... 242
Nifedipine
as therapy in malignant hypertension (abst) ... 900
Nitrates
cause of anemia in home dialysis (abst) ... 593
Nitrogen mustard
treatment on hydronephrotic kidney ... 10
used in glomerulonephritis models ... 162
Nodules
associated with light-chain deposition disease, Editorial Review on ... 1
Norepinephrine
acute renal failure induced by ... 422
and calcium antagonists ... 719
NSAID (non-steriodal anti-inflammatory drugs)
compared with clometacin (abst) ... 779
Nutrition
*n.* assessment of patients on CAPD (abst) ... 230
in peritoneal dialysis ... 253
*n.* status of 50 patients on hemodialysis (abst) ... 230

Obstruction, ureteral
tubuloglomerular feedback in ... 294
Occlusion, renal artery
in ischemic acute renal failure ... 689
Osteodystrophy, dialysis
osteomalacic dialysis *o.*
high aluminum bone content related to (abst) ... 586
$^{99m}$Tc pyrophosphate bone scintigraphy in (abst) ... 528
Osteodystrophy, renal
bone histomorphometry in diagnosis of (abst) ... 896
during chronic hemodialysis and hemofiltration (abst) . 579
Osteomalacia, aluminum-related
$1,25(OH)_2D_3$ and $24,25(OH)_2D_3$ effects on (abst) ... 490
Ouabain
plasma of renal failure effects on (abst) ... 896
Oxygen
renal *o.* deprivation in renal ischemia, Editorial Review on ... 375

Paraplegia
associated with Tamm-Horsfall urinary glycoprotein (abst) ... 242
Parathyroid hormone (*PTH*)
affected by $24,25(OH)_2D_3$ in chronic uremia ... 791
and prostaglandin $E_2$ in proximal tubule ... 404
in elderly on dialysis (abst) ... 531
related to bone histology in dialysis ... 869
Parathyroidectomy
postoperatively managed in hemodialysis (abst) ... 567
Pediatric nephrology
acute renal failure in infancy (abst) ... 628
adult height in *p.* patients with chronic renal failure (abst) ... 497
aluminum loading in children with chronic renal failure 201
captopril in hypertensive children (abst) ... 494

children on hemofiltration (abst 2) ... 560
growth in children with chronic renal failure ... 52
hemodialysis catheters in children (abst) ... 607
Henoch-Schönlein syndrome in children (abst) ... 495
Hickman catheter for hemodialysis access in larger children (abst) ... 581
hypnosis for renal needle biopsy in children, Technical Note on ... 351
infantile polycystic kidney disease in South Africa, 1970-1983 (abst) ... 898
marker of early diabetic nephropathy in children (abst) 627
membranous glomerulonephritis in Zimbabwean children (abst) ... 899
microsurgery, video-tape demonstration, Brescia and Cimino arterio-venous fistula in children (abst) ... 541
neuromuscular reaction in children with chronic renal failure (abst) ... 525
percutaneous catheter used in children (abst) ... 541
prostaglandin E in idiopathic hypercalciuria in a child 176
prospective protocol for ureteropelvic junction obstruction in (abst) ... 520
renal transplantation in children with urinary tract infection (abst) ... 640
serum ferritin level in children on hemofiltration (abst) 586
thyroid status in uremic children (abst) ... 493
treatment of renal osteodystrophy in children (abst) ... 489, 515

Perfusion
ex vivo *p.*
effects on kidney preservation for transplantation (abst) ... 237
of isolated human renal tubules (abst) ... 899
*p.* pressure
effects on renal transplantation (abst) ... 236
*p.* solutions
dimethyl sulfoxide in, Technical Note on ... 471

Peritonitis
CAPD *p.*
in Durban, South Africa (abst) ... 895
report on ... 733
treatment of
antibiotic effects on (abst) ... 610
co-trimoxazole (abst) ... 591
intraperitoneal versus intravenous antibiotics in (abst) ... 538
oral treatment of (abst) ... 597
10- or 21-day treatment? (abst) ... 544
vancomycin and gentamicin (abst) ... 531
fungal *p.*
in CAPD (abst 2) ... 245
intermittent peritoneal dialysis *p.* ... 567
sclerosing *p.*
etiology of (abst) ... 566
spontaneous bacterial *p.*
in CAPD (abst) ... 895
staphylococcus *p.*
treated during CAPD (abst) ... 588

pH
peritoneal fluid pH
in CAPD (abst) ... 895
plasma pH
and GFR as determinants of phosphate reabsorption 128

Pharmacokinetics
aztreonam *p.*
effects of hemodialysis and peritoneal dialysis on ... 308
steroid *p.*
in renal transplantation (abst) ... 237

Pharmacotherapy
in hypertension ... 881

Phenytoin
used in treatment for IgA nephropathy (abst) ... 223

Phosphate
*p.* binders
aluminum containing *p. b.* in chronic renal failure ... 201
*p.* depletion
impaired myocardial lipid metabolism in ... 18
dietary *p.* restriction ... 302
*p.* excretion
in kidney graft recipients (abst) ... 654
in proximal straight tubules ... 404
*p.* loading
effects on renal tubular disorder (abst) ... 231
*p.* reabsorption
determined by GFR and plasma pH ... 128

Phospholipid
defect in synthesis of ... 18

Phospholipidosis
gentamicin-induced *p.*
in kidney cortex ... 838

Phosphorus
and calcium in dialysis patients (abst) ... 578
*p.* kinetics
during hemodialysis and hemofiltration (abst) ... 586

Piperacillin
treatment for renal cysts (abst) ... 488

Plasma
effects on 22Na and 86Rb transport in essential hypertension (abst) ... 220
*p.* exchange
evaluated (abst) ... 622
in experimental renal autoimmune disease (abst) ... 243
in Guillain-Barré syndrome (abst) ... 505
*p.* volume recovery in chronic renal failure ... 848

Plasma aluminum
increase of (abst) ... 603

Plasma cell clone
associated with AL-type amyloidosis, Editorial Review on ... 1

Plasma creatinine
in anti-GBM antibody-mediated nephritis ... 444

Plasma DNA
quantitative measurement of hemodialysis and (abst) ... 556

Plasma high density lipoprotein
in proximal tubule ... 411

Plasma pH
and GFR as determinants of phosphate reabsorption ... 128

Plasmapheresis
and hemodialysis for systemic diseases (abst) ... 619
as limited assistance (abst) ... 503
in nephrotoxic serum nephritis (abst) ... 244
in urinary sodium excretion experiment ... 275
single needle *p.*
comparison of filters for (abst) ... 540
to treat acute vascular rejection (abst) ... 657

Plasma renin activity
in nephrotic syndrome ... 324

Pneumonitis, uremic
proteolytic enzymes in (abst) ... 499

Poisoning
acute theophyllin *p.*
treated with hemoperfusion/hemodialysis (abst) ... 590
acute triline *p.*

treated with plasmapheresis/hemoperfusion (abst) ... 594
Polyamine
in anemia of renal failure (abst) ... 504
Polycystic kidney disease
adult onset *p.k.d.*
re-evaluation of prognosis of ... 190
hydrothorax in (abst) ... 779
infantile *p.k.d.*
in South Africa, 1970-1983 (abst) ... 898
Polymethylmethacrylate membranes
role in complement activation ... 194
Polymorphism
of complement genes in glomerulonephritis ... 855
Potassium
aldosterone in *p.* adaptation in collecting tubule ... 798
cyclic AMP in *p.* depleted rats ... 384
*p.* excretion
by isolated perfused rat kidney (abst) ... 236
*p.* physiopathology
in cystinosis (abst) ... 224
*p.* supplement in hypertension (abst) ... 900
Potentiostatic CC technique
on renal crystal growth, Technical Note on ... 767
Prednisolone
associated with skin cancer and renal transplantation (abst) ... 236
dosage based on weight? (abst) ... 631
effects on cellular immunity (abst) ... 647
in cadaveric renal transplantation (abst) ... 366
treatment for immune complex-induced glomerulonephritis (abst) ... 238
Pregnancy
abdominal ultrasound in (abst) ... 242
hemodialysis in (abst) ... 526
complement and properdin factor B in (abst) ... 525
hypertensive *p.*
antihypertensive therapy in (abst) ... 232
report on (abst) ... 233
salt-losing tendency in (abst) ... 492
physiological *p.*
renal ultrasonic monitoring in (abst) ... 491
primate *p.*
angiotensin II and systemic vascular resistance in (abst) ... 235
renal biopsy in hypertensive women postpartum, Technical Note on ... 85
renal hemodynamics during ... 24
renal transplantation after (abst) ... 237
Preservation, kidney
Belzer II solution used (abst) ... 644
intermediate normothermic perfusion for transplantation (abst) ... 645
Pressure
interstitial *p.*
in obstructive nephropathy ... 294
*p.* natriuresis
by perfused kidney ... 683
Procaine
effects on peritoneal dialysis ... 392
Propranolol
predialysis administration of (abst) ... 584
Prostacyclin
perfusion pressure effects on ... 683
Prostaglandin
and kallikrein-kinin system in malignant hypertension, Nephrology Forum on ... 209
*p.* E
and thromboxane release in prospective renal graft recipients (abst) ... 643
associated with idiopathic hypercalciuria and hyperreninemia ... 176
*p.* $E_2$
affected by angiotensin II ... 30
and PTH in proximal tubule ... 404
effects in hydronephrosis ... 10
effects on rat renal microcirculation (abst) ... 235
released from macrophages ... 331
in captopril-induced natriuresis (abst) ... 492
in essential hypertension (abst) ... 367
renal *p.*
in acute postsinusoidal portal hypertension (abst) ... 220
role in renal water metabolism in cirrhosis ... 72
*p.* secretion
by perfused kidney ... 683
6-keto-$F_{1\alpha}$
affected by angiotensin II ... 30
Prostatism
with obstruction, Nephrology Forum on ... 476
Protamine sulfate
used to induce 'malignant' focal glomerular sclerosis (abst) ... 244
Protein
assessed by single pool hemodialysis model (abst) ... 895
low molecular weight *p.*
noninvasive measurement of (abst) ... 519
peritoneal dialysis and loss of, Editorial Review on ... 253
*p.* transport
across peritoneal mesothelium (abst) ... 543
urinary *p.*
immunofixation of (abst) ... 518
selectivity index of (abst) ... 524
Proteinuria
affected by cobra venom factor ... 896
after $\beta$2-microglobulin injection ... 170
and renal failure in light-chain deposition disease, Editorial Review on ... 1
induced by glomerular injury (abst) ... 238
in patients with cancer (abst) ... 619
in spontaneous glomerulonephritis ... 701
minimal lesions in nephrotic syndrome and ... 324
related to Heymann nephritis (abst) ... 366
Pruritus, uremic
treated with hemoperfusion (abst) ... 596
Pulmonary infections
in post-transplant patient (abst) ... 898
Puromycin-aminonucleoside
used to induce 'malignant' focal glomerular sclerosis (abst) ... 244
Purpura, Henoch-Schönlein
homozygous null $C_4$ phenotypes in ... 855
Pyelonephritis
acute *p.*
P-fimbriated *Escherichia coli* as agent of (abst) ... 501
role of cell-mediated immunity ... 816

Radiology
renal artery digital substraction *r.*
used to study renovascular hypertension (abst) ... 233
Ranitidine
effects on chronic renal therapy (abst) ... 507
Reabsorption, absolute proximal
and urinary sodium excretion ... 275

Receptors
postsynaptic adrenergic
in chronic hypotension associated with terminal uremia (abst) ... 222
Recipient, kidney
early infections in (abst) ... 630
Reflux, vesicoureteral
in adults (abst) ... 506
Refractometer
compared with multistix (abst) ... 897
Renal autoregulation
beta adrenergic blockade effects on (abst) ... 512
cimetidine effects on (abst) ... 513
Renal cystic disease
tubular cell and basement membrane changes in ... 35
Renal disease
human serum albumin for diagnostic use (abst) ... 523
in South Australian aboriginal population (abst) ... 240
Renal disease, endstage
associated with adult onset polycystic kidney disease ... 190
hypertension in (abst) ... 536
premature ventricular contractions in (abst) ... 552
surgical treatment of aneurysm in (abst) ... 540
Renal failure
accelerated by pregnancy in reflux nephropathy (abst) ... 486
causes of, in Northeastern USA series (abst) ... 552
erythrocytes in (abst) ... 896
related to cyclosporin A blood levels (abst) ... 658
Renal failure, acute
and tubular damage (abst) ... 503
associated with clometacin (abst) ... 779
caused by histiocytic interstitial neprhitis (abst) ... 490
cis-dichlorodiammineplatinum cause of improvement after (abst) ... 493
complications of viral hepatitis (abst) ... 505
evaluation of 608 patients, 1969-1983 (abst) ... 587
experimental *a.r.f.*
model of, with cyclosporin A and short ischemia (abst) ... 500
following abdominal aneurysmectomy (abst) ... 897
glycerol-induced *a.r.f.*
aminophylline effects on (abst) ... 245
in high risk patients (abst) ... 561
ischemic *a.r.f.*
Editorial Review on ... 375
membrane damage in ... 153
nephron heterogeneity in ... 422
renal artery occlusion in ... 779
isotopic renography and (abst) ... 523
postischemic *a.r.f.*
effects of α-propranol and captopril against (abst) ... 501
rhabdomyolysis *a.r.f.*
study of (abst) ... 241
spontaneous arteriovenous hemofiltration in (abst) ... 564
studied 1976-1978 and 1980-1982 at *H.*F. Verwoerd Hospital, Pretoria, South Africa (abst) ... 897
thyroid function in (abst) ... 492
uranyl-acetate induced *a.r.f.*
glomerular alterations in ... 808
Renal failure, chronic
adrenergic blockade on serum potassium in (abst) ... 584
aldosterone in *c.r.f.* after transplantation (abst) ... 647
aluminum toxicity in children with ... 201
anemia of (abst) ... 897
body weight during (abst) ... 549
bone marrow cells in ... 741
CAPD effects on hyperlipidemia (abst) ... 563
coronary arterial disease in (abst) ... 515
C-reactive protein as infection marker in (abst) ... 520
cytotoxicity in dialysis patients with (abst) ... 601
dietary protein restriction in (abst) ... 516
dietary treatment in (abst) ... 511
effects of $24,25(OH)_2D_3$ on PTH and bone histology in ... 791
erythrocyte glucose-6-phosphate dehydrogenase in (abst) ... 563
growth in children with ... 52
$H^3$ cholesterol in (abst) ... 510
hemofiltration versus hemodialysis in (abst) ... 247
human pancreatic polypeptide and somatostatin in (abst) ... 618
hyperchloremia in (abst) ... 495
hyperestrogenemia in males with (abst) ... 566
lead excretion in German/Australian study of (abst) ... 240
lisuride treatment after (abst) ... 494
mechanism of hypozincemia in (abst) ... 506
microcomputer monitoring (abst) ... 495
motor/sensory neurons in (abst) ... 525
naloxone infusion in (abst) ... 617
PTH and bone histology in (abst) ... 505
phosphate restriction, keto-acids, and vitamin D effects on (abst) ... 496
physical properties of red cell in (abst) ... 896
plasma volume recovery in ... 848
protein binding of aluminum in (abst) ... 588
protein restriction in (abst) ... 510
raised serum nickel concentrations (abst) ... 555
ranitidine effects on (abst) ... 507
salbutamol effects in (abst) ... 578
skeletal muscle in (abst) ... 621
sulindac and indomethacin effects in (abst) ... 487
tissue enzymes in (abst) ... 511
type of hypertension when *c.r.f.* present (abst) ... 221
urine excretion of ascorbic acid in (abst) ... 648
with gout ... 319
zinc kinetics in (abst) ... 498
zinc treatment effects on cell-mediated immunity in (abst) ... 498
Renal failure, diabetic
cardiac performance in (abst) ... 616
hyperparathyroidism in (abst) ... 614
Renal failure, early
dietary protein restriction in (abst) ... 516
Renal failure, endstage
cyclosporin A in (abst) ... 643
Renal failure, ischemic
medullary perfusion defect in ... 283
Renal failure, severe
serum free T4 and free $T_3$ levels in (abst) ... 606
Renal failure, terminal
serum potassium in (abst) ... 222
Renal function
decline with age ... 861
sulindac and indomethacin effects on (abst) ... 242
Renal insufficiency, acute and chronic
and leukoses (abst) ... 625
Renal insufficiency, chronic
carnitine administration in (abst) ... 496
hemodialysis/hemofiltration effects on serum lipids in (abst) ... 566
premature red blood cell elimination in (abst) ... 613
Renal plasma flow
during pregnancy ... 24

Renal preservation solution
isolated rat kidney subjected to (abst) ..... 634
Renal replacement therapy
hemodynamic tolerance in (abst) ..... 574
Renal reserve
measured by amino acid/dopamine infusion (abst) ..... 514
Renal stone
growth in urine, Technical Note on ..... 767
Renal vascular resistance
associated with pressure natriuresis ..... 683
Renin
less renal *r.* in hypertensive pregnant women, Technical Note on ..... 85
plasma *r.* activity
in nephrotic syndrome ..... 324
*r.* release
role of $TxA_2$ in (abst) ..... 779
Renin-angiotensin-aldosterone system
angiotensin II blockade effects on ..... 823
associated with essential hypertension (abst) ..... 502
in nephrotic syndrome (abst) ..... 243
in pregnancy-induced hypertension (abst) ..... 495
Retinopathy, diabetic
in peritoneal dialysis (abst) ..... 539
Rhabdomyolysis acute renal failure
study of (abst) ..... 241
Rib, Adam's
and lower urinary tract, Nephrology Forum on ..... 476
Rickets, vitamin D deficiency
serum and urinary $\beta_2$ microglobulin in (abst) ..... 621
Roentgenograms
of patients on maintenance dialysis (abst) ..... 229

Salivary secretion
diuretics used to study (abst) ..... 236
Saralasin
effects on blood pressure, plasma renin, and aldosterone ..... 823
Scintigraphy, bone
and aluminum toxicity (abst) ..... 602
in dialysis patients (abst) ..... 602
Sclerosis
glomerular *s.*
in aminonucleoside nephrosis (abst) ..... 369
'malignant' focal glomerular *s.*
induced by puromycin-aminonucleoside and protamine sulfate (abst) ..... 244
peritoneal *s.*
in CAPD in Durban, South Africa (abst) ..... 895
Seminal fluid
in essential hypertension (abst) ..... 367
Septic shock
and acute renal failure (abst) ..... 514
Serum creatinine
affected by number of births (abst) ..... 501
Serum ferritin
in chronic hemodialysis patients ..... 451
Serum proteins
loss into dialysate, Editorial Review on ..... 253
Shunt, hexose monophosphate
in hemodialysis patients (abst) ..... 896
Silver methenamine
used in renal electron microscopy (abst) ..... 245
Single-needle dialysis system, double-pump
evaluated (abst) ..... 567
Sodium
*s.* diet
low *s. d.* in nephrotic syndrome ..... 324
*s.* excretion
in hypertension ..... 342
urinary *s. e.* associated with intracapillary pressures/flow rates ..... 275
glomerular dynamics in *s.* replete dogs ..... 263
in dialysate concentrations ..... 744
*s.* permeability
in Bartter syndrome (abst) ..... 227
*s.* pump
inhibition of (abst) ..... 232
*s.* sensitivity
in essential hypertension (abst) ..... 367
*s.* transport
inhibited by autologous tubular fluid (abst) ..... 232
urinary *s.* excretion in acute postsinusoidal portal hypertension (abst) ..... 220
Sodium acetate
hemodynamic effects of (abst) ..... 594
myocardial contractility during *s. a.* infusion ..... 744
Sodium chloride
angiotensin II blockade effects on intakes of ..... 823
*s.c.*-loading
in primary aldosteronism, Nephrology Forum on ... 769
Sodium chloride-losing syndrome
associated with Bartter syndrome (abst) ..... 224
Sodium orthovanadate
hemodynamics and renal effects of (abst) ..... 219
Sodium pentobarbiturate
used to kill rats for cell cultures, Technical Note on ... 875
Na,K-ATPase
in renal cortex with cirrhosis of liver (abst) ..... 626
$Na^+/K^+$ transport
as genetic marker of essential hypertension (abst) 218, 221
in hypokalemia (abst) ..... 227
Specific gravity
defined by multistix (abst) ..... 897
Spironolactone
and captopril effects on idiopathic edema (abst) ..... 226
*Staphylococcus aureus*
cause of peritonitis in CAPD (abst) ..... 895
in hospital hemodialysis unit (abst) ..... 583
Staphylococcus infections
in hemodialysis (abst) ..... 561
Starling forces
and urinary sodium excretion ..... 275
in obstructive nephropathy ..... 294
Stenosis
renal artery *s.*
cause of renal function deterioration in (abst) ..... 232
unilateral renal artery *s.*
captopril effects on (abst) ..... 368
Steroid
effects on leukocyte-mediated glomerulonephritis ..... 162
in renal transplantation (abst) ..... 220
*s.* pharmacokinetics
in renal transplantation (abst) ..... 237
Subset
NK-1 and NK-15
monitored in transplant recipients (abst) ..... 647
T-cell
in renal transplant patients (abst) ..... 653
Sulindac
and indomethacin effects on renal function and blood

pressure (abst) ... 242
Sympathoadrenal response
to submaximal exercise in hemodialysis ... 66

T-cell
activation by single hemodialysis session (abst) ... 550
in cadaveric kidney allograft recipients (abst) ... 632
in pyelonephritis ... 816
T-cell subset
in transfusions in hemodialysis ... 436
monitored in
renal allografts (abst) ... 220
renal transplantation recipients (abst) ... 237
β-Thalassemic
in hemodialysis patients in Southern Italy (abst) ... 537
Thallium Technicium Substraction Scintiscanning (TTSS)
used to study hyperparathyroidism (abst) ... 897
Thromboxane $A_2$
in hydronephrotic kidney ... 10
Thromboxane $B_2$
released from macrophages ... 331
Thyroid
*t.* abnormalities
uncorrected by renal transplantation (abst) ... 636
Tissue
*t.* hydration
in chronic renal failure ... 848
*t.*, kidney
arginine vasopressin in ... 785
*t.* typing
in malignant hypertension (abst) ... 900
T-lymphocyte subsets
effects of blood transfusions on *T-l.* in uremia (abst) ... 218
Trabecular bone
in dialysis and transplant patients (abst) ... 528
Transferrin
aluminum binding by (abst) ... 234
Transplantation, renal
acute toxoplasmosis following (abst) ... 639
after removal/prevention of anti-HLA antibodies (abst) 656
anergy as predictive factor for (abst) ... 629
arterio-venous-fistula thrombosis after (abst) ... 654
assay (EA inhibition) evaluated for (abst) ... 644
bioavailability of cyclosporin A in (abst) ... 659
bone disease after (abst) ... 229
cadaveric *r. t.*
acute tubular necrosis in (abst) ... 366
cyclosporin A in (abst) ... 366
ESRD patients waiting for (abst) ... 634
from anencephlic neonate donors (abst) ... 638
imported kidneys for (abst) ... 637
lignocaine pretreatment in (abst) ... 652
low-dose steroids in (abst) ... 644
pneumatosis intestinalis after (abst) ... 658
prognosis for recipients surviving 10 years after (abst) ... 229
replacement of renal vein in (abst) ... 638
cancer in *r. t.* recipients in Johannesburg Hospital (abst) ... 898
Center results in United Kingdom and Ireland, 1977-1981 (abst) ... 636
compared with dialysis ... 44
CAPD used for patients entering *r. t.* (abst) ... 230
cyclosporin A in *r. t.*
compared to conventional immunosuppression (abst) 641
conversion to azathiprine in (abst) ... 638
*c. A*/corticosteroids/azathioprine in (abst) ... 635
in cadaveric donor *r. t.* (abst) ... 228
low doses in (abst) ... 647
data of North Italy *r. t.* program (abst) ... 646
*r. t.* donor
diabetic donors (abst) ... 657
proteinuria in (abst) ... 645
donor-specific *r. t.*
blood transfusions prior to (abst) ... 219
blood transfusions in (abst) ... 640, 648, 898
graft survival prolonged by (abst) ... 649
effects of perfusate composition, volume, and perfusion pressure on (abst) ... 236
effects on uremic skin alterations (abst) ... 501
evaluated with V-CAME-RA and $^{99m}$Tc-DTPA (abst) ... 652
5-year experience in Middle East (abst) ... 629
for amyloidosis patients (abst) ... 655
glycosylated proteins in (abst) ... 650
high- or low-dose steroids in (abst) ... 220
histopathologic findings of (abst) ... 616
HLA Class I mismatching after graft failure (abst) ... 656
HLA-DRW 6 positive recipients in (abst) ... 632
human milk IgA concentration after (abst) ... 637
immunoglobulin abnormalities in (abst) ... 633
immunosuppressive agents in, Nephrology Forum on ... 353
immunosuppressive regimens in, one-center study (abst) ... 639
in patients on CAPD (abst) ... 245, 538
in urban black population in South Africa (abst) ... 899
infectious complications monitored after (abst) ... 653
kidney preservation for (abst 2) ... 237
longterm successful *r. t.* (abst) ... 654
lymphocele treated after (abst) ... 644
natural killer activity in (abst) ... 635
overhydration after (abst) ... 642
platelet transfusions preparative for (abst) ... 631
pneumocystis carinii pneumonias in (abst) ... 630, 648
polycythemia erythropoietin-independent after (abst) ... 641
pregnancy after (abst) ... 237
pulmonary infections after (abst) ... 898
ranitidine to prevent gastro-duodenal complications after (abst) ... 650
*r. t.* rejection
diagnosed (abst) ... 518, 641
technetium-$^{99m}$ tin colloid to diagnose (abst) ... 658
related to skin cancer and inhibition by prednisolone (abst) ... 236
renal function and blood pressure after (abst) ... 367
renal radionuclide perfusion index in (abst) ... 527
return to dialysis after (abst) ... 651
role in hypertension (abst) ... 630
steroid pharmacokinetics in (abst) ... 237
T-cell subsets monitored in (abst) ... 237
transfusions related to ... 436
varicella-zoster virus after (abst) ... 655
Transtracheal aspiration
for post-transplant pulmonary infections (abst) ... 898
Tubule
aldosterone in potassium adaptation in ... 798
collecting *t.*
in renal cystic disease ... 35
cortical collecting *t.*
affected by arginine vasopressin ... 725
distal *t.*
early and late models for ion transport in (abst) 231
*d. t.* function in calcium nephrolithiasis (abst) ... 226

Na and $H_2O$ resorption in (abst) ..... 486
histamine in ..... 144
isolated human renal *t.*
perfusion of (abst) ..... 899
proximal *t.*
in acute renal failure ..... 422
lipoprotein metabolism in ..... 411
PTH and prostaglandin $E_2$ in ..... 404
$^{99m}$Tc-DMSA clearance to measure dysfunction of (abst) ..... 528
studied by in vitro isolated microperfused technique (abst) ..... 634
renal distal *t.*
dimethyl sulfoxide in, Technical Note on ..... 471
renal *t.*
absorption of β2-microglobulin ..... 170
disorder induced by maleic acid (abst)
Tubule lumen
net volume transport in, Technical Note on ..... 471
Tubuloglomerular feedback
furosemide effects on ..... 112
25OHD
levels of 25OHD in patients on dialysis (abst) ..... 218

Ultrasonography
and radionuclides to diagnose kidney grafts and tumors (abst) ..... 525
of arterio-venous fistulas (abst) ..... 522
renal graft *u.*
assessment of (abst) ..... 521
Ultrafiltration
glomerular *u.*
furosemide effects on ..... 112
in chronic renal failure ..... 848
Ultrasonography
abdominal *u.*
used to detect urological abnormalities in pregnancy (abst) ..... 242
to assess retroperitoneal hematomas after percutaneous renal biopsy (abst) ..... 226
to detect adult onset polycystic kidney disease ..... 190
Ultrastructure
glomerular *u.*
and colloidal iron staining in protein overload nephropathy (abst) ..... 239
Ultraviolet system, Travenol ®
in vitro evaluation of (abst) ..... 583
Uninephrectomy
consequences of (abst) ..... 524
United States Public Health Science Service Study
on hypertension, Nephrology Forum on ..... 881
Uranyl acetate
used to induce acute renal failure ..... 808
Urea
clearance of *u.*
procaine effects on, in peritoneal dialysis ..... 392
Uremia
adrenoreceptor response in (abst) ..... 491
amino acids and keto analogues in (abst) ..... 494
body composition during (abst) ..... 529
bone formation in ..... 869
bone formation decreased in (abst) ..... 603
bone histomorphometry of (abst) ..... 597
cardiac arrhythmias in (abst) ..... 527
chronic *u.*
bone histology in ..... 791
platelet function in (abst) ..... 218
deferoxamine predictive test in (abst) ..... 603
evaluated by chromatographic procedure (abst) ..... 519
glucosylation of proteins in (abst) ..... 508
influence of blood transfusions on (abst) ..... 218
insulin resistance in (abst) ..... 512
low protein diets in (abst) ..... 498
*u.* metabolism
during hemofiltration (abst) ..... 544
microcytic anemia in ..... 269
neutral steroid metabolites in (abst) ..... 503
PTH and $H_2$ antagonists in (abst) ..... 617
PTH and protein catabolism in (abst) ..... 489
phosphorus body pool in (abst) ..... 576
physical exercise in (abst) ..... 503
platelet life span in (abst) ..... 601
polycystic kidney disease in (abst) ..... 510
serum "markers" of muscle in (abst) ..... 524
Na, K cotransport in (abst) ..... 508
somatosensory-evoked potentials in (abst) ..... 518
terminal *u.*
postsynaptic adrenergic receptors in chronic hypotension associated with (abst) ..... 222
thyroid dysfunction in (abst) ..... 498
vaccination policy for *u.* patients (abst) ..... 488
volume expansion in (abst) ..... 521
zinc levels in (abst) ..... 500
Ureteral obstruction, partial
pathophysiological changes in ..... 122
Urethral syndrome
hormonal deficiency related to, Nephrology Forum on 476
Uric acid
permeability of parietal peritoneum to (abst) ..... 551
Urinalysis
used to monitor renal allograft dysfunction (abst) ..... 654
Urinary excretion
captopril/spironolactone effects on *u. e.* in patient with idiopathic edema (abst) ..... 226
Urinary hydroxyproline
role in calcium balance ..... 752
Urinary infection
single-dose netilmicin in (abst) ..... 242
Urinary tract, lower
Adam's rib and, Nephrology Forum on ..... 476
Urinary tract infection
associated with Tamm-Horsfall urinary glycoprotein (abst) ..... 242
netilmicin and cefoperazone compared for treatment of (abst) ..... 242
single-dose therapy for (abst) ..... 243
Urinary tract obstruction
associated with Tamm-Horsfall urinary glycoprotein (abst) ..... 242
Urine
crystal growth in, Technical Note on ..... 767
evaluated with multistix (abst) ..... 897
Urolithiasis
calcium phosphate *u.*
acidifying therapy in (abst) ..... 507
2.8 di-hydroxyadinine
family study of (abst) ..... 226
Uropathy, obstructive
as cause of renal failure in dialysis (abst) ..... 557

Vascular instability, high
hemodialysis in treatment of (abst) ..... 594

Vascular lesions
in malignant hypertension, Nephrology Forum on..... 209
Vascular responsiveness, systemic
in primate pregnancy (abst)..... 235
Vascular pole
complement fixation in (abst)..... 220
Vascular system
procaine effects on..... 392
Vasculitis
renal involvement in (abst)..... 622
Vasopressin
role in blood pressure regulation (abst)..... 231
Verapamil
effects on
GFR and renal vascular resistance..... 719
ischemic acute tubular necrosis (abst)..... 513
renal function (abst)..... 485
Veterans Administration Cooperative Study
on hypertension, Nephrology Forum on..... 881
Vitamin $B_{12}$
studied in cuprophan standard dialyzer (abst)..... 601
Vitamin C
aggravates secondary hyperoxalemia in chronic hemodialysis (abst)..... 535
Vitamin D
enzyme activities in nephron related to, Editorial Review on..... 101
$1,25(OH)_2D_3$ versus calcium carbonate for hyperparathyroidism (abst)..... 536
serum $1,25\text{-}(OH)_2$-vitamin D
role in calcium balance..... 752
$24,25(OH)_2D_3$
effects on PTH in chronic uremia..... 791
Vitamin E
in hemodialysis patients (abst)..... 583, 896
Voltage, transepithelial
in cortical collecting tubules..... 725
Volume expansion, acute
sodium transport inhibited during (abst)..... 232

Water
intake in patients on chronic dialysis (abst)..... 247
permeability in cortical collecting tubules..... 725
retention in cirrhosis..... 72
Wegener granulomatosis
cyclosporin in (abst)..... 639
SSA antibodies as marker of (abst)..... 617
treated with cytotoxic agents and membrane PP (abst). 516

X-ray fluorescence
in bone lead detection system..... 319

Zinc
in patients with urolithiasis (abst)..... 522